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ABSTRACT
99m jc tetrofosmin is a new ethylene, diphosphine ligand with unique 
properties, developed for myocardial perfusion imaging. The aim of this study was to 
define the imaging characteristics which would allow proper structuring of imaging 
protocols based on the physical attributes. Furthermore, this study evaluates the 
diagnostic role of 99m j c tetrofosmin in the detection of ischaemic heart disease. The 
study was performed in three stages in a sequential manner.
In the first stage, 23 patients with known ischaemic heart disease were studied 
to evaluate the safety, kinetics and the imaging protocol of 99mxc tetrofosmin. 99mfpc 
and tetrofosmin labelling was carried out rapidly and at room temperature from a kit. 
99m jc tetrofosmin was found to be safe in man with rapid myocardial uptake and good 
retention. There was rapid clearance from the background structures such as lung, 
blood and liver, allowing early diagnostic imaging (even 5 minutes post injection). 
There was no evidence of redistribution on serial imaging allowing imaging as late as 4 
hours post injection. The one day protocol was as good as a two day protocol for the 
detection of reversible ischaemia.
In the second stage, a further 50 patients with suspected and 10 persons with 
low probability of ischaemic heart disease were studied using 201x1 and 99mxc 
tetrofosmin imaging. 99mxc tetrofosmin images were of superior quality than 201xi. 
There was high concordance between 201xi and 99mxc tetrofosmin images for the 
overall (90%) and regional (>82%) diagnosis of perfusion defects. The sensitivity for 
the detection of coronary artery disease (>50% luminal narrowing) was 82%, 85% and 
91% using 201xf planar and SPECT 99mxc tetrofosmin, respectively, with a normalcy 
rate of 100% for 99mxc tetrofosmin imaging.
In the third stage, 30 patients with known or suspected ischaemic heart disease 
underwent dobutamine stress 99mxc tetrofosmin imaging and a separate day rest 
study. Excellent quality SPECT images were obtained using 99mxc tetrofosmin. The 
sensitivity for the detection of coronary artery disease was 96%.
In conclusion, tetrofosmin is available in kit formulation and preparation of 
99mxc tetrofosmin does not require boiling. Early imaging is possible and 99mxc 
tetrofosmin does not redistribute. One day protocol may suffice and diagnostic ability is 
comparable to 201xi imaging. In this study a high overall sensitivity for the detection 
of coronary artery disease was shown by 99mxc tetrofosmin imaging.
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CHAPTER 1
HISTORICAL BACKGROUND
The introduction of Laennec's paper stethoscope revolutionised the 
practice of medicine. "I took some sheets of paper and rolling them very tightly, I 
applied one end to the precordial region and placing my ear at the other end, I was 
surprised as I was gratified to hear the beating heart much more clearly and 
distinctly than if I had applied my ear directly to the chest. It occurred to me that 
this could become a useful method..." (R T H Laennec, 1846).
1.1 APPLICATION OF RADIOISOTOPES IN CARDIAC PATIENTS
The introduction of Laennec's paper stethoscope revolutionised the 
practice of medicine. However, the technological revolution of the twentieth 
century has brought with it a new approach in the diagnosis and management of a 
patient. This new approach to medical problems is the application of radioisotopes 
to evaluate pathophysiological status of the human body, and its contribution to 
diagnosis and management has paralleled the growth of technology.
An isotope may be defined as two or more forms of the same element 
having the same atomic number, differing mass numbers and the same chemical 
properties. These different forms of an element may be stable or unstable. There 
are over 270 known nuclidic forms of stable elements; 40 of these exist in nature 
and are termed naturally occurring nuclides. In addition to these, more than 900 
radio-nuclides have been produced artificially. The first radionuclide study in man 
took place in 1927 when Blumgart and colleagues published 'Studies on the 
velocity of blood flow' (Blumgart & Weis, 1927). Aqueous solutions of radon 
were injected intravenously and the velocity of blood flow between one arm and 
the other was measured using a cloud chamber (Blumgart & Yens, 1927). 
Prinzmetal et al (1949) defined radiocardiography as a "method of recording
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graphically the passage of radioactive blood through the cardiac chambers by 
means of a specially constructed ink-writing Geiger-Mueller counter". A carefully 
shielded Gieger-Mueller tube was placed over the précordium; 0.1 to 0.2 millicurie 
of radiosodium (Na-24) was rapidly injected into one of the antecubital veins, and 
the counts were recorded by means of a specially devised ink-writing counter. The 
curve thus represented the concentration of radiosodium in the structures 
underlying the tube. In earlier experiments, Prinzmetal et al (1948) performed 
these techniques in normal subjects and obtained both diphasic and monophasic 
curves. At the time, it was difficult to understand this finding until further studies 
revealed that after an ordinary rapid intravenous injection, completed in half a 
second, it might take as long as twelve seconds before the last trace of 
radiosodium to leave the vein. The precordial tracings in normal subjects 
consisted of principal waves connected by a plateau-like transitional point. The 
first wave was called the R-wave which represented the passage of radiolabelled 
blood through the right side of the heart. The second wave, which represented the 
passage of blood through the left side of the heart, was termed L-wave. This 
procedure was applied to patients in the succeeding years and proved to be useful 
in the diagnosis of several cardiac conditions.
1.2 MYOCARDIAL PERFUSION IMAGING
The possibility of using radiotracers to detect regions of reduced 
myocardial perfusion was first explored by Yates in 1952 using phosphorus-32. 
Radionuclide methods for non invasive evaluation of regional myocardial blood 
flow are based on the observations of Sapirstein (1956) who showed that the total 
extraction of any tracer that has a high extraction rate during the initial capillary 
transit is primarily determined by blood flow. This principle applies to particulate
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indicators that do not recirculate and to recirculating indicators with high 
extraction rates in tissue, such as potassium and other similar cationic tracers 
caesium, rubidium and thallium. In 1965, Love first reported the use of rubidium- 
86 (Rb-86) in dogs and humans for estimation of myocardial perfusion. Radio­
potassium (K-43) was used to detect and evaluate transiently ischaemic 
myocardium by imaging patients after exercise (Zaret et al, 1973). The 
application of rubidium-81 (Rb-81) for the evaluation of regional myocardial 
perfusion was reported by Berman et al, (1975).
1.2.1. Thallium-201 myocardial perfusion scintigraphy
Thallium-199 was suggested as a perfusion imaging agent on the basis of 
its biological similarity to potassium (Kawana et al, 1970). Subsequently thallium- 
201 (201x1) was used to obtain myocardial scintiscans in the goat (Bradley-Moore 
et al, 1975) and the authors demonstrated peak myocardial concentration at 10 to 
25 minutes after injection. 20l j ]  has advantages of lower photon energy (69 
and 83 keV) and greater myocardial concentration (1.7 to 3.7% of the 
administered dose) compared with potassium-43, rubidium-81 and caesium-129 
(Lebowitz et al, 1975; Strauss et al, 1975). Exercise 201x1 scintigraphy was first 
described in 1976 as a non-invasive test for detecting coronary artery disease 
(Ritchie et al, 1976; Shames et al, 1976). Early experiences with the exercise 
201x1 imaging utilised two separate injections of the tracer during exercise and at 
rest. In 1977, Pohost et al reported the disappearance of 201xi myocardial 
defects present on initial images in experimental dogs over a 2 hour period after 
transit ischaemia. This phenomenon, which was called "redistribution", was 
subsequently observed in patients with coronary artery disease (Pohost et al, 
1977). The initial accumulation of 201xi in the myocardium is dependant on both 
coronary blood flow and cellular extraction (Strauss et al, 1975; Di Cola et al,
1977). The use of in the acute phase of myocardial infarction was reported 
by Wackers et al (1976) who documented the value and limitation of 201xi 
scintigraphy for the diagnosis of acute myocardial infarction.
Redistribution of 201xi: In the earlier days, imaging after a second dose of 201xi 
conventionally given one week later was necessary to distinguish between 
myocardial infarction and transient ischaemia. Pohost et al (1977) described that 
transient under perfusion or myocardial ischaemia may be distinguished from the 
old infarction by sequential imaging over a 4-6 hour period after a single dose of 
201x1. This was based upon an observation that there is gradual redistribution of 
201xi into the exercise induced defects corresponding to the regions of 
myocardium supplied by coronary arteries with significant stenoses.
1.2.2. 99mxc labelled myocardial perfusion imaging
As 201xi was being evaluated as a myocardial perfusion agent, a few of the 
observers noted the disadvantages of 201x1, during late 70's (Poe, 1977; Chevru, 
1979; Freeman, 1980). The drawbacks of 201xi noted were its cost, its low-energy 
photopeak (70-80 keV mercury X-ray) with consequent tissue attenuation and its 
relatively long half life (73 hours). These drawbacks, it was thought, could be avoided 
through the use of a myocardial imaging agent based on 99mxcj whose
gamma radiation is ideal | / for diagnostic imaging applications (Eckelman 1977;
Hayes, 1978; Deutsch 1979). In 1977, Strauss et al postulated that in relation to 
201xi, a 99mxc agent would offer a two fold increase in resolution and allow a four 
fold increase in the dose that could be administered. Development of a myocardial 
perfusion agent based o n  99mxc was thus an important -albeit to that date appeared 
elusive - goal of cardiovascular nuclear medicine (Pitt & Strauss, 1979). It is known 
that isotopes of group I cations accumulate in normal heart tissue, through
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involvement with the Na+, K+ - dependent adenosine triphosphate system; that is they 
function as K+ analogs (Nishiyama et al 1976). Deutsch et al (1981, b) postulated and 
showed that +1 charged complexes of 99mxc might mimic the in vivo behaviour of 
T1(I) and be taken up by normal heart tissue. Prior to this work, no cationic complexes 
of 99mxc had been prepared and evaluated as radio-pharmaceuticals, presumably 
because knowledge was lacking about the synthetic and co-ordination chemistry of 
technetium.
These tracers were developed for the diagnosis of ischaemic heart disease and 
also for the risk stratification of patients with known ischaemic heart disease which 
was recognised as a major health problem particularly in the western world.
CHAPTER 2
ISCHAEMIC HEART DISEASE
2.1. INTRODUCTION
Ischaemia refers to a lack of oxygen due to inadequate perfusion. Ischaemic 
heart disease is a condition of diverse aetiologies all having in common a disturbance 
of cardiac function due to an imbalance between oxygen supply and demand. 
Ischaemic heart disease is the major killer in the western world. Within the United 
Kingdom the average annual death rate due to ischaemic heart disease is 300-1100 per 
100,000 population per year. Until recently, the mortality due to ischaemic heart 
disease was declining in many countries but not in the United Kingdom. However, 
since the! usage of thrombolytics ! following myocardial infarction, the mortality has 
reduced. (ISIS 3, 1992)
2.2. PATHOPHYSIOLOGY AND RISK FACTORS
The most common cause of ischaemia of the myocardium is atherosclerotic 
disease of the epicardial coronary arteries, which by causing thickening and hardening 
of the medium-sized arteries, reduces the lumen of these vessels causing an absolute 
decrease in myocardial perfusion in the basal state or limiting appropriate increases in 
perfusion when demand for flow is augmented. The feature that sets atherosclerosis is 
the lipid, which in the advanced plaque is often represented by a central necrotic core 
that is rich in cholesterol esters and is often accompanied by visible cholesterol crystals 
(Wissler, 1984). The atherosclerotic lesion is grossly soft and grummous with a 
necrotic core which is responsible for the name of the disease process, derived from 
the Greek term 'athera', meaning gruel or porridge. The major components of 
atherosclerotic plaque are its cells, mostly smooth muscle cells, and its lipids, much of 
which is extracellular (Ross et al, 1976). In addition, there are fibrous proteins and 
complex carbohydrate products. The relative proportions of these components vary
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greatly from one plaque to another and during the sequence of development or 
regression of a given plaque. An obstructing thrombus, in a major coronary artery can 
form over a well developed atheromatous plaque and lead to sudden coronary 
occlusion and acute myocardial infarction.
The majority of people below the age of 65 afflicted with atherosclerosis have 
one or more identifiable risk factors other than ageing per se. The risk factor concept 
implies that a person with at least one risk is more likely to develop a clinical 
atherosclerotic event and to do so earlier than a person with no risk factors. The 
presence of multiple risk factors further accelerates atherosclerosis. The clustering of 
risk factors in individuals is particularly important because, when risk factors coexist, 
they tend to interact such that their combined effect is greater than the sum of 
individual components.
The risk factors vary in terms of importance in the population but there is a 
general agreement that hypercholesterolaemia, hypertension and cigarette smoking 
may be the most potent factors involved in causation of atherosclerosis. The evidence 
of the association between serum cholesterol level and atherosclerosis is extensive and 
unequivocal (Kannel et al, 1979). Of the two main types of cholestérols described, 
LDL cholesterol is directly related to risk, and HDL shows an inverse relationship 
(Gordon et al, 1977). Elevated blood pressure, either systolic or diastolic, is predictive 
of an increased risk of developing coronary artery disease (Kannel, 1975). Meta­
analysis of the major blood pressure lowering trials, was performed by Yosuf and co­
workers (1988). They reviewed 14 major trials, which together involved 45,000 
patients for an average of 5 years. In nine of these trials, a definite benefit was seen in 
stroke reduction. The impact on coronary disease was much less clear. Smoking is a 
major risk factor for myocardial infarction and death due to coronary artery disease 
(Aronow, 1976 and Wilhelmsson et al, 1975). Total mortality, total cardiovascular
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mortality and incidence of coronary artery disease are increased by about 1.6 times in 
male cigarette smokers.
Diabetes mellitus has also been recognised as a risk factor for vascular diseases. 
Hyperglycaemia and abnormal glucose tolerance test are associated with increased risk 
of developing coronary artery disease (Fuller et al, 1980). Several additional risk 
factors have been identified, such as age, sex, race and geographical factors. A family 
history of coronary artery disease, obesity, menopause, oral contraceptives, physical 
inactivity and type of personality are among other factors which are considered as risk 
factors in the development of coronary artery disease (Levy et al, 1984).
2.3. DIAGNOSIS OF ISCHAEMIC HEART DISEASE
Clinically, ischaemic heart disease can have an acute manifestation (such as 
acute myocardial infarction or unstable angina) or chronic manifestation like stable 
angina pectoris. Acute myocardial infarction results from total occlusion of the 
coronary artery usually due to a thrombus on an atheromatous plaque. Unstable angina 
results from fracture or rupture of the fibrous cap and the resulting ulceration of the 
atheromatous plaque surface. Chronic stable angina may progress into acute 
myocardial infarction or unstable angina.
Diagnosis of acute myocardial infarction is performed traditionally using 
clinical history, cardiac enzymes and resting electrocardiogram. Since the evolution of 
thrombolytic therapy, early diagnosis has become very important (ISIS 3, 1992). 
However, in a proportion of patients the above tests may not indicate definite 
diagnosis of myocardial infarction at the time of presentation. Since the development
of 99111X0 basedand ^O ljj myocardial imaging agents, radiotracers are being evaluated 
as a new method of diagnosis of acute myocardial infarction in doubtful cases.
Selection of appropriate investigation for the diagnosis and risk stratification of 
chronic ischaemic heart disease still remains challenging in the field of cardiology. 
Exercise electrocardiography and myocardial perfusion scintigraphy are two of the 
established and reliable non-invasive tests. Coronary angiography still remains the only 
definite way of diagnosing the anatomical site and the severity of coronary artery 
stenosis.
2.4. EXERCISE STRESS TESTING
The diagnostic utility of the electrocardiogram was recognised by Feil and 
Siegel as early as 1928, when ST and T wave changes following exercise were 
reported in three of four patients with chronic stable angina. Master and Oppenheimer 
developed a standardised exercise protocol to assess functional capacity and 
haemodynamic response in 1929.
2.4.1. Diagnostic implications
The sensitivity of exercise electrocardiography for single-vessel disease ranges 
from 25 to 71 per cent, with exercise-induced ST-segment displacement most frequent 
in patients with left anterior descending coronary artery disease followed by those with 
right coronary artery disease, and is least frequent in patients with isolated left 
circumflex coronary disease. Approximately 75 to 80 per cent of the diagnostic 
information on exercise-induced ST-segment depression is contained in leads V4-6.
9
Some of the published reports correlating the exercise test with coronary 
angiography are shown in Table 2.4.1. Gianrossi et al in 1989 performed an overview 
or meta analysis of 147 consecutive published reports involving 24,074 patients who 
underwent both coronary angiography and exercise testing. The mean sensitivity was 
68 percent (range 23 to 100) and mean specificity was 77 percent, (range 17 to 100) In 
patients with multivessel coronary artery disease, the mean sensitivity was 81 (range 40 
to 100) per cent and mean specificity was 66 (range 17 to 100) per cent as shown by 
Detrano et al (1989). The mean sensitivity was 86±11 per cent and mean specificity 
was 53±24 per cent for left main or three-vessel coronary disease.
The use of Bayesian theory incorporates the pre-test risk of disease and the 
sensitivity and specificity of the test (likelihood ratio) to calculate the post-test 
probability of coronary disease. The results of the patient's clinical information and 
that of exercise test are used to make a final estimate of the probability of coronary 
disease. For example, exercise testing to diagnose coronary artery disease in young or 
middle-aged asymptomatic subjects without risk factors is not useful, since the pre-test 
risk is very low and a normal or abnormal exercise electrocardiography result does not 
alter significantly the post-test risk of coronary artery disease (Patterson et al 1989). 
The diagnostic power of the exercise test is maximal when the pre-test probability of 
coronary artery disease is intermediate (30 to 70 percent).
2.4.2. Prognostic Implications
Several studies have evaluated the prognostic implications of exercise stress 
testing. Ellestad and Wan in 1975 studied 2700 patients undergoing maximal stress 
testing and found that an ischaemic ST segment response to exercise, predicted an 
incidence of 9.7 percent per year of a new coronary event (progressive angina, 
myocardial infarction, or death), compared with an incidence of 1.7 per year associated
10
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with negative test results. In this study, coronary events occurred at rate of 15 percent 
per year among patients whose electrocardiographic evidence of ischaemia began at a 
moderate level of exercise and 4 percent per year among patients who manifested 
ischaemia after seven minutes of exercise. Furthermore, cardiac events were more 
common in patients who had an ischaemic response to exercise and a previous 
myocardial infarction than in patients without previous infarction. It is of interest that 
patients with chronotropic incompetence had a higher incidence of coronary events 
even in the presence of negative electrocardiographic responses to exercise. McNeer 
and associates in 1978 found that survival was 99 percent at 12 months and 93 percent 
at 48 months for 876 non surgically treated patients with coronary artery disease who 
had either negative exercise tests or exercise duration that reached at least stage IV of 
the Bruce protocol, or had a maximal heart rate of >160 beats per minute. In contrast, 
survival was 85 percent at 12 months and 63 percent at 48 months among 134 patients 
who had positive tests in stage I or II. Survival was the lowest (31% at 48 months) for 
33 patients who had positive tests in stage I and II and had maximal heart rates of 
<120 beats per minute. Doyle and Kinch (1980) found that in 2437 men, the 
probability of subsequent angina pectoris or myocardial infarction was higher among 
patients who had abnormal exercise electrocardiographic responses. Allen and co­
workers (1980) provided 5 year follow-up information on 888 asymptomatic 
individuals with no known coronary artery disease who had maximal treadmill exercise 
testing. The incidence of coronary artery disease was 1.1 percent per year. In the same 
study in men over age 40, ischaemic ST segment response correlated with subsequent 
coronary artery disease. In contrast, in men who are aged 40 or younger, treadmill 
exercise testing did not correlate with subsequent coronary artery disease.
In the Seattle Heart Watch Study of 2365 healthy men reported by Bruce and 
colleagues(1980), the predictors of subsequent coronary artery disease were presence 
of chest pain during exercise testing, duration of exercise <6 minutes using the Bruce
11
protocol, failure to achieve >90 percent of maximal predicted heart rate for age, and 
the presence of an ischaemic ST segment depression. The 10 years' experience of the 
Seattle Heart Watch Study was later reported on by Bruce and co-workers (1983), 
who found that of 3611 men and 547 women who were initially free of clinical heart 
disease, subsequent coronary artery disease events occurred in 4.9 percent of patients 
at a mean follow up of 6.1 years. The incidence of future cardiac events was 2.9 
percent among asymptomatic healthy persons, 5.5 percent among patients with atypical 
or non-anginal chest pains, and 10 percent among hypertensive patients. The presence 
of any conventional risk factor in conjunction with two or more selective maximal 
exercise test predictors significantly increased the cumulative 6 year incidence rate. In 
1981, Podrid and co-workers obtained follow up information on 142 men with clinical 
coronary artery disease who had reproducible, marked ST depression during exercise 
testing (>2 mm). At an average follow up of 59 months, the annual mortality rate was 
1.4 percent, and the annual requirement for bypass surgery was 1.3 percent. Survival 
correlated with exercise tolerance but not with the degree of ST segment depression, 
peak exercise heart rate, or peak blood pressure during exercise. Kent and co-workers 
in 1982 found that among patients with three-vessel coronary artery disease who had 
good exercise capacity at exercise testing, there was an annual mortality rate of only 4 
percent. In contrast, patients with three vessel coronary disease and poor exercise 
capacity had a much worse prognosis. Weiner and associates (1984) also showed that 
patients with multivessel disease can be stratified into different risk groups depending 
on the exercise tolerance. Patients with reduced exercise tolerance have a much worse 
prognosis than those with normal exercise tolerance.
2.4.3. Limitations
Despite its wide use as a diagnostic tool, exercise electrocardiography has 
many limitations. The sensitivity of exercise testing is not very high (Gianrossi et al,
12
1989). The specificity of exercise-induced ST-segment depression for obstructive 
coronary artery disease is also low. Senior et al (1994) have shown in a study of 60 
patients that the specificity of exercise electrocardiography was as low as 17%. 
However, in this study nearly 40% of patients had left ventricular hypertrophy.
The specificity of ST depression is less in women than in men. The decreased 
specificity results in part from a lower prevalence and extent of coronary artery disease 
in young and middle aged women. Women tend to have a greater release of 
catecholamines during exercise, which could potentiate coronary vasoconstriction and 
augment the incidence of abnormal exercise electrocardiography (Clark et al 1988). 
Another drawback of exercise test is the inability to localise the coronary artery disease ! 
(Dunn, 1981; Abouantoun S,1984). '
Severe systemic hypertension may interfere with subendocardial perfusion and 
cause exercise-induced ST-segment depression in the absence of atherosclerosis, even 
when the resting electrocardiogram does not show significant ST or T wave changes.
Digitalis glycosides can produce exertional ST-segment depression even if the 
effect is not evident on the resting electrocardiogram. Absence of ST-segment 
deviation during an exercise test in a patient receiving a cardiac glycoside is considered 
a valid negative response. Anti-ischaemic drug therapy with nitrates, beta-blocking 
drugs, or calcium channel blocking drugs will prolong the time to onset of ischaemic 
ST-segment depression, increase exercise tolerance, and, in a small minority of patients 
may normalise the exercise electrocardiographic response in patients with documented 
coronary artery disease (Ellestad 1986; Froelicher 1987). The time and dose of drug 
ingestion may affect exercise performance. In some laboratories, cardioactive drug 
therapy is withheld for 3 to 5 half-lives and digitalis for 1 to 2 weeks before diagnostic 
testing. However, this is impractical in many cases.
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In addition to the above disadvantages, nearly 30-40% of the patients cannot be 
stressed adequately to obtain a conclusive result (Iskandrian AS, 1981). This may be 
due to age, poor physical fitness or due to the physical condition which limits the 
amount of exercise that the patients can perform.
2.5. CARDIAC CATHETERIZATION
2.5.1. Historical review
Cardiac catheterization was first performed (and so named) by Claude Bernard 
in 1844 (Cournand, 1975). The subject was a horse, and both the right and left 
ventricle were entered by a retrograde approach from the jugular vein and carotid 
artery. An era of investigation of cardiovascular physiology in animals then followed, 
resulting in the development of many important techniques and principles (e.g. 
pressure manometry, the Pick cardiac output method), which awaited direct 
application to the patient with heart disease. Although others had previously passed 
catheters into great veins, Werner Forssmann is generally credited with being the first 
person to pass a catheter into the heart of a living person - himself (Barry and 
Grossman, 1984). He passed a catheter 65 cm through his left antecubital vein, guiding 
it by fluoroscopy. He looked through a mirror held by his nurse in front of the 
fluoroscopic screen, until it entered his right atrium. He then walked to the Radiology 
Department, where the catheter position was documented by a chest roentgenogram. 
During the following two years, Forssmann continued to perform catheterization 
studies, including six attempts to catheterise himself. Forssmann's primary goal in his
14
catheterization studies was to develop a therapeutic technique for the direct delivery of 
drugs into the heart.
Andre Cournanad (1941) and Dickenson Richards (1945) produced a 
remarkable series of investigations of right heart physiology in man. The application of 
cardiac catheterization to study the circulation in normal and diseased states, was 
described by Cournanad et al, in 1945.
Congenital heart disease was first studied by Dexter et al in 1947. They went 
further than their predecessors by passing the catheter to the pulmonary artery, and in 
addition they mentioned some observations on the 'oxygen saturation' and the source 
of pulmonary capillary blood obtained from the pulmonary artery 'wedge' position 
(Dexter et al, 1946).
Further developments came rapidly such as retrograde left heart catheterization 
which was first reported by Zimmerman (1950) and Limon-Lason (1950) (Barry and 
Grossman, 1984). The percutaneous technique developed by Seldinger in 1953 was 
soon applied to cardiac catheterization of both the left and right heart chambers. 
Trans-septal catheterization was developed by Cope (1952) and Ross (1959). Selective 
coronary arteriography was developed by Sones in 1959 and modified for 
percutaneous approach by Richetts et al (1962) and Judkins (1967). A balloon-tipped 
flow-guided catheter was developed by Swan and Ganz (1970), which allowed for 
catheterization outside a specialised laboratory.
The therapeutic potentials of cardiac catheterization were reported by Gruntzig 
et al (1979) who introduced the technique of coronary angioplasty. Intracoronary 
administration of thrombolytic agents in patients with acute myocardial infarction was 
introduced by Rentrop et al (1981), Ganz et al (1981) and Markis et al (1981).
2.5.2. Diagnostic and prognostic implications
Cardiac catheterization is usually indicated when there is need to confirm the 
presence of clinically suspected condition like ischaemic heart disease, define 
anatomical location and severity when the clinical assessment suggests that the patient 
may benefit from revascularization procedure. It is also used in some cases for the 
diagnosis of chest pain of uncertain cause where there is confusing evidence regarding 
obstructive coronary artery disease.
Numerous studies have directly and indirectly related the artériographie 
findings to risk assessment in patients with mild and severe coronary disease. Because 
15 to 20 per cent of coronary arteriograms in the average cardiac catheterization 
laboratory reveal normal or mildly diseased vessels despite the presenting symptom of 
chest pain, it is important to know the prognosis of these patients. A review of 4051 
such cases in the CASS registry revealed a 7 year survival rate of 96 per cent among 
patients with normal coronary arteries and 92 per cent among patients with less than 
50 per cent stenosis of one or more coronary segments (Kemp, 1986). Among 1977 
patients followed in the Duke University Cardiovascular Disease Data bank, those with 
normal vessels had an infarct-free 10 year survival rate of 98 per cent (Papanicolaou, 
1986).
| The Coronary Artery Surgery Study (CASS) investigators found that both
I the number of diseased coronary vessels and left ventricular ejection fraction 
I (EF) as measured by cardiac catheterisation were important in risk stratification of 
patients. However, EF was a more imortant predictor of survival. Thus, patients with 
one-vessel disease and an EF of more than 50 per cent had 95 per cent 4 year survival. 
If EF ranged from 35 to 49 per cent, survival was 91 per cent, and if EF was less than 
35 per cent, survival dropped to 74 per cent. In patients with two-vessel disease, 
survival rates at 4 years were 93 per cent, 83 per cent, and 57 per cent, respectively, in
16
these three EF categories. In patients with three-vessel disease, survival rates at 4 
years were 82 percent, 71 percent, and 50 percent, respectively (Mock et.al, 1982).
2.5.3. Digital and quantitative coronary arteriography
Digital coronary arteriography is a video-based, computer assisted method of 
imaging that was developed in the early 1980's. It was once thought that this 
technology might replace cine imaging, but this has not yet happened. The analog 
video signal is passed through an analog-to-digital converter, and this digitised signal is 
stored in computer memory as optical density information for each of hundreds of 
thousands of tiny box like "pixels" that make up each frame of the image. A series of 
images is stored on tape or disk.
The most important advantage of digital coronary arteriography is that the 
images can be manipulated in various ways, either to enhance visualisation or for 
quantitative analysis. Subtraction techniques produce images without overlying 
densities such as bone and improve contrast resolution, allowing better visualisation of 
poorly opacified structures. By subtracting a stored digital image from a fluoroscopic 
image, a "road map" can be obtained. This allows visualisation of the arterial anatomy 
for accurate manipulation of wires or catheters under fluoroscopic control. Motion is 
a major problem when using digital subtraction techniques.
Parameters such as coronary flow reserve, myocardial perfusion, and degree of 
coronary stenosis can be measured using digital images. Quantification of arterial 
stenosis has so far proved to be the most widespread and useful quantitative 
application of digital coronary arteriography (Little et al, 1988). Subjective analyses of 
coronary angiograms have demonstrated significant intra-observer and inter-observer 
variability in grading the degree of coronary artery stenosis (Zir 1976; Detre 1975;
17
DeRouen, 1977). Therefore, several quantitative methods have been developed which 
allow automatic quantitation of arterial stenosis by computer.
2.5.4. Limitations
Coronary angiography is the only way of clearly delineating the anatomical 
lesion in the coronary artery. However, it is an invasive and an expensive procedure. 
The presence of coronary artery disease defined only angiographically does not ensure 
that the patient's symptoms result from ischaemia, nor does it define a population that 
is homogeneous with respect to either myocardial function or prognosis.
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CHAPTER 3
MYOCARDIAL PERFUSION IMAGING
The use of radiotracers for cardiac imaging or Nuclear Cardiology has 
developed as a new discipline from 1970's and since that time, new techniques have 
evolved progressively.
Nuclear Cardiology techniques generally can be divided into two generic 
categories. The first involves the assessment of the cardiac performance. For these 
studies radioactive tracers which remain within the intravascular space during the 
period of study are employed. The second category involves the study of myocardial 
perfusion, viability and metabolism. In this instance, radioactive tracers are employed 
that pass through the myocardial capillary network and are accumulated intracellularly.
3.1. NUCLEAR PHYSICS
3.1.1. Radioactivity
Nuclides may be stable or unstable. Some unstable nuclides can gain stability by 
emitting particles or photons or both. These unstable nuclides are called radionuclides, 
and the process of emitting particles or photons or both is called radioactive 
disintegration, or decay. The radioactive decay process is not affected by physical 
characteristics such as pressure, temperature, or chemical combination. Thus, 
chemicals may be labelled, or tagged, with the radionuclides for nuclear imaging 
without changing the i chemical i behaviour. There are three basic decay modes:
1 Alpha (a) decay
2 Beta (6) decay
3 Gamma (y) decay
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3.2. INSTRUMENTATION
3.2.1. Scintillation Detectors
3.2.1.1. NalfTl) crystal
Certain materials emit a flash of light, or scintillation, when struck by ionising 
radiation. These materials are called scintillators, the radiation detectors made of such 
materials are referred to as scintillation detectors. The most commonly used 
scintillation detector is a sodium iodide crystal (Hofstadter R, 1949). It is one of the 
inorganic scintillators that scintillate because of its crystal lattice characteristics.
3.2.1.2. Photomultiplier tube
As shown in Figure 3.2.1.2, a photomultiplier tube consists of a photocathode 
and a series of metal plates called dynodes, usually 10 to 12 in number. Each dynode 
is maintained at a successively higher positive potential, for example, about 100 V. 
For every 3 to 10 light photons reaching the photocathode, one electron is released, 
which is called the photo-electron. The electrons released from the photocathode are 
accelerated towards the first dynode, resulting in the release of several secondary 
electrons. This electron multiplication process is repeated until the final pulse of 
electrons is collected at the anode with a multiplication factor ofl0& to 10?.
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Figure 3.2.1.2: Block diagram of a photomultiplier tube
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3.2.1.3. Anger scintillation camera
The Anger scintillation camera provides an image of the overall distribution of 
the radioactivity within the body. This instrument is composed of a single large, flat 
sodium iodide (1/4 to 1/2 an inch) crystal that is optically coupled to an array of 
photomultiplier tubes, generally arranged in a hexagonal array. The exact number of 
photomultiplier tubes depends in part on the size of the field of view. With a standard 
field of view camera (250 to 300 mm in diameter) a minimum of 37 photomultiplier 
tubes are required. With the large field of view cameras (400 to 500 mm in diameter) 
there often are 61 or 75 tubes to provide better spatial resolution. Because of the size 
of the heart, detectors less than 300 mm in diameter are frequently used for cardiac 
studies (Zaret, 1986). Gamma rays from the patient interact with the sodium iodide 
crystal and are converted to light (Figure 3.2.1.3). Subsequently, the scintillations are 
translated by the photomultiplier tubes into voltage pulses, which are used to calculate 
the position of the interaction, as well as thes energy , of the gamma emission. The 
intensity of the energy signal is amplified subsequently, such that the output pulse from 
the photomultiplier tube is proportional to the total energy absorbed within the field of 
view of the tube.
3.2.2. Collimators
Photons that pass through the body can now be detected with the gamma 
camera. In photography, a focusing lens is used to project an image onto film; 
however, gamma camera rays cannot be focused. Instead, the use of a collimator 
allows only those gamma rays travelling in the appropriate direction to reach the 
detector. The rest of the gamma rays are absorbed; thus, this is called absorptive 
collimation. Because of this inefficiency (only a small portion of useful photons pass
Collimator
Photo-
Multipliers
Electronics
Display
Patient
"\I/ \ | /  \[/ \]/ \[/~
Lead shield
Pulse height
analyserPosition Computer
Cathode 
ray tube
Figure 3.2.1.3. : Block Diagram of a Gamma Camera
through the collimator and reach the detector), radionuclide images are of poorer 
quality than x-ray images. Collimators are made of heavy metals, usually lead but 
occasionally tungsten.
The purpose of the collimator is to approximate the origin of the photon 
emission within the patient to an analogous location within the crystal. Parallel-hole 
collimators are commonly used in the imaging laboratory (Iskandrian, 1987). 
Collimators are designed for high resolution or high sensitivity. High resolution 
collimation permits better spatial resolution (the ability of the detector source to 
discriminate between neighbouring sources of activity and resolve better various 
components within the field of view) but with a loss of count sensitivity (the number of 
counts the camera may acquire per unit time). Alternatively, a high sensitivity 
collimator would result in maximising the count rate at the expense of spatial 
resolution. The compromise between the two is termed a low energy all-purpose or 
general purpose collimator, which is intermediate with respect to sensitivity and 
resolution.
For imaging with 201ti a general all-purpose parallel-hole collimator is 
preferred to ensure adequate count density. With ^ ^ T c  -labelled imaging agents, the 
count rate is sufficiently high to allow use of high resolution parallel-hole collimator.
3.2.3. Computers
Nuclear cardiology has greatly benefited from the tremendous development in 
the field of digital computers '. Data can now be processed on-line, using
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small dedicated nuclear medicine computers. The computer is used to acquire, display, 
analyse, store and transmit images.
3.2.3.1. Image Acquisition
A matrix of bytes or words is reserved in the computer memory to divide the 
camera field of view into a predetermined grid. Matrix size for acquisition is usually 
128 X 128 for planar myocardial perfusion imaging and 64 X 64 for single photon 
emission computed tomographic image acquisition. The larger the matrix size, the 
better the spatial resolution, but this is accomplished at the expense of the larger 
memory space. Acquisition procedure may be terminated manually or by a 
predetermined count or time.
There are mainly two types of image acquisition: (1) Planar imaging and (2) 
Tomographic imaging.
3.2.3.1.1. Planar Imaging
When : ' 2017 ] images are acquired, the stress images are started within 10
minutes of the injection and delayed or redistribution imaging is performed. 2 to 4 
hours later. Planar images are acquired in 3 or 4 standard views. These include 
Anterior, Left anterior oblique (40°- 45°, some centres acquire both at 40° and at 
70°) and Left lateral views. These views and their relationship to the cardiac anatomy 
and coronary anatomy are shown in Figures 3.2.3.1.1.1 and 3.2.3.1.1.2. The detector
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Figure 3.2.3.1.1.1: Three standard planar views and their relation to cardiac 
anatomy
LAD - Left anterior descending artery 
RCA - Right coronary arteiy
LCx - Left circumflex artery________
I Appearance of the myocardium
Ref: Fogelman et al, 1988
X
O
cti
CD
_cg
CD
c
2
8
o
ii
CD
C4
CD
C<
CO
<N
cn
2
I
RC
A 
- 
Ri
gh
t 
co
ro
na
ry
 
ar
te
ry
 
LC
x 
- 
Le
ft 
cir
cu
mf
lex
 
ar
te
ry
head is angled in such a way that it is close to the patient's chest wall. The heart should
be placed in the centre of the field of view. During delayed imaging the position of the 
I heart is kept as close as possible to that during stress by placing the camera in the same 
| position.
3.2.3.1.2. Tomographic Imaging
In planar radionuclide imaging, two-dimensional projections are obtained of the 
three dimensional distribution of the radiopharmaceutical, within the patient. The 
disadvantages of planar imaging are tissue attenuation, segmental overlap and poor 
regional separation. However, tomographic imaging allows the visualisation of the 
three dimensional distribution of the radiopharmaceutical, within the patient. 
Transmission and emission tomographic techniques were first investigated nearly a 
quarter of a century ago by Oldendorf (1961) and Kuhl et al (1963). However, it has 
only been within the past few years that single photon emission computed tomography 
(SPECT) has emerged as a diagnostic modality of clinical value (Dymond DS et al, 
1979).
Emission computed tomography has developed in two complementary 
directions: 1) detection of annihilation coincidence radiation from positron emitters, 
and 2) detection of gamma radiation from single photon emitters such as 99mpc
Types of SPECT imaging
SPECT imaging may be divided into two forms: (1) longitudinal tomography in 
which the image plane through the patient is parallel to the long axis of the body and 
(2) transaxial tomography in which the image plane is transverse to the long axis of 
the body. Seven-pinhole tomography belongs to the former and rotational tomography 
belongs to the latter. Seven-pinhole tomography has major problems because of
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propagation of perfusion abnormalities into neighbouring sections and reduced image 
contrast as well as spatial resolution (Tamaki, 1981).
Rotational tomography could be divided into circular or elliptical. In the former 
type, the camera as it moves around the patient, describes a circular arc. In the latter, 
the camera movement is combined with simultaneous patient movement by means of a 
specially designed body contour table. The alleged advantage of elliptical tomography 
is to maintain a minimum distance as possible between camera and the patient 
throughout the arc of rotation. Most of the experience with rotation tomography, has 
been acquired from circular tomography. In fact, elliptical tomography may show 
more distortion than circular tomography (Eisner RL et al, 1986).
Quality control
Despite the fact that SPECT imaging is superior to planar cardiac imaging, 
SPECT has many sources of artefacts. To minimise this, strict adherence to quality 
control is essential for SPECT imaging. This should include camera field uniformity, 
assurance of adequacy of data collection, determination of centre of rotation, and 
testing for component failure that may prove to be a source of artefacts, loss of 
resolution, and increasing noise level. Field uniformity is generally checked with a 
99mTC flood source (Iskandrian A et al, 1987); floods are acquired daily for 3 million 
counts to detect day to day performance and weekly for 30 million counts without the 
collimator, for uniformity correction. The original unprocessed 32 images are reviewed 
in a closed loop cine format to determine the presence of attenuation artefact, patient 
motion, and to assure that the entire heart is present within the field of view 
throughout the study.
The acquisition time per image varies from 20 to 60 seconds, the number of 
images vary from 32 to 64, and the acquisition arc may be either 180 or 360 degrees
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around the patient. In the 180 degree tomography, generally 32 images are obtained in 
a arc extending from 45 degree right anterior oblique to 45 degree left posterior 
oblique projections (Eisner RL et al, 1986), each projection being acquired for 40 
seconds. The patient is positioned supine on the imaging table and is instructed to 
avoid any motion during the imaging period, which lasts approximately 22 minutes. 
For 201xi a low-energy, all purpose parallel-hole collimator with a 20% energy 
window centred on the 69 to 83 keV x-ray peaks and a 15% energy window centred 
on the 167 keV peak of ^ O ljl is used (DePasquale E et al, 1988). For 99mxc agent a 
high resolution parallel hole collimator with a 20% energy window centred around 140 
keV is used (Garcia EV et al, 1990). All projections are stored on a 64 X 64 matrix.
Acquisition of 180 Vs 360 degree tomography
Since the myocardium is situated close to the left anterior wall of the thorax, it 
appears that posterior images of the heart will suffer from the effects of attenuation 
and loss of spatial resolution due to lung tissue, vertebral bone, and supporting tissue 
(Tamaki, 1982; Coleman RE, 1982; Go RT, 1985; Eisner RL, 1986). Therefore, the 
posterior images contain much less myocardial information and more noise than the 
anterior images. Tamaki et al (1982) showed that 180 degree rotational tomography 
had a better resolution in phantom studies and in man. In general, the defect was 
better seen with 180 degree rotational tomography and the defect-to-normal count 
ratio was lower with 180 degree than with 360 degree tomography, indicating a better 
lesion contrast with the former. Similar results were reported by Eisner et al (1986). 
In contrast, Go et al (1985) found that 180 degree tomography produces a higher 
incidence of false positive results and image distortion than does 360 degree 
tomography. Longer acquisition time is necessary with 360 degree tomography and 
there is greater attenuation through the body particularly with 201xi due to its low
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energy and poor count statistics that depend on the dose of 201T1. Hence 180 degree 
tomography is the method commonly used.
3.2.3.2. Processing Images
3.2.3.2.1. Planar imaging
Processing is required for better visualisation and quantitation of cardiac 
images; this is accomplished by smoothing and background subtraction.
Smoothing: Images are smoothed using a nine point smoothing system for better 
visualisation of the images.
Background Subtraction : The image contrast of the heart is decreased, owing to non 
target activities contributed by lungs and other soft tissue. It is necessary to subtract 
these non target activities (tissue cross-talk) for better visualisation and quantitation of 
radioactivity originating in the heart.
3.2.3.2.2. SPECT imaging
Individual projection images from tomographic acquisitions have low counts 
and hence noise is present. These individual images will also have background activity. 
To suppress this noise and to decrease the background activity, filtering is performed 
(King MA et al, 1984; Madsen MT et al, 1985). Filtering is performed by convoluting 
each projection by a mathematical function called a 'filter'. The filter has central 
positive components with negative components at the sides, the overall effect being to 
cancel out the blurring. The optimum filter parameters for a particular image will 
depend on the size of the organ of interest, the image matrix size, the amount of noise 
in the image, and the gamma camera response to the size of that image. Designing an
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optimum filter for images always involves a trade off between loss of resolution and 
noise control.
The filtered images are then reconstructed. The image reconstruction 
techniques used in transaxial tomography were introduced by Bracewell (1956). 
Reconstruction involves the projection of the data back along the individual rays 
distributing the activity equally between the pixels along the beam. The process is 
repeated for all the projections and count-rate per pixel is obtained by simple addition 
of the different values. Such a reconstruction method is called 'back projection'. Then, 
transaxial tomograms each of 1 pixel thickness (approximately 6 mm) is generated. 
The tomograms are then aligned to the long axis of the heart and oblique-angle 
tomograms parallel to the long and short axis of the left ventricle are generated from 
the original transaxial tomograms using a co-ordinate transformation with 
commercially available algorithms (Maublant J et al, 1981; Prigent F et al, 1986).
3.2.3.3. Displaying Images
3.2.3.3.1. Planar images
Planar images are displayed on a monitor screen consisting usually of 128 X 
128 matrix size. The modern display monitor has a grey scale allowing up to 256 grey 
shades for different intensity images. A black and white monitor display is commonly 
used; however, a colour monitor may be used with arbitrary colour coding for better 
appreciation. The linear grey scale is normalised to the "hottest pixel" within the heart.
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3.2.3.3.2. SPECT images
Orthogonal tomographic slices (sagittal, frontal and transverse) are oriented 
with respect to the long-axis of the body. Oblique angled tomograms align the 
myocardium either perpendicular or parallel to the long axis of the left ventricle and 
they therefore standardise the configuration of the myocardial slices for all patients, 
regardless of the shape and the position of heart within the chest cavity (Borrelo JA, 
1981). The following tomographic planes are used (Figure 3.2.3.3.2):
1. Short axis tomograms in which serial slices extend from the apex to the base. 
These tomograms resemble the left ventriculogram in the left anterior oblique 
projection and the left anterior oblique view of planar images. This view 
provides a representation of all three vascular territories; the left anterior 
descending artery distribution corresponds to the upper and left quadrants 
(anterior wall and septum, respectively), the right coronary artery to the 
inferior quadrant (inferior wall) the left circumflex artery to the right quadrant 
(lateral wall).
2. Vertical long axis tomograms in which the slices extend from the septum 
toward the lateral wall. These slices resemble the right anterior oblique 
contrast ventriculogram. The segments seen are the anterolateral superiorly 
(left anterior descending coronary artery distribution), the apex and the inferior 
wall (right coronary artery distribution). The base of the left ventricle is seen 
to the left of the images.
3. Horizontal long axis tomograms in which the serial slices extend from the 
inferior wall toward the anterior wall. In this projection, the apex is aligned 
superiorly with septum to the left (left anterior descending distribution) and the
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lateral wall (left circumflex distribution) to the right.. The base of the heart is 
seen at the bottom of the images. The septum in this projection is shorter than 
the lateral wall because the membranous septum adjacent to the base of the 
heart is void of perfusion activity.
3.2.3.4. Image interpretation
3.2.3.4.1. Planar imaging
Exercise and rest/delayed images are displayed side by side for visual 
interpretation. Unprocessed images are reviewed in the beginning and then reported 
either qualitatively or semi-quantitatively by noting the uniformity of tracer distribution 
in the myocardium. Lung uptake of the agent (particularly for 201ti studies) are 
recorded. Any dilatation of left ventricular cavity during stress is noted.
3.2.3.4.2. SPECT imaging
Both grey scale and the colour scale images are used for interpretation. In the 
colour scale, 16 colours from the black (0% activity) to the white (100% activity) are 
used. Each colour change represents a 6% difference in count activity. The images in 
each projection can be viewed as static images or in a closed-loop cine format. Eight 
slices of the initial and the corresponding eight slices of the delayed images are 
displayed simultaneously. It is known that the membranous septum and apex are areas 
of reduced uptake, and that the short axis slices may show non uniformity of wall 
thickness related to papillary muscles (Carver RP, 1985; Clausen M, 1986 ).
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Figure 3.2.3.3.2.: Orientation of tomographic planes to cardiac anatomy
Comparison between rotational tomography and planar imaging
The three dimensional presentation of the images is the first advantage of 
SPECT imaging over planar imaging (Ritchie, 1982; Garcia 1985). SPECT imaging 
provides good demonstration of the location of the abnormality and the extension of 
the abnormality into adjacent segments. For example, it is possible in a patient with 
right coronary artery disease to define the extent of the involvement of the inferior 
wall, and to demonstrate that this abnormality extends to the adjacent septum as well 
as to the adjacent postero-lateral wall. Second, SPECT imaging provides a better 
contrast for detection of perfusion abnormalities because of the lack of overlap and 
superimposition (Iskandrian, 1987). Third, assessment of the extent of coronary 
disease and recognition of individual diseased vessels may be better with SPECT 
imaging than with planar imaging (Table 3.2.3.4.1). Finally, because of the better 
contrast and higher quality of the images, SPECT imaging may be better than the 
planar imaging in the detection of moderate or mild degrees of coronary artery stenosis 
and even in screening asymptomatic individuals at high risk for coronary artery disease 
(Nohara et al, 1984). In the study by Nohara et al, most of the improvement was seen 
in the detection of left circumflex disease which is the most difficult territory to 
evaluate by planar imaging.
To date, no large clinical study has conclusively yet shown a dramatic 
improvement of the tomographic imaging over planar imaging with respect to overall 
diagnosis of coronary artery disease. There may be improved detection of individual 
coronary lesions particularly of the left circumflex territory, mild coronary lesions and 
in the quantitation of the extent of coronary artery disease.
SPECT imaging has certain disadvantages. First, it is susceptible to artefacts 
because of the reconstruction which uses all the individual images assuming that the
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heart is stationary with uniform attenuation in all areas. This is not true if patient 
movement occurs, or if the patient is obese or has large breasts. The recognition of 
such artefacts can usually be made from examination of the raw data set before 
interpretation of the tomograms. Second, because of the reconstruction, high levels of 
quality control must be maintained especially uniformity and centre of rotation to 
exclude technical artefacts. (Figure 3.2.4.3.2). Third, the counts per pixel can be low 
particularly with ^O lji especially in obese patients after redistribution. This may lead 
to poor image quality. However, this can be offset by using longer acquisition times or 
using 99mTc based agent which yield much higher count rates from the higher injected 
dose. Table 3.2.3.4.2 shows the advantages and the disadvantages of SPECT imaging 
when compared to planar myocardial imaging.
! Gated perfusion images using 201x1 are not routinely performed because of low
count rate. However, with the development of the 99mjc based agent this approach 
| has promise.
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Horizontal Long Axis
Short Axis
Vertical Long Axis
Figure 3.2.4.3.2.: SPECT images showing artefacts due to defects in the centre
of rotation
Table 3.2.3.4:1. Comparison between tomographic and 201x1 planar imaging for 
the diagnosis of ischaemic heart disease.
AUTHOR NO. OF PLANAR SPECT
(YEAR) PATIENTS
 Sens% Spec%_____ Sens%_____ Spec%
Tamaki(1981) 28 MI 75 89 96 89
19 No CAD
Maublant (1982) 64 MI 89 93 98 93
15 No CAD
Ritchie (1982) 38 MI 63 93 87 93
15 No CAD
Kirsch (1983) 45 MI 68 78 93 70
40 No MI
Sens - Sensitivity 
Spec - Specificity
MI - Myocardial Infarction 
CAD - Coronary Artery Disease
Table 3.2.S.4.2.: Advantages and the disadvantages of SPECT imaging in
comparison with planar myocardial imaging
Planar SPECT
ADVANTAGES
Resolution Moderate Good
Overlapping of myocardial territories Yes No
Variable image appearance between patients Yes No
Overall Sensitivity for the detection of CAD Good Excellent
Overall Specificity for the detection of CAD Good Good
Sensitivity for detection of individual coronary lesion Moderate Good
COMPARABLE
Ease of Interpretation Good Good
Patient comfort Good Good
DISADVANTAGES
Susceptibility to artefacts 
Need for strict quality control 
Time required for acquisition
Minor More
Yes More so
«20 min « 20-25 min
3.2.3.5. Artefacts during Planar And SPECT Imaging
3.2.3.5.1. Normal variations on planar and SPECT imaging
A well known normal variation on planar perfusion images is that of apical 
thinning. This appears as a narrow slit-like area of diminished activity at the apex.
On short-axis SPECT images slightly less regional activity can be appreciated 
in the septal area, compared to the lateral wall. The basal short-axis slices always show 
a definite septal defect, which represents lack of radiopharmaceutical uptake in the 
membranous septum. Similarly, the septum is shorter than the lateral wall on 
horizontal long-axis views.
3.2.3.5.2. Artefacts common to planar and SPECT imaging
In patients imaged in a supine position, the left hemidiaphragm may attenuate 
radiation emanating from the inferior wall and cause apparent inferior wall defects 
particularly on steep (70°) left anterior oblique (LAO) planar images and also on 
SPECT images when the patient is imaged in the supine position (Johnstone, 1979). 
This artefact can be avoided by turning the patient on the right side.
One of the most disturbing artefacts is that due to breast attenuation. This may 
cause an anterolateral defect on the planar anterior view, an antero-apical defect on the 
planar left lateral view, and variable defects on planar LAO views. Usually breast 
artefacts are fixed, however the breast may be in a different position after exercise and
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at delayed imaging, causing different attenuation artefacts. On planar images, breast 
attenuation defects can be large. However, they often have a typical appearance as if a 
"curtain is drawn" over part of the heart. On SPECT imaging, breast attenuation 
artefacts are often less extensive than on planar imaging and indistinguishable from true 
perfusion defects. Additional planar images may be helpful to be aware of the 
possibility of breast artefacts or grated perfusion images with normal wall thickening 
and motion may give a clue to the presence of an artefact.
A less frequent artefact seen mainly in patients with severe lung disease, is that 
of right ventricular attenuation. This causes decreased uptake in the infero-septal area 
on the anterior view in planar images and slightly diminished activity in the infero- 
septal region on SPECT imaging. In doubtful cases planar imaging with the patient 
sitting up will clarify (Wackers FJ Th, 1988).
Complete left bundle branch block (LBBB) is a source of problems. On planar 
and SPECT 201x1 exercise images, patients with LBBB may have false-positive 
defects (Hirzel HO, 1984, DePuey GE, 1988). Usually they involve the antero-septal 
area. These defects are mostly fixed and occur predominantly in patients with large 
and dilated left ventricles (Hodge J, 1987). In the presence of LBBB, in patients with 
normal heart size, definite defects particularly if they are reversible, are most likely to 
be caused coronary artery disease. In patients with a large left ventricle, it is very 
difficult to differentiate between defects caused by coronary artery disease and by 
LBBB. Regardless of the size of the left ventricle, inferior wall defects in the presence 
of LBBB are always caused by coronary artery disease.
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3.2.3.5.3. Artefacts specific for SPECT Imaging
Artefacts are particularly troublesome and may be difficult to recognise on 
SPECT imaging. If on planar imaging one view is of suboptimal quality, the remaining 
two views may be acceptable for diagnostic interpretation. For SPECT imaging, the 
entire set of 32 images has to be of optimal quality.
During tomographic acquisition, the heart may change from a vertical position 
immediately post-exercise, to a more horizontal position towards the end of image 
acquisition, due to changes in patient's breathing pattern. This is called "upward 
creep" of the heart and my cause artificial inferior wall defects (Friedman J et al, 1989). 
To avoid these artefacts, it has been recommended that image acquisition is not started 
immediately post-exercise, but is delayed for approximately 10 minutes to allow the 
patient to rest.
3.3. METHODS OF STRESSING THE HEART
Exercise myocardial scintigraphy is a useful tool in the evaluation of patients 
with known or suspected ischaemic heart disease. It provides unique, non-invasive, 
functional information which is complementary to electrocardiographic data and to the 
essentially structural information obtained from the more invasive technique of 
coronary angiography.
Various methods are used to stress the heart during myocardial perfusion study 
in patients with suspected or diagnosed ischaemic heart disease. There are mainly two 
types of stressing the heart: (1) Dynamic exercise and (2) Pharmacological stressing. 
Dynamic exercise testing has long been used as a provocative manoeuvre for detecting 
coronary artery disease (Master AM 1950, Wood et al 1931). Dynamic exercise 
consists of rhythmic contractions of alternating extensor and flexor muscles. Dynamic
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exercise may be of isotonic (bicycle and treadmill testing) or isometric (handgrip test) 
types. Dynamic exercise using bicycle or treadmill is the most commonly used method 
of stressing the heart clinically (detailed methodology is described in sections 5.2.33 
and 5.3.3.1).
3.3.1. Pharmacological Stress Testing
Pharmacological stress is used in patients under certain circumstances; like 
those who cannot perform exercise. The sensitivity of exercise 20111 scintigraphy for 
detecting angiographically significant coronary artery disease decreases when achieved 
peak heart rate is less than 85% of the maximum predicted rate (220 minus age) 
(Young D et al, 1987; Iskandrian et al, 1989). A substantial proportion of patients (30 
to 40%) with known or suspected coronary artery disease cannot achieve such high 
levels of physical stress and hence cannot be adequately assessed using dynamic 
exercise (Iskandrian et al, 1981).
To date, three pharmacological agents are commonly used to stress the heart. 
They are dipyridamole, adenosine and dobutamine.
3.3.1.1. Dipyridamole stress testing
Dipyridamole, a phosphodiesterase inhibitor, blocks adenosine degradation and 
increases circulating levels of cyclic adenosine 3'-5' mono-phosphate and adenosine by 
about twofold. Adenosine is a potent endogenous vasodilator, primarily of the 
coronary arterioles and pre-capillaries and increases coronary blood flow velocity four 
to five times baseline in normal coronary arteries (Wilson et al, 1985). Compared with 
exercise, there is greater hyperaemia and less myocardial oxygen demand, so that
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disparity in perfusion to regions supplied by normal versus stenotic coronary arteries is 
comparatively amplified without necessarily causing ischaemia.
Dipyridamole can be administered intravenously and the peak increase in 
coronary blood flow occurs approximately 4 to 5 minutes after completion of the 
intravenous infusion (Wilson RF, 1985). Dipyridamole is infused at 0.57 mg/kg over 4 
minutes while the patient is being monitored. At least 3 minutes after the infusion, 
201ti is injected intravenously and imaging is begun within the next 5 to 15 minutes.
Leppo JA (1989) collated the results of five studies that compared the 
sensitivity and specificity of exercise and dipyridamole 2017] scintigraphy for detecting 
coronary artery disease. The combined sensitivity was 79% for both dipyridamole and 
exercise, with specificity of 95% and 92%, respectively. Several studies have shown 
the prognostic value of dipyridamole 20171 imaging in patients undergoing major 
vascular surgery (Leppo JA, 1984; Boucher CA, 1985).
The disadvantages of dipyridamole stress testing is that it cannot be given in 
patients with asthma or obstructive lung disease and relatively high incidence of minor 
side effects. Ranhosky and Kempthorne-Rawson have recently reported (1990) the 
side effects encountered with intravenous dipyridamole in 3,911 patients studied by 64 
investigators. A total of 10 patients (0.25%) had major adverse events. However, 
46.5% had minor side effects including chest pain (19.7%), headache (12.2%), 
dizziness (11.8%), ST-segment changes (7.5%), premature ventricular contractions 
(5.2%), nausea (4.5%), hypotension (4.6%), flushing (3.4%), and breathlessness 
(2.6%). Four hundred fifty-four patients required parenteral administration of 
aminophylline to treat these side effects. Though the diagnostic sensitivity is relatively 
high for dipyridamole perfusion studies, it has been suggested that the extent of
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perfusion defect using this technique is not as good a prognostic marker as other 
indices of left ventricular function (Rose et al, 1993).
3.3.1.2. Adenosine stress testing
Adenosine is a potent vasodilator, although the exact mechanism is not yet 
clear. Wilson et al (1989) showed that maximal hyperaemia after intravenous 
adenosine administration occurred in approximately 10 seconds, and blood flow 
returned to normal 37 seconds after adenosine was stopped. Coronary blood flow 
velocity increased 4.4 times above baseline at an infusion dosage of 100 pg/kg/min.
In a typical protocol, adenosine is infused under electrocardiographic 
monitoring at a rate of 140 pg/kg/min for 6 minutes and the perfusion agent is injected 
at the end of the third minute.
Verani et al (1990) reported the correlation between 20171 scintigraphy after 
adenosine and coronary angiography in 57 patients. The sensitivity for one-, two-, and 
three-vessel disease, respectively, was 73%, 90% and 100%. Nguyen et al (1990) 
evaluated adenosine in 53 patients with and 7 without coronary artery disease proved 
by coronary angiography. Sensitivity and specificity were found to be 92% and 100%, 
respectively.
Despite the adequate sensitivity and specificity demonstrated in a few clinical 
trials, adenosine suffers similar disadvantages as that of dipyridamole with high 
incidence of side effects. An additional problem is the development of conduction 
abnormalities with adenosine. Verani et al (1990) and Nguyen et al (1990) have 
reported no deaths or myocardial infraction related to adenosine testing. Bateman et al 
(1992) found that the most common serious side effect was transient heart block
occurring in 9%. Ninety-six percent of patients had one or more of the following 
symptoms: chest pain, 50%; headache, 15%; flushing, 53%; shortness of breath, 55% 
and ischaemic electrocardiographic changes, 7%. Severe hypotension or hypertension; 
conduction system abnormalities more advanced than first-degree AV block or sinus 
node disease without a permanent pacemaker; bronchoconstrictive lung disease, 
including asthma are contraindications to the test.
3.3.1.3. Dobutamine stress testing
3.3.1.3.1. Pharmacodynamics of Dobutamine
Dobutamine was synthesised in the early 1970s by Tuttle and Mills (1975). 
Dobutamine, is a synthetic, sympathetic amine with predominant B-receptor effects. 
Dobutamine is a racemic mixture of two isomers. The dextro-form binds to B- 
receptors while the levoform acts on a-receptors. In cardiac muscle, the net result of 
both isomers stimulating a  and Bl-receptors is a potent positive inotropic effect and 
due Bl-receptor stimulation a weak positive chronotropic effect. In the vasculature, 
the a  1-receptor stimulation leads to vasoconstriction and B2-receptor stimulation leads 
to vasodilatation, which partially cancel each other.
Clinically, these various effects are dose dependent and somewhat variable. In 
general, the positive inotropic effect occurs at a lower dose, with progressive 
tachycardia beginning at a slightly higher dose. Clinically, dobutamine acts primarily as 
a positive inotrope, producing a significant increase in dP/dt, stroke volume, and 
cardiac index (Meyer, 1976; Pozen, 1981). Myocardial oxygen consumption increases 
as a result. Due to the balanced effects on vascular smooth muscle as well as reflex 
changes resulting from increased stroke volume, the net impact on blood pressure is
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unpredictable. Mean blood pressure increases in most patients, although the magnitude 
is variable and a small decrease occurs in some. Systemic and pulmonary vascular 
resistance decrease.
3.3.1.3.2. Dobutamine as a cardiac stress agent
In experimental models of regional ischaemia, dobutamine causes an increase in 
coronary blood flow to the normal zone and a variable effect on coronary blood flow 
to the ischaemic area (Tuttle et al, 1977; Vatner et al, 1979 and Warltier et al, 1981). 
Some investigators have demonstrated an increase in perfusion to the ischaemic 
myocardium during dobutamine infusion, although the magnitude of this increase is 
less than in normal areas. Vatner and Baig (1979) studied chronically instrumented 
conscious dogs before and after coronary artery occlusion. They demonstrated a dose- 
dependent decrease in coronary blood flow to the severely ischaemic zone during 
dobutamine infusion. This decline in coronary blood flow was correlated with a 
deterioration in regional systolic function and required the development of tachycardia 
to occur. Carlson et al (1988) found that although, net coronary blood flow was not 
changed by dobutamine, the infusion did cause a shift in perfusion from endocardium 
to epicardium. This redistribution of flow may produce a form of transmural steal to 
account for the subendocardial ischaemia and resultant systolic dysfunction. The 
potential utility of dobutamine as a stress agent was examined by Fung et al (1987). 
These investigators compared the ability of dobutamine and dipyridamole to produce 
regional ischaemia in an open-chested dog model of experimental coronary artery 
narrowing. Dobutamine may have the advantage of actually precipitating myocardial 
ischaemia. Using simultaneous echocardiography and 99nrrc sestamibi imaging Senior 
et al (1994) have demonstrated reduction of wall thickening and reversible ischaemia 
during dobutamine infusion at high doses. Thus, dobutamine may be a better marker of 
prognosis than dipyridamole due to its ability to actually precipitate ischaemia.
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3.3.1.3.3. Performance of the test
Dobutamine is infused at incremental doses of 5 to 40 jig/kg/min at 3-5 minute 
intervals, the dose being increased by 5 gg/kg/min at each stage. Electrocardiographic 
monitoring is carried out continuously while blood pressure, heart rate, and 12-lead 
electrocardiograms are recorded every 3 minutes (Bateman et al, 1992). Perfusion 
agent is injected at the maximally tolerated dosage of dobutamine.
3.3.1.3.4. Safety
Patients with unstable arrhythmia, significant hypotension or hypertension or 
unstable angina should not be studied with dobutamine. In Mason's study (1984) there 
were no complications during dobutamine scintigraphy. Angina occurred in 50% of 
the patients, and significant ST-segment depression in 50%. Senior et al, 1994, have 
shown that dobutamine stress testing is safe. In this study, 60 patients with suspected 
ischaemic heart disease underwent dobutamine stress testing with no serious adverse 
events except in two patients who had self terminating ventricular tachycardia.
3.3.1.3.5. Diagnosis of ischaemic heart disease
Mason et al (1984) reported a sensitivity of 94%, with 15 of 16 coronary 
disease patients detected by the presence of reversible 201^1 perfusion defects during 
dobutamine perfusion scintigraphy. The specificity was 87% with a single false 
positive.
Comparison of the above three pharmacological stress agents is shown in Table
3.3.1 .
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3.4. THALLIUM-201
3.4.1. Kinetics of Thallium-201
There is extensive literature on 201^1 imaging (more than 2,500 published 
papers). Only some of the important articles are discussed below. Thallium is a 
monovalent cationic metal. ^ T l  js cyclotron-produced by bombarding natural 
thallium metal with protons, producing 201pb which decays by electron capture with a 
half-life of 9.4 hours to give 201 j i  201jj decays by emitting mercury x-rays at 69-83 
keV (88 per cent) and gamma rays at 135, 165, and 167 keV (12 per cent). Its 
physical half-life is 73 hours; however, its biological half-life is approximately 58 hours 
(Zaret, 1992). The estimated absorbed radiation dose to the kidney is 0.54 mGy/MBq, 
to the large intestine 0.36 mGy/MBq and the effective dose equivalent to the whole 
body is 0.23 mSv/MBq. Due to the relatively long half-life of ^Oljl, only a small 
amount of dose can be administered. For planar imaging, usually 74 MBq is 
administered, whereas for tomographic imaging 74 to 92 MBq is given. The first pass 
myocardial extraction of 201j} js per cent and is relatively high. The initial 
myocardial accumulation of ^ O ljl is proportional to myocardial blood flow except at 
very high flow rates. Once 201yj jias entered the myocyte, a continuous exchange of 
201ti takes place across the cell membrane. This process involves the Na+, K+- 
ATPase pump. The intrinsic half-life of 201jj within the myocardial cell is 
approximately 85 minutes. However, because of continued cellular re-accumulation of 
2^1x1, the effective half-life of 201xi from the heart is 7.5 hours. Images obtained 
early and late after injection of 201xi5 provide different pathophysiological 
information.
1. Images immediately after injection reflect the flow-dependent initial distribution 
and thus regional myocardial blood flow.
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2. Images taken after a delay of 3 to 4 hours reflects potassium pool and hence 
myocardial viability. However, recent studies have shown that delayed imaging 
alone may underestimate the amount of viable myocardium as discussed later in 
the chapter.
3.4.2. 201^1 imaging
For the diagnosis and evaluation of patients with ischaemic heart disease, 
different modalities of 201T1 imaging are used clinically. These include 201T1 imaging 
during stress, redistribution imaging at 2-4 hours, delayed rest imaging at 18-24 hours, 
imaging after reinjection of 201T1 and rest imaging on a separate day.
3.4.2.1. Stress imaging
The stress 2^ T l  image approximates closely to the regional myocardial blood 
flow at the time of injection. The contrast between normal and abnormal myocardium 
occurs because the coronary blood flow increases five to ten times during exercise, but 
the blood flow to the myocardium supplied by a stenotic vessel hardly increases at all. 
The effect of coronary stenosis on blood flow at rest and exercise is shown in Figure 
3.4.21.
The level of stress, rather than the method used to produce the stress, appears 
to be most important in determining the sensitivity of the 20^Tl exercise test for 
coronary artery disease. Okada et al (1980) found no difference in the sensitivity of 
the 201xi exercise test using treadmill or bicycle exercise (86 percent) in 50 patients 
with coronary artery disease. Hand grip, a form of isometric exercise, was reported to 
produce adequate stress for diagnostic evaluation using 201xi myocardial imaging
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(Bodenheimer, 1979), although this approach is not generally recommended in patients 
capable of dynamic exercise.
3.4.2.2. Redistribution imaging
Early experiences with exercise myocardial 201ji imaging utilised separate 
injections of the radionuclide during exercise and at rest. 201x 1 was injected at peak 
exercise; the patient was then imaged at the termination of exercise. If these initial 
images were abnormal demonstrating a defect, the patient returned at least 72 hours 
later and was reinjected with 201xi and re-imaged. If the 201xi defect persisted on 
repeat images, then myocardial scar was said to be present. If 201xi perfusion defect 
was no longer present on repeat images, then transient exercise induced myocardial 
ischaemia was said to be present.
In 1977, Pohost et al reported the disappearance of 201xi myocardial defects 
present on initial images in experimental dogs over 2 hour period after transient 
ischaemia. This phenomenon was referred to as 201xi redistribution. 201xi 
redistribution on serial images after a single dose of 201xi given at peak exercise was 
subsequently observed in patients with coronary artery disease. When this technique 
was used, defects observed on images immediately after exercise that filled in on the 
delayed images were believed to represent ischaemia, whereas initial defects that 
persisted were believed to represent scarring. Pohost et al (1977) found in the animal 
laboratory as well as clinically that most redistribution occurs within 3 to 4 hours.
The normalisation of the perfusion defect has been ascribed (1) to disparate 
rates of washout from a normal myocardium and an ischaemic myocardium (Gewirtz et 
al 1978; Schwartz et al 1978: Beller et al 1980; Pohost et al, 1981; Leppo et al 
1981; Nishiyama et al 1982; Okada et al 1982) and (2) to continuous 201x1
uptake ("wash-in"). In the first explanation, because the normal myocardium has a 
higher initial uptake, its subsequent 201 j j  clearance is also higher. On the other 
hand, because the ischaemic myocardium has less initial 201x 1 uptake, its later 
clearance is less (based on pressure gradients across cellular membranes). Two to 4 
hours after initial injection, the disparity in the clearance between the two areas would 
result in similar 201xi concentration in the normal and ischaemic myocardium and, 
hence, in the disappearance of the initial defects.
The ischaemic myocardium may actually continue to extract 201xi from the 
intravascular compartment at a time when the normal myocardium is undergoing a 
201t1 clearance process. The continued uptake in the ischaemic myocardium is 
possible if the gradient between the intravascular and the intracellular compartments 
favours inward motion of the 201T1 into intracellular compartment. This is likely to 
occur if the initial 201xi concentration in the ischaemic myocardium is very low.
In summary, the kinetics of 201xi indicate initial distribution of 201xi in 
proportion to the regional blood flow and a high extraction efficiency followed by 
clearance from the myocardium. The movement of 201T1 into the intracellular spaces 
soon after intravenous injection and subsequently out into the intravascular space can 
be ascribed to changing gradients: the 201T1 concentration is higher in the blood 
initially and much lower subsequently than is the intracellular concentration. The rate 
of clearance is different in ischaemic and normal areas. The process of redistribution 
involves disparate washout rates from normal and ischaemia areas, as well as an actual 
increase in 201T1 concentration in ischaemic areas when flow is re-established (Figure 
3.4.2.2). Myocardial necrosis, on the other hand, is manifested by initial defects that do 
not show any evidence of redistribution.
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3.4.2.3. Delaved imaging
Verani et al observed continued 201x1 redistribution for up to 24 hours and 
described the finding in 1979. Following this finding, Blood et al in 1981 observed 
that a defect was seen in 3 to 6 hour redistribution image in a patient without previous 
myocardial infarction, while Leppo et al(1979) observed the same phenomenon 
without an epicardial scar. Pohost et al (1979) and Clitsakis et al (1981) observed the 
persistence of the defect at 3 to 4 hour images in the presence of normal wall motion. 
Gutman et al in 1983 described that in their study even segments demonstrating late 
redistribution are potentially viable and late 201 j j  imaging has been utilised by some 
people to identify reversible ischaemic myocardium (Cloninger et al, 1988). Kiat et al 
(1988) found in their study that 61% of 4 hour non-reversible defects were reversible 
by late redistribution imaging. Because 95% of these late reversible defects 
subsequently improved after intervention, late redistribution imaging in those patients 
effectively reclassified 57% of myocardial segments that would otherwise had been 
categorised as infarcted. However, although biologic elimination o f 201x1 is minimal 
(10 percent excreted in 10 days) and physical decay of 201xi is about 22 percent of the 
dose in 24 hours, images taken 24 hours after the 2Olqq injection are usually 
technically inadequate (Okada et al, 1980) with low target to background ratios 
(Ohtani et al, 1990).
3.4.2.4. 201xi re-iniection
Since the extent of a persistent defect on 3-4 hour delayed images occasionally 
decrease on 24-hour delayed images, over the last few years re-injection of small 
amount of 201xi has been proposed to identify ischaemic myocardium.
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Dilsizian (1990) described that re-injection of 201'pj would detect ischaemic 
but viable myocardium. They studied 100 patients with coronary artery disease using 
single photon emission computed tomographic 20i l l  imaging. The protocol employed 
was that patients received 2 mCi of 201T1 intravenously during exercise, with 
acquisition of immediate post-exercise and 3-4 hour delayed images. Then, after 
obtaining the redistribution images, a second dose of 1 mCi of 201T1 was injected at 
rest. Thirty-three percent of the abnormal segments in these patients showed persistent 
defects on the 3-4 hour redistribution images. Approximately one-half of these 
persistent 2^ T l  defects demonstrated improved or normal 2^ T l  uptake after 
reinjection of the second ^^^Tl dose. In contrast, among patients undergoing 
angioplasty with persistent defects identified on reinjection 201T1 imaging, all had 
abnormal 2^ T l  uptake and abnormal regional wall motion after dilatation. These 
authors concluded that reinjection of 2^iTl at rest after acquisition of redistribution 
images significantly enhances the detection of viable myocardium.
Tamaki et al (1990) demonstrated that about half of the segments showing 
redistribution also had severe coronary stenosis (>90%) and the new fill-in of the 
tracer after the re-injection was more often observed in the segments supplied by 
severe coronary stenosis.
Bonow et al in 1991 showed in their study that re-injection identified 
significantly higher number of myocardial segments which were viable compared to 
redistribution. In this study, 38% of 432 myocardial segments in 16 patients with 
coronary artery disease demonstrated persistent 201T1 defects on redistribution images 
before reinjection. Floro-deoxy glucose uptake suggesting preserved metabolic 
integrity was present in 51% of segments showing marked persistent defects. In these 
defects, an identical number of segments (51%) demonstrated enhanced 201T1 uptake 
after reinjection. Detection of myocardial viability by the two techniques were
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concordant in 88% of segments in these severe persistent defects. The conclusion from 
this study was that the 201ti reinjection protocol was as predictive as Fluoro-deoxy 
glucose imaging with positron emission tomography for detection of viable 
myocardium in patients with chronic coronary artery disease and left ventricular 
dysfunction.
3.4.2.5. 20^Tl resting study
Resting 201ti scintigraphy has been successfully employed in patients with 
severe chronic stable angina or unstable angina to assess myocardial viability prior to 
and following revascularization (Gewirtz et al 1979). Berger et al (1979) reported that 
80% of patients showing initial resting defects with delayed "rest redistribution" 
preoperatively demonstrated a 5% or greater increase in left ventricular ejection 
fraction post-operatively. In that study, only 22% of patients with persistent defects 
preoperatively on rest imaging showed a comparable improvement. Ragosta et al 
(1990) reported that resting 201ti scintigraphy can assist in the selection of patients 
who might benefit from revascularization surgery who have severe depression of left 
ventricular systolic function. Again in this study, approximately two-thirds of 
akinetic/dyskinetic segments showed some preservation of myocardial viability by 
resting 201j i  imaging.
Basu et al (1993) have shown in 44 patients following myocardial infarction, 
that rest injection of 20171 following nitro-glycerine, identifies significantly higher 
number of patients with myocardial viability and also greater amount of myocardial 
viability in most patients, compared to 4 hour redistribution imaging.
3.4.3. Interpretation of studies
3.4.3.1. Qualitative Analysis
Planar myocardial images are interpreted qualitatively by visual analysis, 
although quantitative approaches have been suggested aided by computer 
quantification. Image interpretation can be described as follows:
(i) NORMAL: Homogeneous uptake of the radiopharmaceutical throughout
the myocardium.
(ii) DEFECT: A localised myocardial area with a relative decrease in
radiotracer uptake. Defects may vary in intensity, from slightly 
reduced activity to almost total absence of activity.
(iii) REVERSIBLE DEFECT : A defect that is present on the initial stress
images and no longer present, or present to a lesser degree, on 
the resting or delayed images. This pattern indicates myocardial 
ischaemia. The change over time is called 'redistribution'.
(iv) FIXED DEFECT: A defect that is unchanged and present on both exercise
and rest (delayed) images. This pattern generally indicates 
infarction and scar tissue.
(v) REVERSE REDISTRIBUTION: The initial images are either normal or
show a defect, whereas the delayed images show a more severe 
or the appearance of a new defect (Dudzic et al 1994). This 
pattern is frequently observed in patients who have undergone
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thrombolytic therapy or percutaneous coronary angioplasty. 
This phenomenon is thought to be caused by initial excess of 
tracer uptake in a reperfused area with a mixture of scar tissue 
and viable myocytes. Initial accumulation is thus followed by 
rapid clearance from scar tissue. It is believed to represent 
successful thrombolysis with patent infarct related artery 
(Sridhara et al, 1994, b).
3.4.3.2. Semi-quantitative analysis
201T1 images can be interpreted semi-quantitatively using a polar scoring 
system. This type of interpretation has been used by many studies in the past (Jain et al 
1990). For visual interpretation the planar images can be transformed into a polar 
map with 18 segments. The apex is represented in the centre and septum to the left, 
lateral wall to the right, the anterior and the inferior walls to above and below 
respectively.! (Figure 5.2.3.6.1)
3.4.3.3. Quantitative analysis
Recently, quantitative analysis is being used in some centres since 
reproducibility may vary in some centres carrying out qualitative reporting by many 
individuals, and the use of qualitative 201 images is sometimes difficult and requires 
considerable expertise. It is said that due to the limitations of subjective visual analysis 
0f  20171 myocardial kinetics important potentially available diagnostic information is 
not used. Kinetics of 201x1 is markedly different in ischaemic myocardium compared 
to normal myocardium or scar tissue. 2017] activity gradually decreases (washout) 
with time after termination of exercise. In contrast, exercise-induced ischaemic 
myocardium is characterised by accumulation, no change, or abnormally slow washout
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of 20I 'l l  These differences which cannot be readily appreciated by visual analysis, may 
demonstrate abnormal kinetics.
I In early 1980's an objective computerised method for quantitative analysis 
|of 201t i  kinetics was developed ( Watson et al, 1981; Garcia et al, 1981 ). Slow 
myocardial washout in the absence of a persistent defect has been shown to correlate 
highly with segmental myocardial hypoperfusion (Maddahi et al, 1981; Massie et al,
1983). Diffuse slow washout from all myocardial regions has been defined as an 
indicator of extensive coronary artery disease (Bateman et al, 1984). However, 
diffuse slow washout has occasionally been observed in normal persons and in the 
contra lateral regions supplied by a normal coronary artery in patients with a single or 
double vessel disease. This false positive occurrence of slow washout decreases the 
specificity of washout rate analysis in the detection of myocardial ischaemia. 
However, reliable quantitation of planar 20 I j]  linages requires rigorous quality control 
and scrupulous attention to technical details. Using quantitative analysis, the 
prediction of significant disease in a particular vessel was shown to be better for the 
left anterior descending artery, but worse for the left and right circumflex arteries 
(Wackers et al, 1985). Kaul et al (1986) determined the quantitative 201ft imaging 
variables that optimise the detection of coronary artery disease in 325 patients who 
underwent stress 201 f t  imaging and cardiac catheterization. Initial 201fi Uptake was 
the most sensitive but least specific for the detection of coronary artery disease, 
whereas redistribution was the least sensitive and most specific. Using stepwise logistic 
regression analysis, the best correlate of coronary artery disease was initial 201 f t  
uptake.
51
However, in experienced hands qualitative reporting is probably just as good 
for diagnostic purposes.
3.4.3.4. 2Q1T1 Lung Uptake
Normally no, or very little, 20 I j]  js noted in the lung fields on post-exercise 
images. Increased lung uptake can be quantitated as lung to heart ratio(normal <0.5). 
This abnormality indicates exercise-induced left ventricular dysfunction (Boucher et al 
1980).
The finding of increased 2^ T l  uptake has been observed in clinical studies and 
correlates with elevation of left ventricular filling pressure. The extraction fraction of 
201t1 by the lungs is approximately 0.9 percent and is increased by increasing the 
mean left atrial pressure. The increased lung uptake must represent increased 201 
accumulation in the lung parenchyma but not 201j i  accumulation in the intravascular 
compartment. This can be discerned easily in clinical studies, because when increased 
lung activity is evident the left ventricular cavity represents the intravascular 
compartment, increased activity in the lung represents an extravascular accumulation 
of 201 xi (Kushner et al 1981; Lahiri et al 1982; Brown et al 1984; Okada et al 1984; 
Iskandrian et al 1985). The anterior projection is best for examining the increased lung 
uptake, and the intensity of lung uptake is described either subjectively or objectively.
Increased lung 201xi uptake during exercise was reported to be related to the 
severity of coronary artery disease and the number of myocardial perfusion defects 
(Boucher et al, 1980). In the same group of patients, this was associated with a lower 
resting ejection fraction and a greater prevalence of previous myocardial infarction. In 
experimental animals and in patients with coronary artery disease, increased lung 201xi 
concentration was shown to be due to a transient absolute uptake immediately after
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maximal exercise (Bingham et al, 1980) which was a consequence of left ventricular 
failure (Kusher et al, 1981; Lahiri et al, 1984).
Gibson et al (1982) investigated 61 patients before hospital discharge after 
acute myocardial infarction. Increased 20171 concentration in the lungs after sub- 
maximal exercise testing was found to be related to a greater prevalence of prior 
infarction, less global cardiac reserve as assessed by the four level New York Heart 
Association classification, more advanced Killip class in the coronary care unit, failure 
to achieve the target heart rate, a greater prevalence of exercise-induced ST-segment 
depression, a greater number of myocardial perfusion defects, a lower resting ejection 
fraction and a greater number of asynergic left ventricular segments. In the post­
infarction patient, increased 20 l j ]  iung uptake appears to be a marker of severe and 
functionally more important coronary artery disease associated with the left ventricular 
dysfunction (Gibson et al, 1982; Levy et al, 1983).
In patients with single-vessel coronary artery disease, increased 20171 lung 
uptake was shown to be related to the severity of stenosis of the coronary artery and 
the extent of ischaemia (Liu et al, 1985). After percutaneous transluminal coronary 
angioplasty, 20171 iUng uptake reverted to normal in patients who showed increased 
uptake.
Al-Khawaja et al (1988) evaluated the significance of exercise induced lung 
uptake of 20171 in 101 patients with recent myocardial infarction. The lung uptake of 
201t1 was increased in patients with significant left ventricular dysfunction. The 
sensitivity and specificity of lung 20171 uptake for detecting multivessel coronary 
disease was 70% and 72% respectively.
Jain et al (1990) studied the importance of increased uptake of 201X1 at rest in 
96 patients after acute myocardial infarction. They noted in their study that congestive 
heart failure was the most important determinant and 20171 defect score to be the most 
important correlate of abnormal lung 20171 uptake.
3.4.3.5. Transient Left Ventricular Dilatation
Occasionally, the left ventricle is noted to be larger following exercise than on 
the rest or delayed image. This pattern indicates exercise-induced left ventricular 
dysfunction (Weiss et al 1987).
3.4.4. Clinical Experience With 201 tj imaging
3.4.4.1. Sensitivity of 20171 Imaging
Okada et al (1980) summarised most of the reported experience with exercise 
myocardial 20171 imaging for the detection of coronary artery disease until 1980 
(Table 3.4.4.1). Some studies employed the two dose, exercise-rest 20171 technique 
and others used the single dose 20171 approach. However, because Blood et al (1980). 
demonstrated that both techniques differentiate between ischaemia and scar, and 
because sensitivity and specificity are related only to initial images after exercise (that 
is, the appearance of an initial defect), the results are combined in Table 3.4.4.1. In 
1,817 patients, the overall sensitivity and specificity of the 20171 exercise test for 
coronary disease were 82 and 91 percent, respectively. When studies from Table
3.4.4.1 that did not report exercise electrocardiographic data were excluded, the 20171 
exercise test had a sensitivity of 82% and a specificity of 90%. The overall sensitivity
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and specificity of the electrocardiographic exercise test for coronary artery disease 
were 60 and 81 percent, respectively. In most studies, diagnostic Q waves on the 
electrocardiogram at rest were considered a sufficient criterion for coronary artery 
disease. Using chi square analysis, the 20171 exercise test was significantly more 
sensitive (P <0.0001) and specific (P <0.05) for coronary artery disease than the 
electrocardiographic exercise test. The improved sensitivity of 20171 exercise imaging 
over electrocardiographic exercise testing is due, in part, to the larger number of 
patients with non-diagnostic or inconclusive electrocardiographic exercise tests due to 
either baseline electrocardiographic changes or inability to achieve 85 percent 
predicted maximal heart rate, as described by Okada et al (1978), Bailey et al (1977) 
and McCarthy et al (1979). The accuracy of the 20171 exercise test, although also 
dependent on the level of exercise achieved (McLaughlin et al, 1976), does not appear 
to be as critically related to this factor as the electrocardiographic exercise test.
In a series of 227 patients, Pohost et al (1979) described that in patients 
admitted for coronary angiography, there was no significant difference in sensitivity of 
20171 imaging for those patients who achieved 85 percent predicted maximal heart 
rate and those patients who did not. The 20171 exercise study has been found 
particularly useful in patients with equivocal electrocardiographic tests because of 
hyperventilation, drug effect, ventricular hypertrophy, intraventricular conduction 
delay and bundle branch block, pre-excitation syndrome or previous myocardial 
infarction (Botvinick et al, 1978). The sensitivity of the 20171 exercise test for 
coronary artery disease increases with the increasing extent of diseased vessels and 
increasing severity of stenosis (Dash et al, 1979, Massie et al 1979 and Leppo et al
1979). Dash et al (1979) found that the sensitivity is also high for left main coronary 
artery disease, but the specificity is low. Sensitivity decreases in the presence of 
coronary collateral vessels (Rigo et al, 1979) and in patients taking propranolol with a 
negative electrocardiographic exercise test (Pohost et al, 1979).
Table 3.4.4.1: Some of the published data until 1980 showing the sensitivity and 
specificity o f^O ljl imaging.
Year Investigator Patients________ 20171______________ ECG
(n) Sens Spec Sens Spec
1976 Klein 144 59/73 69/71 61/73 63/71
1976 Peterson 25 16/17 4/8 12/17 5/8
1977 Bailey 83 46/63 20/20 26/63 20/20
1977 Ritchie 101 58/76 23/25 50/76 21/25
1977 Lenaers 70 52/55 14/15 - -
1977 Rosenblatt 18 14/15 3/3 6/8 2/2
1978 Carrilo 55 34/39 16/16 21/39 12/16
1978 Verani 82 38/48 33/34 42/48 21/34
1978 Turner 64 23/34 29/30 25/34 23/30
1978 Ritchie 190 115/148 37/42 62/148 37/42
1978 Bodenheimer 45 21/32 13/13 15/32 -
1978 Johnstone 33 18/26 7/7 - -
1979 McCarthy 128 81/95 26/33 61/95 30/33
1979 Pohost 209 140/161 36/48 103/161 37/48
1979 Dash 96 66/81 15/15 30/81 12/15
1979 Verani 58 38/46 12/12 30/46 -
1979 Meller 55 23/28 23/27 - 14/24
1979 Okada 49 27/33 9/10 23/27 3/4
1979 Hecht 56 46/46 8/10 32/46 7/10
1979 Caldwell 39 30/33 6/6 - -
1979 Borer 53 35/43 9/10 - -
1979 Verani 38 17/21 17/17 - -
1979 Kirshenbaum 61 43/50 10/11 32/50 11/11
Total 1,817 1,071/ 461/506 631/ 318/393
1,305 1,044
Overall 82 % 91 % 60 % 81 %
ECG - Electrocardiogram
Sens - Sensitivity
Spec - Specificity
3.4.4.2. Specificity of 201%) Imaging
The improved specificity of the 20171 exercise test over the 
electorcardiographic test in coronary artery disease is due, in part, to the many causes 
for false positive electrocardiographic exercise tests, some of which were mentioned 
previously. It has been shown that 20171 exercise test was quite specific in patients 
without a history of typical anginal chest pain and with a positive electrocardiographic 
exercise test to predict the presence or absence of coronary artery disease (Okada et al,
1980). Mews et al (1978) demonstrated that the specificity of the 20171 exercise test is 
quite low when patients with isolated sub critical stenosis (30 to 45 percent diameter 
narrowing) are included in the control group. Fifty percent of these patients have 
positive 20171 exercise images in a distribution appropriate for the involved coronary 
artery. Although these sub critical lesions have conventionally been assumed to have 
little clinical importance, it may be inappropriate to consider these positive images as 
false positive results, because inequalities in coronary perfusion were described in 
association with such lesions using xenon-133 washout techniques (Cannon et al 1975, 
Klocke FJ in 1976). Furthermore, the length and number of "sub critical" lesions can 
contribute to their significance. It is also true that the reliability of the coronary 
arteriogram in differentiating truly sub critical (less than 50 percent lesions) from 
critical lesions is probably not great, because the angiographic projection and the 
significance of a lesion at rest may change with stress. The inter-observer agreement 
on the significance of a lesion in this borderline range is small. Because of the 
uncertainty in interpreting the degree of coronary arterial narrowing angiographically, 
20171 stress test may indeed be a means of clarifying the haemodynamic significance of 
a coronary lesion. The diagnostic accuracy of 20171 imaging can be enhanced with 
patient selection. For example, the use of young asymptomatic volunteers as a control 
group might lead to a high specificity because the incidence of even sub critical disease
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is small and their ability to exercise large. Further, because sensitivity is related to the 
extent of disease, a group with a large incidence of three vessel disease would show a 
higher sensitivity than one with single vessel disease.
3.4.4.3. 2Q1T1 Imaging And Prognosis
The detection of coronary artery disease is only one aspect of the clinical value 
of 201T1 stress imaging. An important additional feature is the ability to determine 
prognosis. The first critical finding on 2OI71 images is the presence or absence of a 
reversible defect i.e., ischaemia (Kaul et al 1986). The diagnostic accuracy of 201T1 
images has been discussed by |Kaul et al (1989). Patients with evidence of transient 
ischaemia have a higher incidence of future cardiac events than patients with fixed 
defects. In patients without prior myocardial infarction, semi-quantitative assessment 
of the number of reversible 2^ T l  defects or quantitative measurement of the extent, 
severity, and degree of reversibility of 2^ T l  defects correlates with the occurrence of 
subsequent cardiac events (Brown et al, 1983; Abraham et al, 1986; Ladenheim et al, 
1986; Kaul et al, 1988). Gibson et al (1983) evaluated patients after uncomplicated 
myocardial infarction by quantitative 20171 stress imaging. Patients with a fixed single 
20171 stress defect and without washout abnormalities (i.e., with normal clearance rate 
0f  2OI71 from the heart) at hospital discharge had only a 6 per cent cardiac event rate 
(death, recurrent infarction, or unstable angina). Patients who had high-risk findings 
on predischarge 20171 stress images (multiple defects in more than one vascular 
region, abnormal washout, or increased lung uptake) had a 51 per cent chance of 
cardiac event. Several other investigators have reported similar results on the 
prognostic value of 20171 stress imaging after myocardial infarction using either 
physical (Koss et al, 1987; Gill et al, 1987) or pharmacological stress (Leppo et al,
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1984). Transient post-exercise dilatation of the left ventricle is another scintigraphic 
marker of poor prognosis. Brown et al (1983) reported that patients with recurrent 
chest pain after myocardial infarction frequently had ischaemia within the infarction 
region (75 per cent of patients), whereas only 25 per cent of patients had ischaemia at 
a distance. Patients with evidence of defect reversibility had a substantially poorer 
prognosis and higher incidence of revascularization procedures than did patients who 
did not have demonstrable reversibility.
On the other hand, in 1985 Wackers et al, Pamelia et al and Wahl et al found 
that the presence of normal 201x 1 stress images by quantitative analysis, even when 
coronary artery stenosis is angiographically documented, indicates favourable 
prognosis with low cardiac event rate. A number of studies have shown that a yearly 
non-fatal myocardial infarction rate of 0.6 per cent per year and a mortality rate of 0.5 
per cent per year in patients with normal quantitative 201-pi stress tests.
These data on abnormal and normal ^ T l  stress tests indicate that the extent 
of myocardial perfusion defects, or the lack thereof, provide significant functional or 
prognostic information that can surpass the anatomical information obtained from 
coronary angiograms. Optimally, both techniques are used together.
3.4.4.4. Other clinical uses of 201j j  imaging
An important clinical application of 201T1 imaging is in evaluating patients with 
coronary disease who are considered for major non-cardiac surgery. Boucher et al 
(1985) showed that patients with reversible 201ji defects after dipyridamole infusion 
had a high incidence of peri-operative cardiac events. Levinson et al in 1990, 
Iskandrian et al in 1990 and Lette et al in 1990 observed that the patients with
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extensive defect reversibility and pulmonary 201 j j  uptake were at higher risk than 
those with only small abnormalities.
201xi imaging is also useful in evaluating patients after percutaneous 
angioplasty. Hirzel (1981) showed that exercise 201xi scintigraphy is an excellent 
method to document the changes in myocardial perfusion after dilatation. Similar 
results were obtained by others (Scholl et al 1982; Okada et al 1985; Kinbris et al
1981).
201x1 imaging is also useful in patients undergoing CABG to evaluate changes 
in the myocardial function, for the detection of peri-operative infarction and for the 
prediction of changes in the regional and global left ventricular function. In a study by 
Rozanski (1981) 201xi redistribution pattern was highly predictive of the pattern of 
postoperative asynergy. Gibson et al (1983) found that preoperative quantitative 201xi 
scintigraphy appears useful in predicting response to revascularisation.
3.5 MYOCARDIAL PERFUSION IMAGING WITH 99mXc LABELLED 
COMPOUNDS
3.5.1 Introduction
The clinical use of 201xi myocardial perfusion imaging has been established. 
Although 201xi has good physiologic characteristics for perfusion imaging and 
viability, it has some disadvantages. Its low energy (68-80 keV) is sub-optimal for 
imaging by a gamma camera; it has a relatively long, half-life (73 hours) and high 
absorbed dose which results in sub-optimal radiation dosimetry (Deutsch et al, 1979). 
Due to its long half-life the amount of 201xi that can be injected to a patient is limited
59
and this results in a images of lesser resolution due to lower counts per pixel. Hence 
the resolution of small features is worse Additionally, it has been noted recently that ; 
current 4 hour redistribution images using 201xi may underestimate the amount of 
ischaemia in the myocardium, thus requiring an additional injection of 201x 1 at rest 
(Brown et al, 1991), with consequent increase in the radiation exposure to the patient. 
Furthermore, the availability of 201x1 is difficult, particularly for out of the working 
hours imaging studies, and 201xi is expensive.
To circumvent these limitations, there have been attempts since late 70's to 
develop an imaging agent labelled with 99mTc, as 99mxc was found to have ideal 
physical properties for gamma camera imaging with a high photon flux, a shorter half- 
life (6 hours) and ready availability (Deutsch et al, 1979). Nearly 85% of all diagnostic 
procedures in nuclear medicine are performed with 99mxc (Keyes JW Jr, 1978).
Almost sixteen years ago Strauss et al (1977) suggested that the use of a 
99mxc based myocardial perfusion agent would improve image quality as a result of a 
two fold increase in resolution and upto four fold increase in the administered dose, 
compared to 201 Tl. To date 3 different categories of 99mxc labelled agents have 
been developed for myocardial perfusion imaging: (i) cationic isonitriles, (ii) boronic 
acid adducts and (iii) diphosphines.
The search for 99mxc based cationic isonitrile compounds met with success in 
1982, when the group at the Peter Bent Brigham Hospital, USA announced the 
development of 99mxc isonitriles (Okada et al, 1988). In the subsequent few years 
three 99mxc labelled isonitrile compounds were developed and applied clinically; they 
were 99mxc-t-butyl isonitrile (TBI), 99mxc carboxy isopropyl isonitrile (CPI) and 
99mxc_methoxy isobutyl isonitrile. The first, TBI, was suboptimal for myocardial 
imaging due to its prominent hepatic and pulmonary uptake (Holman 1984, Holman et 
al 1986, Sia et al 1986, McKusick et al 1986). Persistent liver uptake of TBI
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frequently obscured defects in the inferior left ventricular wall. In addition to further 
obscuring myocardial defects, pulmonary TBI behaved as a reservoir of the tracer. 
With the subsequent washout of the tracer from the lungs, a significant amount could 
be delivered to the myocardium and alter the resulting perfusion pattern from that 
corresponding to the initial injection and uptake of TBI. The second tracer, 99mxc 
carboxyisopropyl isonitrile (CPI), demonstrated progressive hepatic accumulation over 
time despite excellent myocardial uptake and also relatively rapid washout from the 
myocardium (McKusick et al 1986, Holman 1987). The third, 99m'pc methoxyisobutyl 
isonitrile, known generically as 99mTc sestamibi, has emerged as the isonitrile with the 
most favourable biologic characteristics for myocardial perfusion imaging (Okada et al 
1988) and provided good quality images (Sinusas et al, 1989). Unlike TBI and CPI, 
99m jc sestamibi has less hepatic uptake with hepatobiliary excretion and minimal lung 
uptake (Wackers et al 1989).
In 1991, 99mye sestamibi was approved for clinical use Berman DS, 1991). 
Preparation of 99mYc sestamibi requires heating which is a distinct disadvantage 
(Gibbons RJ, 1991). Although it provides good quality images, there is significant 
hepatic radiotracer uptake, which is cleared rather slowly over time (Gibbons RJ, 
1991). This delay allows imaging only after 1-2 hours following an injection which 
significantly increases the time patient has to spend in the imaging laboratory. Since 
two separate injections are required for rest and stress images, two day protocol using 
one injection each day is proposed. From the logistic standpoint this is inconvenient for 
the majority of referred patients (Jain et al, 1993).
To overcome this difficulty different strategies have been proposed for the 
same day imaging like initial rest imaging with a smaller dose of 99mq^ sestamibi 
followed by a larger dose at stress (Taillefer et al, 1989); computer subtraction 
techniques (Stirner et al, 1988) and dual imaging technique where 201^1 is injected at
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rest initially followed by exercise imaging using 99mTc sestamibi (Berman et al, 1992). 
However, these methods do not seem to be an ideal, widely applicable approach.
The BATO compounds, which form the other class of 99m'j'c myocardial 
perfusion agents, are neutral lipophilic complexes of boronic acid. The agent from this 
class that has been developed commercially is 99m'pc teboroxime (Seldin, 1989; 
Meerdink et al 1987). Unlike 99m'pc sestamibi, which is less efficiently extracted than 
201ti, 99m jc teboroxime is extracted with greater efficiency than 201t 1 throughout a 
broad range of flow rates (Meerdink et al 1987). Myocardial uptake of 99m'pc 
teboroxime is rapid, with excellent myocardial visualisation at 2 minutes after injection. 
The myocardial clearance, however, is also rapid with bi-exponential, clearance half- 
times of 2 minutes (68%) and 78 minutes (32%) (Iskandrian et al, 1991). These 
properties necessitate the completion of imaging within 15 to 20 minutes from the time 
of injection. Since tomographic acquisition with the standard single detector cameras 
typically requires prolonged imaging times, this agent is not ideally suited for single 
photon emission tomographic imaging. Another limitation is the persistent hepatic 
accumulation of the tracer; its liver residence half-time is approximately 1.5 hours. This 
hepatic uptake occasionally interferes with inferior wall visualisation.
Hence, neither 99mq^ sestamibi nor 99m jc teboroxime are ideal myocardial 
perfusion imaging agents. The third category of 99m jc labelled myocardial perfusion 
imaging agents are diphosphines. 99mq^ tetrofosmin belongs to this group and is a 
lipophilic, cationic, diphosphine.
Early documented case of a 99mrpc cation as a myocardial perfusion imaging 
agent was based on a nitrogen macrocycle (Simon et al, 1979). Later it was shown 
(Chervu LR, 1979) that various isotopes of monovalent cations K+, Rb+, Cs+ etc. can 
be successfully used in myocardial imaging studies. It was generally accepted that these 
cations accumulate through involvement with Na+, K+- dependent adenosine
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triphosphatase system; that is they function as potassium analogs. Harper et al in 1973 
and Walsh et al in 1977 demonstrated that monovalent ammonium derivatives 
including ammonium and other radiohalogenated méthylammonium ions (Haung et al, 
1980) also accumulate in the myocardium. Deutsch et al (1981, a) observed that many 
of the labelled compounds that showed significant myocardial uptake had an inherent 
positive charge or were expected to bear a positive charge at physiological pH. 
Deutsch et al (1980), first described that cationic 99m jc complexes can accumulate in 
normal myocardial muscle, providing for gamma imaging. This was according to the 
previously described fact that other inorganic cations such as K+, Rb+, Cs+ and NH4+ 
also accumulate in the myocardium. One possible explanation that Deutsch et al 
suggested was the existence in the myocardial muscle of relatively non-specific cationic 
acceptor sites that can be probed by a wide variety of cationic agents. However, they 
found that cationic character by itself is not sufficient to ensure myocardial uptake, as 
majority of the cationic 99mrpc complexes investigated in their work did not 
accumulate in the myocardium. They hypothesised that the lipophilicity of the cation is 
an important parameter, since myocardial extraction of any agent must always compete 
with hepatobiliary and renal clearance. Later in 1981, Deutsch et al successfully 
imaged the myocardium of a dog using cationic 9 9 m ^  complex trans- 
^99m,j'c(dmpe)2Cl2]+, where dmpe was bis( 1,2-dimethylphosphino) ethane. Nishiyama 
et al in 1982, studied the kinetics of 99mxc DMPE in the dog. They compared the 
effect of coronary blood flow on the uptake and washout of 201 j ]  and 99nrrc DMPE. 
In the same year 1982, Eakins et al studied the bio-distribution of kit formulated 
99m jc DMPE. However, when these radiotracers were tested in the humans, the 
results were disappointing because of poor myocardial uptake (Dudczak et al, 1983; 
Vanderheyden et al, 1983).
Kelly et al in 1989 described a new functionalised diphosphine complex of 
99nvpc for myocardial perfusion imaging. Lahiri et al in the same year performed the
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myocardial perfusion imaging studies in man using this new 99m jc diphosphine 
complex.
3.6. " mTc TETROFOSMIN
3.6.1. Chemistry
Tetrofosmin reconstituted with an eluate from a 99mrpc generator, contains a 
new funtionalised diphosphine complex of 99mxc Tetrofosmin (P53) has a molecular 
weight of 382, and an empirical formula of C18H40O4P2. The complex of 99nrpe has 
a molecular weight of 895 and a formula of [Tco2(P53)2]+ This compound was 
developed by Amersham International Pic, Amersham, Buckinghamshire, United 
Kingdom. The structural formula of tetrofosmin is shown in the Figure 3.6.1.
Confirmation of the structure of the [99mTc(tetrofosmin)202]+ cation has 
been established by x-ray single crystal analysis of the 99xc analog in combination with 
established high performance liquid chromatography procedures to demonstrate 
equivalence of 99niTc and 99tc species.
3.6.2. Preparation
Technetium is obtained from a generator (Figure 3.6.2). Radionuclide 
generators are constructed on the principle o f the decay-growth relationship between a 
parent radionuclide and its 'daughter'. The production o f radionuclide 99mTC is based 
on the decay o f its parent radionuclide Molybdenum-99(99Mo) :
Tl/2= 67 hrs Tl/2= 6 hrs
" M o   “ “ 7 99mTc ------------- >
P" , y y= 140 kev
When a saline solution is passed through the column the chloride ions exchange with 
the (TCO4) but not the (M0O4)™ ions. After passing through the column saline 
solution contains the sodium pertechnetate.
Tl/2=2.2*105 yrs
^ T c  /  (Stable)
(3-
To stabilise the compound tetrofosmin and in order to facilitate reconstitution, 
the final product is a freeze dried mixture containing:
0.23 mg P53
0.32 mg disodium sulphosalicylate 
0.03 mg stannous chloride dihydrate 
1.00 mg sodium D-gluconate 
sealed under an inert nitrogen atmosphere. Each vial could be reconstituted at room 
temperature by the addition of 1 GBq 99mTc as sodium pertechnetate in 4-8 ml of 
saline. Tetrofosmin kit formulation enables the complex to be formed rapidly at room 
temperature with a ligand concentration as low as 0.03 mg/ml. The kit preparation 
could be stored at room temperature and can be used upto 8 hrs of labelling (Kelly, 
1993).
3.6.3. Pharmacology
| 99m'pc tetrofosmin has a short physical half-life(6 hours). It is distributed into the 
myocardium proportional to the blood blow rates except at high flow rates (Sinusas et 
al, 1994). It is rapidly taken up by the myocardial cell (nearly 1.2% of the injected 
activity). There is slow myocardial clearance. It is excreted by both urinary and faecal 
route (Higley et al, 1993).
When plasma protein interaction is observed, 99mTc tetrofosmin was found to 
have no evidence of specific binding interactions. It was found in animal studies that, 
when tetrofosmin was given intravenously at 7.5 mg/kg (approximately 1050 times the 
maximum human dose), it produced a marked and sustained bradycardia, but no
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1,2-bis[bis(2-ethoxyethyl)phoshino] ethane
Figure 3.6. L: Sti-ucture o f tetrofosmin
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Figure 3.6.2. Block diagram of a 99ititc generator
evidence of arrhythmia. The action of tetrofosmin upon muscarinic, B adrenergic or 
calcium channel (dihydropyridine) receptors is none; thus there is no interaction with 
these groups of drugs.
3.6.4. Early development and animal studies
Following Deutsch and co-workers observation that lipophilic 99mTc cations 
can be taken up by the cardiac muscle, it was found that, within the various cation 
series studied, good myocardial uptakes can generally be achieved by optimising 
lipophilicity (Deutsch et al, 1980). However, there was recurrent failure, in man, to 
achieve adequate clearance from non-target tissues, especially blood and liver and 
sometimes lung (Deutsch et al 1989; Gerundini et al 1986). The development of 
99mTc tetrofosmin can be divided into three parts:
3.6.4.1. Development of Core
Kelly et al (1990) explored the potential of diphosphine complexes because of 
the range of cation cores available with these ligands. These included (1) [TcLg]"1" 
with Tc-I core, (2) [TcC^I^]^" with dioxo core, (3) [Tc(N)L2C1]+ with dichloro core 
and (4) [Tc(NO)L2C1]+ with nitrosyl core. The two later cores had not previously 
been explored in combination with diphosphines (Dilworth et al, 1989; and Thornback 
et al, 1989). The dichloro core was not further evaluated because of its unfavourable 
uptake and clearance characteristics. Because of this, Kelly et al (1990) screened only 
[TcLg]* ,^ [Tc(NO)L2C1]+ and [TcC^f^]"^ cores. They observed that the combination 
of phosphino-ethers with the ligand cores gave rise to two observations. The first was 
that the intrinsic properties of the core dominate the clearance characteristics of the 
complexes. The second observation was that the cores had to match with ligand and
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then cores would optimise uptake and clearance characteristics (Figure 3.6.4.1). The 
significantly higher polarity of the dioxo core was apparent from excretion 
characteristics.
3.6.4.2. Development of functional group
It was found that some of the hydrophilic functional groups had little effect in 
reducing protein binding or in improving non-target clearance, for example alkene, 
silane or thioether (Kelly et al, 1990). Amine and nitrile functions gave rise to mixed 
99m jc complexes, presumably because they provide competing ligating functions. 
Other functional groups, e.g. alcohol, had too overwhelming an effect in modifying 
lipophilic behaviour; others were too fragile to survive any but the mildest labelling 
conditions, e.g. acetal.
The overall conclusion from study by Kelly et al (1990) was that ether 
presented the best choice of functional group because:
a) it is robust to conditions of ligand synthesis and 99nypc labelling;
b) the ether function does not compete with phosphine in binding to
technetium;
c) relatively subtle modification of physicochemical properties can be
introduced through modification of the ether function.
3.6.4.3. Development of the ligand
The optimum ligand structure for each of the three core types were sought 
through a screening programme. A structured protocol was used to develop the ligand
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with optimal characteristics as shown in Figure 3.6.4.3.1. This consisted of a primary 
screen in rats, a secondary screen in guinea pig, and tertiary screen in the mini pig. The 
protocol for development included not only studying the myocardial uptake, 
biodistribution and toxicology, it also assessed the protein binding characteristics. It 
had been demonstrated (Gerundini et al, 1986) that plasma protein binding could 
adversely affect the biodistribution of 99mrpc cations in man, certainly in terms of 
blood clearance, and possibly liver uptake. The study by Higley et al (1994) indicated 
that, if plasma binding can be reduced, then not only plasma clearance but also poor 
heart uptake and increased liver uptake can be overcome. Published studies (Deutsch 
et al 1989; Zanelli et al, 1987) have indicated that specific inter-species differences in 
plasma protein binding could be demonstrated and might account, at least in part, for 
the poor performance of these complexes in man. •
Out of 210 compounds studied, three were chosen for study in man. These 
were respectively P53 for the dioxo core, PL46 for the Tc(I)core and PL37 for the 
nitrosyl core (Figure 3.6.4.3.2). Rat and guinea pig data are shown in Figure 3.6.4.3.3. 
Good heart uptake and retention together with fast blood and liver clearance are seen 
in all cases, except in the case of liver clearance in the guinea pig for PL46. In the pig, 
there was a good heart uptake and non-target clearance for PL37 and P53, but slower 
liver clearance for PL46.
Studies in man by Lahiri et al (1989) confirmed good myocardial uptake and 
clearance for the PL37 and P53 cations. As in the pig, PL46 showed a reasonable 
degree of heart uptake and there was good clearance also from blood but 
unsatisfactory clearance from liver. However, P53 had the optimal characteristics for 
further development into a kit formulation.
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3.6.5. Development in humans
3.6.5.1. Pilot Study
An initial pilot study in 3 healthy male volunteers, aged 34 to 55 years, one of 
whom previously had an uncomplicated myocardial infarction, was carried out by 
Lahiri et al (1989). Each volunteer received 0.2mg 99m jc tetrofosmin (equivalent to 
approximately 85% of the nominal tetrofosmin content). Blood clearance was rapid 
allowing visualisation of the myocardium within 3 to 4 minutes of administration. The 
infarct scar was apparent on imaging within 10 minutes. Rapid liver clearance, but no 
significant myocardial clearance was noted. No adverse reactions were reported and 
no treatment related changes were observed in any of the measured laboratory safety 
parameters. Based on this study a new kit formulation was developed for further 
studies.
3.6.5.2. Phase I Study
The aim of this study was to determine the safety of and tolerance to 99mxc 
tetrofosmin reconstituted with an eluate and to determine the biodistribution and 
clearance of ^ mTc tetrofosmin and hence calculate radiation dose estimates (Higley et 
al, 1993).
A total of 12 healthy male volunteers aged 22 to 35 years, were recruited at the 
Northwick Park Hospital, London and the Aberdeen Royal Infirmary, United 
Kingdom. Following an overnight fast, each volunteer received 138-173 MBq (3.7 - 
4.7 mCi) of reconstituted 99m jc tetrofosmin on two separate occasions. The first
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administration was at rest and the second 7 to 14 days later during exercise which 
resulted in an increase in heart rate to approximately 85% of the volunteers' age- 
predicted maximum. Biodistribution studies were performed by acquiring multiple 
whole body images or multiple serial static images from 5 minutes to 48 hours post­
injection which were then subjected to 'Region of Interest' analyses.
No serious clinical adverse experiences were reported. One volunteer reported 
"feeling warm" immediately following the first injection and experienced a mild bout of 
vomiting some 12 to 14 hours later. This same volunteer also reported a metallic taste 
shortly after the second injection. No clinically significant treatment-related changes 
were observed in any of the measured laboratory safety parameters. However, while 
total white cell counts remained within normal range, a number of volunteers 
experienced small and transient elevations of lymphocyte and neutrophil counts. These 
become apparent within 6 hours of administration and returned (or were returning) to 
baseline by 48 hours post-injection.
The Phase I study showed 99mxc tetrofosmin to have excellent biodistribution 
characteristics (Figures 3.6.5.2). Rapid heart uptake (approximately 1.2% of the 
injected dose) and relatively slow clearance (still approximately 1% of the injected 
dose at 2 hours) was observed and high quality images of the heart were obtained. 
Background clearance was rapid from blood, lung and liver. Background clearance 
was significantly increased following exercise (particularly in terms of liver activity) 
probably largely due to enhanced sequestration of activity in skeletal muscle. 
Excretion was essentially equally divided between urinary and faecal routes and 
accounted for approximately 80% of the injected activity by 48 hours post-injection.
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Figure 3.6.5.2 (A): Biodistribution of ^ ^mTc tetrofosmin in human volunteers
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Figure 3.6.5.2 (B): Biodistribution of ^ ^mTc tetrofosmin in human volunteers
3.6.6. Myocardial uptake
99m'pc tetrofosmin is a monovalent cation with a central Tc core that is 
surrounded by lipophilic ligands co-ordinated through the carbon atom. The transport 
0f  99m jc tetrofosmin involves passive distribution across plasma and mitochondria by 
the large negative transmembrane potentials. When plasma membrane potentials or 
mitochondrial membrane potentials are depolarised, there is inhibition of net uptake 
and retention of 99mfpc tetrofosmin. When mitochondrial and plasma membrane 
potentials are hyperpolarized, there is increased 99m jc tetrofosmin cellular uptake 
independent of flow.
There is a linear relation (r = 0.87) between the initial myocardial uptake of 
99nTfc tetrofosmin and regional myocardial blood flow at flow rates up to 2.0 ml/min 
per gram when the radionuclide is injected after intravenous dipyridamole infusion 
(Sinusas et al, 1994). However, like other diffusible indicators, 99mf^ tetrofosmin is 
shown to underestimate myocardial blood flow, at rates >2.0 ml/min per gram. In low 
flow regions, myocardial uptake of 99m'fc tetrofosmin is higher relative to non­
ischemic uptake than is the microsphere-determined regional blood flow. This may be 
attributed to increased extraction of diffusible indicators at low flows and is 
comparable with what has been observed with 201 jl .
3.6.7. Biodistribution
Smith et al (1992) and Higley et al (1993) described the biodistribution and 
clearance of ^ mTc tetrofosmin in man. They performed imaging on 8 occasions up to 
48 hours, observing blood clearance up to 24 hours, and total urine and faecal 
clearance up to 48 hours.
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Biodistribution was observed by gamma-camera imaging, the first scans 
commencing 5 minutes after injection. Regions of interest (ROI) were drawn around 
the whole body and those organs showing significant uptake to determine their size 
and count content, and adjacent small ROIs were used to correct for body background. 
Special methods were used for those abdominal organs that overlapped on the images. 
For example, the counts due to kidney activity were assumed to be equal to twice 
those in the left kidney which was easier to measure than the right kidney. Background 
corrected counts in ROIs from anterior and posterior images were decay corrected to 
the time of injection and then used to calculate geometric mean counts. All the 
geometric mean counts which were obtained before any excretion had occurred, 
represented 100% administered activity. The curves describing whole-body retention 
(less contents of gastro-intestinal tract and bladder), individual organ retention and 
blood clearance were fitted by eye, by multi-exponential equations for convenience in 
calculating residence times.
In the early gamma-camera images obtained at rest, uptake of tracer was 
clearly evident in several organs: heart, lungs, liver, kidneys, salivary glands, and there 
was early appearance of activity in gall-bladder, gastro-intestinal tract and urinary 
bladder. Reduced uptake was seen in certain organs after exercise, most noticeably in 
liver, lungs and salivary glands, whereas exercise led to a marked increase in skeletal 
muscle uptake. Additionally, it was noted that the appearance of activity in the gastro­
intestinal tract and urinary bladder was significantly delayed in the exercise studies. 
The reduced activity in liver and lungs, in particular, resulted in a clearer image of the 
heart at an earlier stage than in the resting study (Table 3.6.7).
Retention in total body (less contents of bladder and gastro-intestinal tract) fell 
rapidly within the first hour by about 20% in the resting study and 10% after exercise. 
Whole-body retention was consistently higher following exercise despite reduced
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uptake in some organs because of enhanced muscle uptake. Patterns of organ uptake 
and retention fell roughly into three categories:
1) those organs including heart, salivary glands and kidneys, which retained some
of their initial activity at least up to 24 hours (Figure 3.6.7.1);
2) those organs including liver, lungs and thyroid in which retention rapidly fell to
undetectable levels within 4 to 8 hours (Figure 3.6.7.2 ); and
3) the hollow excretory organs which showed high and variable amounts of
activity within the first few hours.
In the heart, initial uptake was about 1.2% in both studies but, in most other 
organs, uptake after exercise was only 50% to 80% of that at rest. Similar proportions 
of administered activity were excreted via gastro-intestinal tract and urinary bladder. 
However there was a slight bias in favour of faecal excretion in the resting study which 
was reversed after exercise.
3.6.8. Clearance of ^^mTc tetrofosmin
Clearance was studied by Smith et al (1992) by using heparinized blood 
samples withdrawn at various times and duplicate 0.5 ml samples were counted to 
determine the % of administered dose per litre of blood. Urine was collected in 
separate polythene bottles over pre-determined time intervals and each was measured 
between two opposed large Nal detectors to determine the % dose excreted in urine 
during these intervals. Faecal samples were collected individually in plastic cartons and 
measured in a similar manner.
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In a study by Smith et al (1992), it was shown that the whole-blood activity fell 
very rapidly to less than 0.2% of administered dose/litre within 30 minutes and 
stabilised at about 0.1% dose/litre (Figure 3.6.8). Initial clearance was slightly faster 
after exercise. Plasma concentration of ^^mTc tetrofosmin initially was approximately 
twice that of red cells and accounted for almost all blood activity in late samples.
3.6.9. Dosimetry
Perhaps the major consideration in all studies in which radionuclides are 
administered to human beings is the amount of activity administered to a patient and its 
consequent radiation dose to vital organs. Smith et al first described the dosimetry of 
99mTc tetrofosmin (1992). Residence times in organs and whole body were estimated 
by integrating the multi-exponential effective retention equations. Separate residence 
times were calculated for heart chambers and for heart wall. The former was estimated 
from the residence time/litre of blood on the assumption that the heart contains 0.5 
litres of blood (ICRP publication, 1975). Residence time in heart wall is then the 
difference between the values for total heart and heart chambers. It was noted in their 
study that the summed residence times in specified organs other than gastro-intestinal 
tract and urinary bladder represent only 15% of the total residence time in whole body 
(less contents of gastro-intestinal tract and bladder) at rest and 9% after exercise.
At rest, the highest organ doses were received by the gall-bladder (4.9 x 10-2 
mGy/MBq) followed by the walls of the gastro-intestinal tract (1.7 to 3.0 xl0"2 
mGy/MBq), urinary bladder (1.9 x lO-2 mGy/MBq) and salivary glands (1.2 x 10"2 
mGy/MBq) with all other organs receiving less than 10"2 mGy/MBq. After exercise, 
the doses to the above organs were reduced to about 70% but doses to other organs 
were slightly higher so that the total body dose was similar at rest and after exercise.
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In the study by Smith et al (1992) the effective dose (ED) to the body was 8.90 
x 10"3 mSv/MBq at rest and 7.10 x 100  mSv/MBq after exercise for a 3.5 hour 
bladder voiding period. However, there was only about a 12% range in ED for a 
change in bladder voiding period from 1 to 4.8 hours. Table 3.6.9 shows the absorbed 
radiation dose estimates for various organs due to 201 %nd 9 9 m ^  tetrofosmin.
From preliminary studies and Phase I study it was found that 99mTc 
tetrofosmin is a safe agent. It was also shown that tetrofosmin can be provided in a 'kit 
formulation1 and 99mTc tetrofosmin can be prepared at room temperature. 99mTc 
tetrofosmin had good myocardial uptake with rapid clearance from blood, liver and 
lungs and was found to have suitable radiation dosimetry. Due to these advantages the 
present project was undertaken to evaluate 99m’pc tetrofosmin in patients with 
ischaemic heart disease.
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Table 3.6.9: Absorbed radiation dose estimates for various organs due to 201xi and
99mxc tetrofosmin
201X1 99mXc tetrofosmin
Organ Rest Exercise
rad/2mCi (mGy/74 MBq) rad/30 mCi(mGy/l 110 Bq)
Adrenals 0.38(3.8) 0.46(4.6) 0.48(4.8)
Brain - 0.24(2.4) 0.30(3.0)
Breasts 0.20(2.0) 0.20(2.0) 0.25(2.5)
Gallbladder wall - 5.40(54.0) 3.69(36.9)
ELI 2.68(26.8) 2.46(24.6) 1.70(17.0)
SI 1.20(12.0) 1.89(18.9) 1.34(13.4)
Heart wall 1.67(16.7) 0.44(4.4) 0.46(4.6)
Kidney 3.98(39.8) 1.39(13.9) 1.16(11.6)
Liver 1.30(13.0) 0.464.6) 0.36(3.6)
Lungs 0.89(8.9) 0.23(2.3) 0.25(2.5)
Muscle - 0.37(3.7) 0.39(3.9)
Ovaries 0.89(8.9) 1.06(10.6) 0.88(8.8)
Red marrow 1.30(13.0) 0.44(4.4) 0.46(4.6)
Bone surface 2.50(25.0) 0.62(6.2) 0.69(6.9)
Salivary glands - 1.30(13.0) 0.89(8.9)
Testes 4.16(41.6) 0.34(3.4) 0.38(3.8)
Thyroid 1.85(18.5) 0.65(6.5) 0.48(4.8)
Bladder wall 0.27(2.7) 2.14(21.4) 1.73(17.3)
Uterus 0.37(3.7) 0.93(9.3) 0.82(8.2)
Total body - 0.41(4.1) 0.42(4.2)
Effective dose 1.57(15.7) 0.99(9.9) 0.79(7.9)
[rem (mSv)]
Reference: Higley et al, 1993
CHAPTER 4
OBJECTIVES OF THE STUDY
The identification of a patient with ischaemic heart disease is an important 
aspect in clinical practice. Several clinical criteria and diagnostic procedures have been 
used to diagnose patients with ischaemic heart disease. Myocardial perfusion imaging 
is one of the important diagnostic tools for patients with ischaemic heart disease. 
However 201ti myocardial perfusion imaging has many disadvantages as discussed 
earlier. So ^^mTc based compounds are being evaluated for myocardial perfusion 
imaging.
99mxc tetrofosmin is a new myocardial perfusion imaging agent developed for 
myocardial perfusion imaging in man. The aim of the study was to compare the 
imaging characteristics of 20ly} ancj 99m’pc tetrofosmin. To assess this, 'Null 
hypothesis' was used. It was assumed that 99mTc tetrofosmin imaging characteristics 
were not better than those of 201 y) imaging.
4.1 OBJECTIVES
This study aims:
1) to evaluate safety and the kinetics of 99m jc tetrofosmin by studying the,
(a) myocardial redistribution kinetics of 99mrpc tetrofosmin in patients with 
ischaemic heart disease
(b) non cardiac uptake of ^^mTc tetrofosmin (e.g. lung uptake) during stress 
and rest in patients with ischaemic heart disease and to compare this with 
201t 1 imaging
(c) myocardial washout kinetics of 99m'pc tetrofosmin in patients with 
ischaemic heart disease.
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2) to identify the optimal imaging protocol with 99mTc tetrofosmin by serial cardiac 
imaging and comparing the one and two day protocols.
3) to evaluate the sensitivity of 99m jc tetrofosmin planar myocardial perfusion
imaging in the identification of patients with ischaemic heart disease and to
compare the results with planar 201 j ]  imaging in the same patient population.
4) to evaluate the sensitivity of 99mt et ro f osmi n  SPECT myocardial perfusion
imaging in the identification of patients with ischaemic heart disease and to
compare the results with planar 99m'pc tetrofosmin imaging in the same patient 
population.
5) to define the sensitivity and specificity of planar and SPECT 99m jc tetrofosmin 
imaging for the detection of coronary artery disease
6) to define the sensitivity and specificity of dobutamine SPECT 99nTpc tetrofosmin 
imaging for the detection of coronary artery disease
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CHAPTER 5
PATIENTS, METHODS 
AND RESULTS
5.1. STUDY DESIGN
A total of 103 patients with known and suspected ischaemic heart disease and 
10 persons with low probability of coronary artery disease were included in this study.
The study was performed in 3 stages sequentially. In the first stage 23 patients 
with known ischaemic heart disease were recruited into the study to evaluate the safety, 
kinetics (including the lung uptake, redistribution phenomenon and washout) and 
optimal imaging protocol for 99mTc tetrofosmin imaging.
In the second stage, a further 50 patients and 10 persons with low probability 
of coronary artery disease were recruited to evaluate the sensitivity and specificity for 
the detection of coronary artery disease and to compare these results with 20Ij} 
imaging. At this stage lower activity of 99mTc tetrofosmin was injected.
In the third stage, 30 patients underwent dobutamine stress testing, to evaluate 
the sensitivity and the specificity of dobutamine stress 99mTc tetrofosmin imaging for 
the detection of coronary artery disease. Study design is shown on the next page.
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STUDY DESIGN
STAGES METHODS ANALYSIS
Stage I 23 patients with known IHD.
201ti _ Stress and redistribution 
planar imaging.
99m jc tetrofosmin -Stress study
Same day rest study. 
Separate day rest study. 
Planar and SPECT imaging.
Safety
Bio-kinetics of ^ ^mTc 
tetrofosmin
-  Redistribution
-  Lung uptake
-  Washout
-  Clearance
Imaging Protocol
Stage II 50 patients with known or suspected IHD.
10 persons with low probability of IHD.
201ti - Stress and 4 hour redistribution. 
(Planar imaging)
99m jc tetrofosmin - Stress and 4 hour rest 
reinjection. (Planar and 
SPECT imaging).
Sensitivity and 
Specificity for 
detection of IHD.
Comparison with
20 in .
Normalcy rate.
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Stage III • 99mfpc tetrofosmin (only) in 30 patients 
with suspected IHD.
• Dobutamine stress and separate day rest 
(SPECT imaging).
• Sensitivity and 
Specificity for 
detection of IHD
IHD Ischaemic Heart Disease
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5.1.1. Inclusion Criteria
Patients with known or suspected ischaemic heart disease
The patients should have had at least one of the following three inclusion criteria:
1 documented myocardial infarction at least 6 weeks old
2 history of chest pain suggestive of ischaemic heart disease
and
A positive diagnosis of ischaemic heart disease indicated by one or
more of the following:
a) typical chest pain on effort with reversible horizontal or 
downsloping ST segment depression (greater than or 
equal to 1 mm) during exercise electrocardiography
b) reversible myocardial ischaemia as determined by 
abnormal ^Oljj scan with reversible defect in at least 
two segments
c) confirmation of coronary artery disease by a positive 
angiographic demonstration of >50% luminal narrowing 
in at least one major vessel within the last 6 months
Other inclusion criteria were:
4 Patients of either sex were considered for inclusion
5 Age >30 years
6 Written informed consent to take part in the study approved by
the Harrow Health Authority District ethical committee.
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Low probability of coronary artery disease
Persons with low probability of coronary artery disease i.e. those who had no 
evidence of heart disease clinically or on exercise electrocardiography and with no 
history of hypertension or diabetes mellitus were recruited into the study. They also 
had to be non-smokers and with no strong family history of ischaemic heart disease.
5.1.2. Exclusion criteria
Patients were excluded from the study if they had any of the following:
a Unstable ischaemic heart disease
b Severe heart failure (NYHA III to IV)
c Significant valvular disease
d Left bundle branch block
e Significant congenital heart defect
f  Cardiomyopathy
Women of child bearing potential
3 Significant hypertension (resting systolic blood pressure > 200 mmHg 
or resting diastolic blood pressure > 110 mmHg)
4 Other known significant concurrent illness
5 Treatment with cardiac glycosides (such as digoxin)
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ETHICS APPROVAL
Approval of the study was obtained from local ethical committee (Harrow 
Health Authority Ethical Committee) and the Administration of Radioactive 
Substances Advisory Committee (ARSAC) of the Department of Health (UK) prior to 
study commencement. Each patient/ volunteer gave written informed consent.
The study was performed over a two year period and as 99m'pc tetrofosmin is a 
new agent, the study was performed in three stages sequentially. To simplify the 
structure of this thesis, the methods and results of the three stages are discussed 
together.
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5.2. STAGE I
5.2.1. Patients
Twenty three patients with known stable ischaemic heart disease were included in 
this group. All the patients satisfied the inclusion criteria discussed in section 5.1.1.
5.2.2. Study design
The study was divided into two sections, 201'j’i studies followed by 99nTpc 
tetrofosmin studies. Each patient had three study days. On the first day each patient 
underwent planar 201x 1 stress and 4 hour redistribution imaging.
Within 3-7 days of 201xi imaging, each patient underwent a resting 99mxc 
tetrofosmin study including serial planar imaging for a period of up to 4 hours post­
injection. SPECT imaging was performed at 150 minutes post injection. Within 1-3 
days of resting 99m j c tetrofosmin study each patient underwent a 99mxc tetrofosmin 
study which involved stress imaging (serial planar imaging and SPECT imaging at 150 
minutes) following graded, ergometric exercise (to the same work load as the 201t i  
exercise study). Same day rest reinjection was performed, 4 hours after the stress 
injection and serial planar imaging and the SPECT imaging were repeated. The study 
design is shown in Figure 5.2.2.
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5.2.3. M ethods
5.2.3.1. Vital Signs
Patients were requested to have only a light breakfast on the morning of the 
study. On arrival they were taken to the imaging laboratory and rested for five minutes. 
Pulse, temperature and blood pressure were measured and a 12-lead electrocardiogram 
was performed. The electrocardiograph was monitored continuously for the first hour 
and intermittently for a further 4 hours post-tracer injection, using limb leads, in order 
to facilitate monitoring during imaging.
5.2.3.2. Blood and urine sampling
Baseline blood samples for haematology (5 ml) and biochemistry (10 ml) were 
obtained. A sample of anticoagulated blood was taken for clearance studies at 2, 5, 10, 
30 and 60 minutes following each injection. The blood samples were taken via a 
cannula placed in the opposite arm to that in which the drug administration was made. 
Prior to sample collection, the cannula was flushed free of saline by withdrawing and 
discarding 2 ml blood. A baseline urine sample (mid-stream) was also obtained. Blood 
samples for haematology (5 ml) and biochemistry (10 ml) were repeated at the end of 
each study day.
5.2.3.3. Exercise Electrocardiography
5.2.3.3.1. Bicycle exercise - Equipment
Symptom-limited exercise testing was performed using a bicycle with an 
accurate speed control to provide graded increase in the workload. A three-channel
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electrocardiographic machine was linked to a microcomputer. Input data was obtained 
from a simultaneous three-channel digitisation of the patient's electrocardiograph 
signals from three bipolar leads. Suitable disposable electrodes were placed over the 
manubrium sterni, fifth rib at the left anterior axillary line (LV5), fifth rib at the right 
anterior axillary line (RV5) and sixth rib at the right midaxillary line (RV6). The right- 
arm cable was connected to the electrode at RV6, the left-arm cable to the manubrium 
sterni, the left-foot cable to LV5 and the right-foot cable to RV5. In addition a 12 lead 
electrocardiogram was obtained at each stage of the exercise.
5.2.3.3.2. Exercise Protocol
The protocol used was a graded, symptom limited exercise test in which the 
initial workload was 25 watts and increasing by 25 watts every 3 minutes (Figure 
5.2.3.3.2). All exercise tests were defined as maximal symptom-limited. Patients were 
clearly instructed to stop when anginal pain of sufficient severity occurred which 
would have resulted in termination of their normal daily activity. In addition, tests 
were stopped when pain in the legs, fatigue or shortness of breath occurred. For safety 
reasons, ventricular tachycardia, ST-depression greater than 4 mm and a reduction of 
systolic blood pressure by more than 20 mm Hg during exercise were also considered 
to be end-points.
5.2.3.3.3. Software
The electrocardiogram was continuously recorded as a 25:1 time-compressed 
record by displaying the template of the normal cardiac cycle at a rate of 1 mm/sec. 
The location of the PR segment was selected as a reference point and the J-point was 
marked automatically by vertical markers on the top lead for each complex, permitting 
visual validation. Blood pressure was measured manually by a mercury-in-glass
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Figure 5.2.3.3.2.: Bicycle protocol for exercise testing
sphygmomanometer and entered into the computer. When the test was completed, a 
final report was generated, which specified: the duration of exercise, maximum heart 
rate, location of ST measurement and worst cases of ST-depression.
5.2.3.3.4. Exercise Testing
Following the recommendations of the American Heart Association (1975), the 
following safety precautions were carefully standardised:
i Temperature - controlled optimally in the exercise laboratory. (24 ± 2° C).
ii All tests were performed with the patient fasting or at least two hours after a 
light meal
iii Patients arrived in the laboratory at least 30 minutes before the test and rested 
in a comfortable area
iv They were not allowed to smoke or consume glyceryl trinitrate tablets on the 
morning of the test
v Patients were allowed to use handrails for balance but not to grip them or 
support their weight on them
After arrival at the exercise laboratory and resting for at least 30 minutes to 
achieve a basal state, all patients had a 12-lead electrocardiogram and clinical 
examination. All the cardioactive medication was stopped for at least 48 hours before 
the study. The patients were asked to lie down and electrodes were placed after proper 
skin preparation. The cables were connected and the exercise system was switched on 
so that the three bipolar leads were fed into the computer. A printout of resting 
electrocardiogram was obtained and analysed. Patients then sat on the bicycle and cuff 
blood pressure was measured using a mercury sphygmomanometer. The sitting systolic 
blood pressure was fed into the computer and the procedure was explained. After
86
warning, the bicycle was started and exercise continued until the patient's symptoms or 
one of the end-points warranted stopping the test.
The values of systolic blood pressure were fed into the computer at the end of 
each stage and at peak exercise. Post-exercise monitoring was carried out with the 
patients in the supine position for a period of 15 minutes. A final report was generated 
at the end of the recovery period and stored on a digital tape.
5.2.3.4. Planar imaging
5.2.3.4.1. Equipment
A single crystal, mobile and fully digital gamma camera (Elscint-Apex 215M) 
was employed in all the planar studies. The camera head contained a detector 
consisting of 1/2 inch thick Nal (Tl) crystal and shielded with 10 mm lead-equivalent. 
In addition, the head contained 37 high performance photomultiplier (PM) tubes 
arranged in a hexagonal array. The camera performance and data acquisition were 
controlled by a minicomputer (Apex processor) with advanced software. Operations 
and programmes were selected from a menu list and routine acquisition procedures 
were programmed into function buttons on the keyboard.
The camera head was equipped with an all-purpose, parallel-hole, low energy 
collimator. The system was programmed to perform self-testing once it was switched 
on, enabling adequate sensitivity and efficiency.
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5.2.3.4.2. Injection of 201 j !
After arrival in the scanning room, patients had an intravenous cannula inserted 
in the forearm just before the exercise test. Exercise testing was performed on bicycle 
and at peak exercise, 74 MBq (2 mCi) of thallous chloride was injected through the 
indwelling cannula and patients were encouraged to continue the exercise for at least 
additional 1 minute. A separate day rest dose was not permitted due to the high 
radioactivity to the patients in this stage.
5.2.3.4.3. 201x1 imaging
The camera's detector was set at 68 keV focused at the photopeak of 201x1 
with an energy window of 15%. Imaging was commenced 10 minutes after injection of 
the tracer with the patient in the supine position in the anterior projection, followed by 
40° left anterior oblique projection and then by 70° left anterior oblique projection. 
While patients were in the lateral decubitus position, a further view was performed in 
the left lateral projection, (Al-Khawaja et al, 1987 b). Imaging was repeated in the 
same order 4 hours after 201xi administration. Acquisition of data was stopped after 
collection of 300,000 counts in each view and data was stored in a 128x128 matrix on 
a dedicated computer (O'Hara et al, 1985).
5.2.3.4.4. Preparation of ^ ^mTc tetrofosmin
Tetrofosmin was available as a freeze dried mixture in a 10 ml glass vial sealed 
under an inert nitrogen atmosphere with a rubber closure. Each vial contained: 0.23 
mg of tetrofosmin; 0.32 mg of disodium sulphosalicylate; 0.03 mg of stannous 
chloride dihydrate and 1 mg of sodium D-gluconate. Each vial was reconstituted with
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6 ml of sterile sodium pertechnetate solution of an appropriate radioactive 
concentration. This was prepared by diluting the eluate from a 99mrpc generator with 
0.9% saline. The vial was then shaken gently to ensure complete dissolution of the 
lyophilised powder and allowed to stand at room temperature for 15 minutes. 
Radiochemical purity determination was carried out within one hour before use. The 
reconstituted injectate was used within 8 hours. An appropriate correction was made 
for radioactive decay that will occur between reconstitution and injection. Appropriate 
radiation precautions and aseptic technique was observed in the preparation and 
storage of the agent.
5.2.3.4.5. Radiochemical purity measurement
A chromatographic system was used to determine the radiochemical purity of 
the injection. A Gelman ITLC/SG strip (2-2.5 cm x 20 cm) was prepared. The origin 
and the cutting positions were marked with a pencil and the solvent front position with 
a suitable ink pen. A test sample of 5 to 20 |a1 volume was applied by needle on to the 
origin position of the strip. The strip was then immediately placed in a prepared 
ascending chromatography tank containing a fresh solution of 35:65 acetone/ 
dichloromethane (1 cm depth).
The strip was removed once the solvent had eluted to the solvent front line, and 
cut into 3 pieces, each piece was then counted. The % radiochemical purity was 
calculated as:
Activity in the middle portion
% 99m'pc tetrofosmin = -----------------------------------------X 100
Total activity of all 3 pieces
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5.2.3.4.5. Injection of the 99m j g  tetrofosmin
Within one week of scintigraphy, 296-370 MBq (8 to 10 mCi) of 99mxc 
tetrofosmin was given intravenously at rest. Within 1-3 days, patients underwent 
exercise to the same work load as for 20I j]  stress and 296-370 MBq (8 to 10 mCi) of 
99mxc tetrofosmin was injected to the indwelling cannula intravenously and patients 
were encouraged to continue the exercise for at least one additional minute. Four 
hours after the stress injection 888 to 1110 MBq (24 to 30 mCi) of 99m jc tetrofosmin 
was injected at rest on the same day.
5.2.3.4.7. 99mxc tetrofosmin imaging
The camera's detector was set at 140 keV focused at the photopeak of 99m%c 
tetrofosmin with an energy window of 15%. Imaging was commenced at 5 minutes of 
post injection of the tracer with the patient in the supine position. The anterior 
projection, followed by 40° left anterior oblique projection and then by 70° left 
anterior oblique projection were acquired. While patients were in the lateral decubitus 
position, a further view was performed in the left lateral projection. Imaging was 
repeated in the same order at 30, 60, 90, 120 and 240 minutes after 99mxc tetrofosmin 
administration. Acquisition was stopped after collection of data for five minutes in 
each view and data was stored in a 128x128 matrix on a dedicated computer.
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5.2.3.5. SPECT imaging
5.2.3.5.1. Equipment
For SPECT studies, a single crystal and fully digital GE 400T gamma camera 
was used. The camera head contained a detector consisting of 1/2 inch thick Nal (Tl) 
crystal and 37 high performance photomultiplier (PM) tubes arranged in a hexagonal 
array. The camera performance and data acquisition were controlled by a computer. 
The camera head was equipped with an all-purpose, parallel-hole, low energy 
collimator. The system was programmed to perform self-testing once it was switched 
on, enabling adequate sensitivity and efficiency.
5.2.3.5.2. Imaging
| After injection of 201x1 the primary intention was to acquire planar images due
| to regulatory requirements and this generally took about 20 to 25 minutes. Hence it 
| was felt that it was inappropriate to acquire SPECT 201T1 images starting so late as in 
! some patients redistribution would have started.
SPECT 99mxc tetrofosmin images were acquired at 150 minutes post injection 
following the acquisition of planar images. The camera's detector was set at 140 keV 
focused at the photopeak of 99mxc tetrofosmin with an energy window of 15%. The 
patient was positioned supine on the imaging table and SPECT images were acquired 
over 180 degree arc extending from 45 degree right anterior oblique to 45 degree left 
posterior oblique projections; 32 images were obtained, each projection being acquired 
for 40 seconds. The patient was instructed to avoid any motion during the imaging 
period.
91
5.2.3.6. Semi-Quantitative Image Analysis
Images after stress and rest were examined for image quality, gross perfusion 
defects and gross reversible defects. All images were analysed by two independent 
observers who had no knowledge of patients history, exercise electrocardiography data
! or coronary angiographic data. The independent observers had several years of
!
' experience in reading the perfusion scans.
5.2.3.6.1. Segmental Diagnosis
The left ventricular myocardium from both planar and SPECT images were 
converted into a polar map consisting of 18 segments as shown in Figure 5.2.3.6.I. 
The apex is represented in the centre and septum to the left, lateral wall to the right, 
the anterior and the inferior walls to above and below respectively. Visual scoring was 
carried out as 0 for normal uptake, 1 for probably abnormal uptake and 2 for definitely 
abnormal uptake. The presence of gross redistribution or reversible ischaemia was 
indicated if the score changed from a higher to a lower value in the delayed images. If 
the score remained unchanged and it was more than '2', then the presence of 'scar' or 
fixed perfusion defects due to infarction was indicated.
5.2.3.6.2. Regional Diagnosis
The left ventricular myocardium was divided into 5 regions; anterior, septal, 
inferior/ infero-posterior, lateral and apex. Based on uptake of the radiopharmaceutical 
in each region, a diagnosis score was given; 0 if the region was normal, 1 if the region 
was reversibly ischaemic, 2 if the region was infarction and 3 if the region was 
demonstrating a mixed defect (i.e. infarction and reversible ischaemia).
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Anterior □
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0 = Normal
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3 = Mixed
Overall Diagnosis
□ ( 0 - 3 )
Figure 5.2.3.6.1.: Polar map analysis of the perfusion studies
report form
5.2.3.6.3. Overall Diagnosis
Based on the regional diagnosis, an overall diagnosis was given per patient as 
having a normal myocardial perfusion scan, having fixed defect or scar in the 
myocardium, having completely reversible ischaemia or having a mixture of both scar 
and reversible ischaemia.
5.2.3.7. Quantitative heart/lung ratio
Quantitative lung uptake was calculated both for 201jj %nd 99m jc tetrofosmin 
images uptake was calculated on planar images by placing an eight by eight pixel 
computer-generated region-of-interest at maximal count density over the planar images 
of the myocardium and lungs. The average counts per pixel in the region-of-interest 
was obtained over the myocardium and lung on serial stress images of 99m jc 
tetrofosmin and exercise and delayed 2017} images and a heart-to-lung ratio was 
calculated. The programme allowed operator intervention to alter the size of regions- 
of-interest according to the maximal count density (Al-Khawaja et al, 1987 a).
5.2.3.8. Quantitative myocardial washout ratio of ^ ^mTc tetrofosmin
Quantitative analysis of the myocardial washout was calculated on serial planar 
99mxc tetrofosmin images. It was performed by placing an eight by eight pixel 
computer-generated regions-of-interest over the normal and ischaemic myocardium 
using the stress and separate day rest images of 99m'pc tetrofosmin. The average 
counts per pixel in the region-of-interest was obtained on serial images of 99nrrc 
tetrofosmin during stress and separate day rest images at 5, 30, 60, 90, 120 and 240 
minutes and the myocardial washout was calculated. This value was then decay
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corrected based on the assumption that the physical half-life of ^ ^mTc tetrofosmin is 6 
hours, using the following formula (Parker et al 1984):
A = Aq x e" ^
where A - is the activity to be calculated at time t 
Aq - is the initial activity 
X - is the transformation constant measured as 
X = 0.693/ T(j/2) where is the physical half-life of the
radiopharmaceutical
5.2.3.9. Quantitative assessment for evidence of redistribution of ^ ^mTc tetrofosmin
Quantitative analysis for evidence of myocardial redistribution over time was 
assessed using serial planar stress images. It was performed by placing an eight by 
eight pixel computer-generated regions-of-interest over the normal and ischaemic 
myocardium using the stress images of 99m'pc tetrofosmin. The average counts per 
pixel in the region-of-interest was obtained on serial images of 99m'pc tetrofosmin 
during stress at 5, 30, 60, 90, 120 and 240 minutes. The defect to normal wall ratio
was calculated over time and assessed for any evidence of redistribution of 99m'pc
tetrofosmin.
5.2.3.10. Cardiac Catheterization
Cardiac catheterization performed within three months of the radioisotopic 
studies was included in the analysis. Patients were admitted to hospital on the morning
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of the procedure. Two days before the elective cardiac catheterization a full blood 
count and blood chemistry was performed. Patients gave informed consent to undergo 
cardiac catheterization and coronary angiography. The groin was prepared by 
removing the pubic hair. Diazepam 10 mg was given orally on the morning of the study 
before sending the patient to the catheterization laboratory.
5.2.3.10.1 Left heart catheterization
Patients were positioned on the fluoroscopic table and under complete aseptic 
conditions, the right groin was exposed. An intradermal wheal of 1% lignocaine was 
raised slowly over the pulsation of the right femoral artery using a 25-gauge needle. 
Skin puncture was made over the femoral artery using the tip of a scalpel blade and 
further infiltration of deeper tissues with 1% lignocaine was carried out.
The femoral artery was cannulated by Seldinger technique. A 8 Fr sheath was 
introduced. The sheath was aspirated, flushed and connected by its sidearm to a 
manifold for monitoring arterial pressure. A pigtail left heart catheter was then flushed 
and loaded with a 145 cm J-guide wire and introduced into the backbleed valve of the 
sheath. The soft end of the guide wire was then advanced carefully through the 
catheter to the level of the diaphragm before the catheter itself was advanced. The 
guide wire was then removed and the catheter was connected to the arterial manifold 
and double flushed with heparinized saline solution. Pressures from the ascending aorta 
and left ventricle were recorded. Left ventriculography was performed by injection of 
contrast from a power injector. Continuous fluoroscopic monitoring and recording of 
results on cine film were carried out in the 30o-45° right anterior oblique projection.
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5.2.3.10.2. Coronary arteriography
At the end of ventriculography, the pigtail catheter was withdrawn, and the 
sheath was immediately double flushed. A Judkins' coronary catheter with end-hole 
design was used for cannulation of the left and right coronary arteries. The catheter 
was advanced to a point just above the diaphragm with a guide wire in place. The 
guide wire was then removed, and the catheter was attached to a specially designed 
manifold system which permitted the maintenance of a 'closed system' during pressure 
monitoring, catheter flushing, and contrast agent administration. Left coronary 
cannulation was performed using usually a left Judkin's catheter with a 4 cm curve (JL
4). The right Judkin's catheter (JR 4) with a 4 cm curve was usually used for right 
coronary cannulation. Contrast media was injected into each coronary artery under 
continuous pressure monitoring and fluoroscopic imaging was carried out in various 
| projections such as right and left anterior obliques at different angles.
The catheter and sheath were removed, and firm manual pressure was applied 
at skin puncture over the femoral artery for at least 15 minutes. The puncture site and 
surrounding area were then inspected for haematoma formation and active oozing, and 
the quality of the distal pulses was assessed before the application of a bandage. 
Patients were transferred to the ward and kept on bed rest with leg straight for 6 
hours. Before full ambulation, the puncture site was again inspected for recurrent 
bleeding, haematoma formation, development of bruit or loss of digital pulses.
5.2.3.10.3. Assessment of coronary artery lesions
Left ventricular angiograms and coronary arteriograms were reported 'blind' by 
two independent and experienced observers. The assessment of myocardial 
contractility, wall motion and assessment of the severity of the coronary artery lesions
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were carried out visually. Severity of an epicardial coronary artery lesion was 
evaluated as >50%, >70% and >90%. A lesion greater than 50% was considered 
significant. Any collateral supplying the diseased artery was also evaluated visually.
5.2.4. STATISTICAL ANALYSIS
Continuously variable data were recorded as a mean (±)SD (standard 
deviation) or mean ±SEM (standard error of the mean). To determine differences 
between means of independent observations in patient subgroups, one-way analysis of 
variance and/or unpaired Student's test were performed. In addition, two-tailed paired 
Student's test was used when relevant. For non continuous variables and categorical 
factors, chi-square analysis was performed. Differences between the means of variables 
in healthy subjects and patients were assessed by unpaired Student's t-test. Linear 
regression analysis using least-squared models was used to assess the association of 
different variables. Kappa statistic, as described by Altman (1991), was calculated for 
the degree of concordance to evaluate the agreement between the two tests. Kappa 
statistic is a measure of agreement which in general takes values between 0 and 1, 
values near 0 indicating very poor agreement whereas values near 1 show that the 
agreement is good.
Sensitivity was defined as the ability of the test to identify those who have the 
disease. Specificity was defined as the ability to identify those who do not have the 
disease. Normalcy rate is defined as the number of patients from the low likelihood 
group with normal scintigraphic patterns divided by the total number of patients in the 
low likelihood group.
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5.2.5. RESULTS
5.2.5.1. Activity Injected
The mean (SD) dose of 201x 1 injected was 74 (2.3) MBq. For 99mxc 
tetrofosmin reconstruction volume was 6 ml; reconstruction activity was 653.6 
(160.6), 531.3 (39.6) and 2007.3 (600.5) MBq for separate day rest, stress and same 
day rest injections respectively. The injected volume was 5 mis. Injected activity was 
356.5 (24.9), 353.7 (20.5) and 986.2 (78.7) MBq respectively for separate day rest, 
stress and same day rest injections. The ratio of volume injected to volume
j reconstructed was 0.83. Reconstruction volume is the volume of the eluate placed in
| vial containing tetrofosmin and reconstruction activity is the activity in this volume,    — ...... . -    ...... ...... .
5.2.5.2. Quality control for 99mxç tetrofosmin labelling
Radio chromatographic quality control strips for 99mxc tetrofosmin were
assessed for detection of labelling efficiency. The top, middle and bottom strip
percentages were 0.2(0.2), 95.9(1.3) and 4.9(2.0) respectively for injection during
stress and 0.2(0.1), 96.1(1,2) and 3.7(1.2) respectively for the same day rest injection.
For separate day rest injection the percentage of a quality control strips were 0.2(0.2),
96.5(1.2) and 3.3(l.l)jfbr top, middle and bottom respectively (Figure 5.2.5.2). | Free 
j pertechnetate moves to the top, free technetium remains at the bottom and the middle
portion is occupied by 99mxc tetrofosmin.
5.2.5.3. Kinetics of 99mxç tetrofosmin
5.2.5.3.1. Lung Uptake
Quantitative lung uptake and myocardial uptake were obtained on the planar 
images using an 8 * 8 pixel region of interest as described in the section 'Patients and
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Methods'. The ratio between them was then calculated as lung/ heart ratio. Following 
injection of ^^mTc tetrofosmin during stress, the mean(SD) lung/heart ratio was 0.38 
(0.08) at 5 minutes; the ratio was 0.35 (0.07), 0.33 (0.06), 0.32 (0.08), 0.31 (0.08) 
and 0.33 (0.09) at 30, 60, 90, 120 and 240 minutes respectively. There was no 
significant increase in the lung uptake of 99m jc tetrofosmin during stress (p=NS) 
compared to 4 hours later (Figure 5.2.5.3.1.1). Linear regression analysis revealed a 
poor non-significant correlation between exercise lung/heart ratio of 99m jc 
tetrofosmin and exercise time (r=0.3). There was no significant correlation between 
lung/heart ratio and peak heart rate during exercise (r=0.3).
In contrast, in the same group of patients at the same level of exercise, there 
was a significantly greater uptake of 20171 during exercise (p<0.01) (Figure 
5.2.5.3.1.2) The mean (SD) lung/heart ratio was 0.50 (0.08) at 10 minutes and 0.43 
(0.07) at 4 hours after exercise.
Lung uptake of 99mxc tetrofosmin was calculated in patients where anterior 
and inferior fixed defects were diagnosed by both 20171 %nd 99m7 c tetrofosmin. With 
anterior wall defect, the mean(SD) exercise lung/heart ratios of 99m7c tetrofosmin 
were, 0.41 (0.11), 0.41 (0.12), 0.40 (0.11), 0.38 (0.10), 0.39 (0.12) and 0.37 (0.10) 
respectively at 5, 30, 60, 90, 120 and 240 minutes. Similarly in patients with inferior 
defects, the ratios were 0.37 (0.12), 0.36 (0.12), 0.36 (0.14), 0.39 (0.11), 0.35(0.11) 
and 0.37 (0.12) respectively at 5, 30, 60, 90, 120 and 240 minutes. The ratios were 
slightly higher with anterior compared to those with inferior myocardial infarction, 
although the difference was not statistically significant.
Out of 23 patients, 13 were diagnosed as having fixed defects by both imaging 
agents using planar imaging; and in these patients the mean(SD) lung/heart ratio was 
0.39(0.09), 0.38 (0.08), 0.36 (0.08), 0.37 (0.07), 0.33 (0.08) and 0.37 (0.07) at 5, 30,
99
60, 90, 120 and 240 minutes respectively with 99m jc tetrofosmin; the ratio was 0.51 
(0.1) and 0.43 (0.08) at 10 min and 4 hours respectively with 20171 imaging. Thirteen 
were concordantly diagnosed as having reversible defects and in these patients the ratio 
was 0.38 (0.08), 0.37 (0.08), 0.37 (0.07), 0.36 (0.08), 0.34 (0.09) and 0.36 (0.07) at 5, 
30, 60, 90, 120 and 240 minutes respectively with 99m jc tetrofosmin. The lung/heart 
ratio was 0.47 (0.09) and 0.42 (0.09) at 10 minutes and 4 hours respectively with 
201t1 imaging. The ratios were not statistically significantly different between those 
with fixed and reversible defects.
5.2.5.3.2. Right Ventricular Uptake
Right ventricular wall was seen on resting 20171 images in 12 patients (16.4%); 
of these 12, 7 had anterior defect and 5 infero-posterior defect; 7 patients had fixed 
defects and 5 had reversible defects. The prevalence of right ventricular uptake of 
201t i  was not significantly different on exercise images.
Right ventricular wall was seen on resting planar images of 99mxc tetrofosmin 
in 21 patients (34.7%); of these, 14 had anterior defects and 7 inferior defects; 13 had 
fixed defects and 8 had reversible defects. On SPECT images the right ventricle was 
seen at rest in 23 patients (31.5%); of these, 12 had anterior defects and 11 had infero- 
posterior defects; 14 had fixed defects and 9 had reversible defects. The prevalence 
was not significantly different on exercise images. Although slightly higher number of 
patients with right ventricular uptake of 99mxc tetrofosmin had multivessel disease, 
there was no significant correlation between right ventricular 99mxc tetrofosmin 
uptake and the extent of coronary artery disease.
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5.2.5.3.3. Liver Uptake
Uptake of 99mTc tetrofosmin by the liver was seen in 41 patients (56.16 %) on 
stress planar images. Liver uptake was noted in 96% of patients at 5 and 30 minutes, 
71% at 60 minutes, 21% at 90 minutes, 4% at 120 minutes and 8% at 240 minutes 
following injection at rest on the same day. The percentages were slightly less 
following injection during stress. However, except in two patients, where liver uptake 
interfered with the diagnosis at 5 minutes post injection in the left lateral view, in all 
the other patients, liver uptake did not interfere with the diagnosis even in the inferior 
wall defects.
5.2.5.4. Analysis for evidence of redistribution of ^ ^mTc tetrofosmin
Quantitative defect to normal myocardial wall ratio was calculated on serial 
stress planar 99m'pc tetrofosmin imaging as described in section on 'Patients and 
Methods'. The mean(SD) defect to normal ratios were 0.75 (0.10), 0.75 (0.10), 0.74 
(0.09), 0.73 (0.10), 0.73 (0.10) and 0.72 (0.10) at 5, 30, 60, 90, 120 and 240 minutes 
respectively (p=NS), suggesting absence of redistribution (Figure 5.2.5.4.1).
Thirteen patients were concordantly diagnosed as having reversible defects. In 
these patients, the mean(SD) defect to normal ratio was 0.75(0.09), 0.77(0.1), 
0.75(0.1), 0.74(0.09), 0.74(0.1) and 0.73(0.07) at 5, 30, 60, 90, 120 and 240 minutes, 
respectively (p=NS). In another 13 patients who had only fixed defects as detected by 
both imaging techniques, the mean defect to normal ratio was 0.67(0.1), 0.65(0.08), 
0.64(0.07), 0.62(0.08), 0.61(0.09) and 0.60(0.06) at 5, 30, 60, 90, 120 and 240 
minutes, respectively (p=NS) (Figure 5.2.5.4.2). The defect to normal ratio was 
significantly lower in patients with fixed compared to reversible defects (p<0.05).
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5.2.5.5. Washout of ^ ^mTc tetrofosmin from the myocardium and lung
Quantitative, physiological (decay-corrected) washout of 99mTc tetrofosmin 
was calculated on serial planar images. Washout was calculated from the normal and 
ischaemic myocardium and the lung following stress injection and following separate day 
rest injection. The physiological washout of 99nrpc tetrofosmin was 4% and 5% /hour 
for normal and ischaemic myocardium post exercise for first two hours after injection, 
and these values were 0.4% and 0.6% respectively / hour for the rest study (Figure 
5.2.5.5). There was stable retention o f  99m jc tetrofosmin in the myocardium for up to 4 
hours after an injection. The myocardial to background ratio was optimal for diagnostic 
imaging up to 4 hours after injection of 99m jc tetrofosmin both after stress and rest 
injection.
5.2.5.6. Clearance of 99mTc tetrofosmin
Clearance was obtained by calculating the percent injected activity in the whole 
blood and plasma for up to 60 minutes after injection of 99m jc tetrofosmin during 
stress and rest (both same day and separate day rest). There was rapid clearance from 
the blood soon after injection of 99m jc tetrofosmin at rest. After an injection 
following stress there was an increase in the plasma and whole blood activity for up to 
5 minutes after injection and then there was a rapid clearance from the blood. Even as 
early as 5 minutes after the injection, rapid clearance provided adequate myocardium 
to background ratio for imaging the heart both at stress and at rest. The pattern of 
clearance is shown in Figures 5.2.5.6.1 and 5.2.5.6.2.
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5.2.5.7. Safety Data
5.2.5.7.1. Clinical parameters
There were no significant changes in the baseline parameters observed in heart 
rate or blood pressure following administration of ^ ^mTc tetrofosmin during rest. One 
patient developed a self terminating episode of torsade de pointes during recovery 
from exercise (about 2 minutes after he had received the injection of 99nrrc 
tetrofosmin). It was thought to be stress induced and not related to the injection of 
99nrpc tetrofosmin.
5.2.5.7.2. Laboratory parameters
There was no significant change in any of the biochemical parameters with the 
injection of 99m jc tetrofosmin. There was no clinically significant change in the white 
blood cell count following injection of 99m'pc tetrofosmin. In 3 patients neutrophil 
counts rose from within the normal range to above following administration of 99mxc 
tetrofosmin. In 1 patient values remained elevated at 48 hours post injection. 
However, the percentage increase from baseline was small and was not clinically 
significant. In only one patient did the lymphocyte count rise above normal following 
injection of 99mrpc tetrofosmin, but the rise was clinically insignificant.
103
0.2% 0.2%
96.9% 96.1%
3.9% 3.7%
0.2%
96.5%
1.3%
&
Figure 5.2.5.2.: Radiochromatic quality control strips for
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5.2.5.8. Comparison of One and Two day 99mTc tetrofosmin Protocols
Stress and same day rest injection of 99m jc tetrofosmin formed the one day 
protocol whereas stress and separate day resting study formed the two protocol.
5.2.5.8.1. Planar imaging
There was good concordance in the overall and regional diagnosis of ischaemia 
by one and two day protocols.(Figure 5.2.5.8.1). However, there were 3 patients 
where a discrepancy in the type of the defect was seen in the inferior wall. In two 
patients, the one day protocol diagnosed mixed defect (ischaemia and fixed) in the 
inferior wall whereas the two day protocol diagnosed infarction only. In both these 
patients 201 identified mixed defect in the inferior wall. In one patient, the two day 
protocol diagnosed mixed defect in the inferior wall whereas the one day protocol 
diagnosed only infarction. In this patient 20171 diagnosed ischaemia in the inferior 
wall.
The percent agreement in diagnosis over all image segments between the 201 
and 99mTc tetrofosmin one day protocol is shown in Table 5.2.5.8.I. There was good 
agreement between 201j| imaging and the one day 99m jc tetrofosmin imaging 
protocols at different time points.
Agreement in the diagnosis between 201 y; and two day 99m jc tetrofosmin 
imaging studies are shown in Table 5.2.5.8.2. As shown in the table 5.2.5.8.2, there 
was good agreement between 201 j j  and 2 day protocol.
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5.2.5.8.2. SPEC! imaging
There was excellent concordance in the overall and the regional diagnosis of 
ischaemia between the one and two day protocol (Figure 5.2.5.8.2). There was no 
discrepancy either in the region of the diagnosis or the type of the diagnosis between 
one and two day protocol. However, there was discrepancy in five segments at rest, 3 
segments showed recovery in the inferior wall and 2 segments in the lateral wall with 
the same day re injection. However, this did not change the overall diagnosis in any 
patient.
Patient demography and detection of coronary artery disease
The demography of the study population and the results of sensitivity for the 
detection of coronary artery disease are combined with those of Stage II patients and 
are given in sections 5.3.4.2.1 and 5.3.4.5.3 respectively.
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5.3. STAGE II
5.3.1. Patients
Fifty patients with known or suspected ischaemic heart disease or patients with 
atypical chest pain and normal 201 j j  scan were included in this group. All the patients 
satisfied the inclusion criteria.
5.3.2. Study design
Each patient had two study days. On the first day each patient underwent 
planar 201xi stress and 4 hour redistribution imaging. Within 2 weeks each patient 
underwent 99mxc tetrofosmin study-which involved stress imaging following graded, 
ergometric exercise (to the same work load as 201xj exercise study) and same day 
reinjection, 4 hours after the stress injection. (Study design in Figure 5.3.2.1). After 
each injection of ^ mTc tetrofosmin planar image acquisition was started between 15 
to 60 minutes. Planar images were acquired in four standard views. Following planar 
imaging SPECT images were acquired.
In addition, 10 persons with low probability of ischaemic heart disease (<3%) 
were included into the study. Each person had one study day wherein he underwent 
99mTc tetrofosmin study involving stress imaging following graded, ergometric 
exercise. This group had same day reinjection, 4 hours after the stress injection. (Study 
design in Figure 5.3.2.2). Planar imaging acquisition was started between 15 and 60 
minutes followed by SPECT imaging.
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5.3.3. M ethods
5.3.3.1. Exercise electrocardiography
5.3.3.1.1. Treadmill testing
Maximal, symptom-limited exercise testing was performed using a treadmill 
(Marquette CASE system) which comprised a motor-driven nylon belt with an 
accurate speed control running on a platform, the front end of which could be elevated 
to provide a gradient and increase the workload.
Input data was obtained from a simultaneous three-channel digitisation of the 
patient's electrocardiograph signals from 12 leads. Suitable disposable electrodes were 
placed over the chest (VI to V6) and the limb leads were fastened to the back in the 
usual way. Care was taken to shave excess hair and clean the skin with isopropyl 
alcohol to reduce artefacts. Twelve lead electrocardiogram was performed at baseline, 
each stage of the exercise and during recovery. Heart rate and ST-segment analysis 
were measured from the printouts.
5.3.3.1.2. Treadmill protocol
The standard Bruce protocol was used. The protocol comprised starting 
walking speed of 1.7 mph during the first stage at 10% gradient, with the speed being 
increased every three minutes (Figure 5.3.3.1.2.). The metabolic equivalent of exercise 
(METS) were calculated by the computer using the standard nomograms.
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Stage Time Speed Gradient
 _____________ (min)________ (mph)________ (%)
1 3 1.7 10
2 3 2.5 12
3 3 3.4 14
4 3 4.2 16
5 3 5.0 18
6 3 5.5 20
7 3 6.0 22
Figure 5.3.3.1.2.: Bruce's protocol for treadmill exercise testing
5.3.3.1.3. Software
A commercially available microcomputer-assisted system for exercise was 
modified so that it could control the exercise protocol and analyse the 
electrocardiographic changes. The computer detected each QRS complex and 
classified each beat according to the morphology and time of occurrence. During the 
pre-exercise phase, the dominant rhythm beat type was detected and the template of a 
normal beat was constructed; the QRS onset and offset points (E- and J- points) were 
also detected. Thereafter, the software determined whether all subsequent beats were 
normal or ectopic. Only normal beats were processed for ST-segment values and all 
abnormal beats were recorded at a paper speed of 25 mm/sec. The normal beats then 
underwent incremental averaging and the J-point depression or elevation and slope at 
J+60 msec segment using a reference point which was the most horizontal part of the 
PR segment. The electrocardiogram was continuously recorded as a 25:1 time- 
compressed record by displaying the template of the normal cardiac cycle at a rate of 1 
mm/sec. The location of the PR segment was selected as a reference point and the J- 
point was marked automatically by vertical markers on the top lead for each complex, 
permitting visual validation. At one-minute intervals during exercise and post-exercise 
periods, a summary was printed at the top of the record and included: minutes of 
exercise, heart rate, ectopic rate and ST-segment depression. Blood pressure was 
measured manually by a mercury-in-glass sphygmomanometer and entered into the 
computer. When the test was completed, a final report was generated, which specified: 
the exercise protocol, duration of exercise, maximum heart rate, ectopic counts, 
location of ST measurement and worst cases of ST-depression and slope in each lead, 
heart rate, ectopic rate and blood pressure. Finally, average electrocardiographic 
complexes and digital values for rest, immediate pre-exercise period, every three 
minutes of exercise, immediate recovery period and each minute thereafter were 
printed out. The maximal ST-segment changes were also recorded. The final reports 
were stored in a digital recorder for future reference and analysis.
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The exercise testing procedure was similar to the one described in section
5.2.3.3.4.
5.3.3.2. Imaging
5.3.3.2.1. Planar imaging
Planar 201 ancj 99mrpc tetrofosmin scintigraphy were performed using the 
same gamma camera method as described in section 5.2.3.4.
In stage II patients (n=60) the amount of radioactivity injected was 
considerably less; the reconstruction volume was 6 ml; mean (SD) reconstruction 
activity was 479 (48) and 2090 (265) MBq for stress and same day rest injections 
respectively. The injected activity was 289.9(12) and 822.5 (24.2) MBq for stress and 
same day rest injections respectively.
5.3.3.2.2. SPECT imaging
The same gamma camera that was used for SPECT imaging in Stage I was 
used in this stage as well for the acquisition of SPECT imagng. The image acquisition 
was similar to the procedure described in section 5.2.3.5.
5.3.3.2.3. Semi-quantitative image analysis and statistical analysis
The same methods used for analysis of the results from the patients in stage I 
group were used here.
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5.3.4. Results
For the purpose of convenience the results given below are for a total of 73 
patients, obtained by combining Stage I and Stage II patients.
5.3.4.1. Quality of images
| Quality of the images visually assessed by the experienced readers was better
with 99mTc tetrofosmin compared to ^Oljl. With most 20 I j ]  images the quality was
recorded as good. With planar 99m'pc tetrofosmin images nearly 20% was recorded as 
excellent and most others as better than 20ly) images. Of the 201 j ]  images 3.6% were 
scored as poor images at stress and 4.7% at redistribution. With 99mTc tetrofosmin 
2% each of 70° left anterior oblique at stress and rest and 4% of the left lateral view at 
stress and rest were recorded as of poor quality. However, diagnosis could still be 
made using these images. About 75% of the SPECT images were recorded as excellent 
in quality and remaining 25% as good in quality.
5.3.4.2. Demography of the study population
The study population consisted of 73 patients who were selected randomly 
over a period of two years and there were also 10 persons with low probability of 
coronary artery disease selected for the study. All patients and persons with low 
probability of coronary artery disease fulfilled the entry criteria as mentioned in the 
section on Inclusion criteria. There were 71 men and 12 women patients, but all of the 
10 persons with low probability of coronary artery disease were males. The mean (SD) 
age of patient population was 61.7 (8.8) years, range being 36 to 79 years. However, 
the mean age of low probability group was 38.5 (7.2) years, range being 25 to 52 
years. The low probability group was significantly younger (p<0.001) than the patient 
population. There were 61 Caucasian and 22 Asians in the study group.
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5.3.4.2.1. Patient demographic data
Twenty four patients had no history of cigarette smoking, 28 were ex-smokers, 
and 21 were smokers. A history of essential hypertension was present in 19 patients, 
diabetes mellitus in 5 and hyperlipidaemia in 12 patients. Twenty-two patients had a 
family history of ischaemic heart disease (angina, myocardial infarction, congestive 
heart failure and cardiac death).
Thirty one patients (42.5%) had history of documented myocardial infarction in 
the past and also had a history of chest pain on exertion at the time of entry into the 
study. However, 9 (12.3%) had a history of myocardial infarction only without angina 
and 25 patients (34.4%) had only angina on exertion without history of myocardial 
infarction. Three patients had coronary artery bypass graft operation in the past and 10 
had coronary angioplasty to at least one of their major epicardial coronary arteries 
(Figure 5.3.4.2.1.1).
Fifty four patients were taking sublingual short acting nitrates when required,
18 were on long acting nitrates (oral or buccal), 15 were on beta-adreno receptor
blockers, 44 were on calcium antagonists, 6 patients were taking angiotensin
converting enzyme inhibitors and 12 patients were on diuretics. Sixty patients were
taking aspirin daily (Figure 5.3.4.2.1.2). Twenty-four patients were on multiple anti- 
anginal medication. All these medications were stopped for a period of 48 hours before
the study except sublingual nitrate which was stopped on the morning of the study.
The resting electrocardiogram revealed previous Q-wave myocardial infarction 
in the anterior wall in 4 patients, inferior myocardial infarction in 9, and 7 patients had 
suggestion of non Q-wave myocardial infarction. Three patients had voltage criteria for 
left ventricular hypertrophy on their electrocardiograms (Figure 5.3.4.2.1.3).
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5.3.4.3. Exercise electrocardiography
There was no significant difference in the haemodynamic parameters obtained 
during bicycle exercise or treadmill testing during either 201 j j  or 99m jc tetrofosmin 
studies. During bicycle testing in 201ti study the mean (SD) exercise time was 6.9 (2) 
minutes; mean maximum heart rate was 129 (15.5) beats/ minute; mean maximum 
systolic blood pressure was 164 (22.2) mm Hg and mean maximum double product 
(heart rate x systolic blood pressure) was 21156 (4451.8). During treadmill exercise in 
201xi study the mean exercise time was 6.4 (2.3) minutes; mean maximum heart rate 
was 136 (21.3) beats/ minute; mean maximum systolic blood pressure was 156 (25.6) 
mm Hg and mean double product was 21216 (4845.6). Since there was no significant 
difference between the parameters during 99mxc tetrofosmin study and the 201xi 
study, the exercise haemodynamic parameters of both bicycle and treadmill exercise are 
able to be combined for the purposes of analysis.
In the patient group (n=73), the mean (SD) exercise time was 6.5 (2.4) minutes 
(range 2.07 to 11 minutes) and in persons with low probability of coronary artery 
disease (n=10) the mean was 11 (1.7) minutes (range 7 to 12.93 minutes) (p<0.001). 
Angina pectoris was experienced in 45 patients, dyspnoea in 25 patients and fatigue in 
22; the remaining were either asymptomatic during exercise or stopped with leg 
fatigue. In the low probability group exercise was terminated due to dyspnoea in all 
and none developed angina pectoris. Horizontal or downsloping ST segment 
depression (> 1 mm) was noted in 46 patients and in one person in low probability 
group. The mean maximum heart rate and double product achieved by the patients 
were 132 (21.8) beats/min and 21218 (4705.8), respectively and by low probability 
group were 169 (15.4) beats/min and 28207 (2206.8), respectively (p <0.001).
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5.3.4.4. Analysis in the patient group
5.3.4.4.1. Comparison of exercise testing between 20^Tl and 99mj c tetrofosmin 
studies
Overall Comparison
The total mean (SD) exercise time during 201 stress testing was 6.7 (2.2) 
minutes and that during 09mxc tetrofosmin stress testing was 7 (2.2) minutes. The 
difference in exercise time was not statistically significant (p=NS) (Figure 5.3.4.4.1.1). 
During 201x1 stress testing, 44 patients developed angina, 28 dyspnoea and 20 
developed fatigue. The rest either had no symptoms during exercise testing or stopped 
due to leg fatigue. During 99mxc tetrofosmin stress testing 46 patients developed 
angina, 30 developed dyspnoea and 17 developed fatigue (Figure 5.3.4.4.1.2). 
Horizontal or downsloping ST-depression of more than 1 mm was seen in 40 patients 
during 201j i  stress testing and 34 patients during 99mxc tetrofosmin testing. The 
difference was not statistically significant (p=NS). During 201ti stress testing the 
mean (SD) maximum heart rate achieved was 131 (22.1) beats/minute, mean maximum 
blood pressure was 169 (24.4)/ 86 (11.1) mm Hg and mean double product was 
22184 (4127). During 99m jc tetrofosmin stress testing the mean maximum heart rate 
reached was 130 (21.7) beats/minute, mean maximum blood pressure was 167 (23.9)/ 
85 (10.6) mm Hg and mean maximum double product was 21676 (4868) (Figure
5.3.4.4.1.3). The haemodynamic differences between 201 j j  ancj 99mxc tetrofosmin 
stress testing were not statistically significant (p=NS).
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Comparison between defect types
Overall diagnosis of fixed perfusion defect was made in 13 patients and 
reversible defects in 41 patients by 20171 imaging, whereas ^^mTc tetrofosmin 
imaging diagnosed 18 patients as having fixed and 39 as reversible defects respectively. 
During 20171 stress testing, in patients with fixed defects, mean maximum heart rate 
achieved was 122 (21.6) beats/ minute, mean maximum blood pressure was 155
(31.7)/ 82 (11.9) mm Hg and mean maximum double products was 19000 (5201.5); 
whereas in those with reversible defects mean maximum heart rate attained was 131
(19.3) beats/ minute, mean maximum blood pressure achieved was 167 (22.9)/ 83
(11.8) mm Hg and mean maximum double product was 21742 (4075.4). During 
99m7c tetrofosmin testing, in patients with fixed defects, mean maximum heart rate 
was 132 (21) beats/ minute, mean maximum blood pressure was 145 (19.8)/ 75 (13.9) 
mm Hg and mean maximum double product achieved was 19152 (3419.4); however in 
those with reversible defect the mean maximum heart rate was 141 (22.6) beats/ 
minute, mean maximum blood pressure was 149 (20.4)/ 77 (8.6) mm Hg and the mean 
maximum double product was 21010 (3948.8). The difference in the haemodynamic 
parameters between 2017] ancj 99ni7c tetrofosmin stress imaging with respect to fixed 
and reversible defects were not statistically significant (p=NS) (Table 5.3.4.4.1).
Identification of Coronary Artery Disease
The sensitivity of exercise electrocardiography for the detection of coronary 
artery disease was calculated. Out of 61 patients with documented coronary artery 
disease, exercise electrocardiography was abnormal (horizontal or down sloping ST 
segment depression of > 1 mm) in 40 patients (sensitivity 66%). In 21 patients with 
documented coronary artery disease there was no significant ST depression during
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exercise. Out of these 21, 9 patients did not reach 85% of age predicted maximum 
heart rate and exercised for less than 9 minutes. In these 21 patients, planar 201x1 
imaging identified coronary artery disease in 16 (76%) and planar 99m jc tetrofosmin 
imaging identified in 15 (71%)j________________ j
There were 4 patients with all three normal coronary arteries and 10 with low 
probability of coronary artery disease. Out of these 14, exercise electrocardiography 
was normal in 10 (specificity 71%) (Figure 5.3.4 4.1.4.). There were 4 women with / 
normal coronary arteries. Out of these 4, 2 had significant ST depression on exercise 
and two had no ST depression during exercise. Hence the specificity of exercise 
electrocardiography in women was 50%.
5.3.4.5. Myocardial Perfusion Imaging
5.3.4.5.1. Time between injections and image acquisition
The mean time between stress and rest injection of 99m jc tetrofosmin was 
4.35 (0.8) hours. Time between 201xj injection and start of image acquisition was 12
(2.3) minutes. In stage II, patients the interval between 99m jc tetrofosmin injection 
and start of image acquisition was 27 (20) minutes for stress and 24 (9) minutes for 
rest injection for planar images and 52 (18) minutes for stress and 44 (11) minutes for 
rest for SPECT images respectively. For the purposes of calculating sensitivity and 
specificity, 30 minute planar images were taken into consideration from stage I 
patients.
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Figure 5.4.4.4.1.3.: Exercise haemodynamic parameters during
Tl-201 and Tc-99m tetrofosmin studies
Table 5.3.4.4.1: Exercise haemodynamic parameters with 201xi and 99mxc tetrofosmin 
imaging in patients with reversible and fixed defects
Patients with reversible defects
201xi
Heart Rate 131(19.3)
(beats/min)
Systolic Blood Pressure 167(22.9)
(mmHg)
Double Product 217.4(40.8)
(x 100)
Patients with fixed defects
201xi
Heart Rate 122(21.6)
(beats/min)
Systolic Blood Pressure 155(31.7)
(mmHg)
Double Product 190(52)
(x 100)
99mxc tetrofosmin 
141(22.6)
149(20.4)
210.1(39.5)
99mxc tetrofosmin 
132(21)
145(19.8)
191.5(34.2)
All values expressed as Mean(SD) 
p=NS for all values
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Figure 5.3.4.4.1.4.: Sensitivity and specificity of exercise
electrocardiography for the diagnosis 
of coronary artery disease
5.3.4.5.2. Sensitivity for Detection of Perfusion Defects 
Diagnosis of fixed defects
Fixed perfusion defects were identified in 39 patients with 201x1 imaging and 
43 patients with planar ^ mTc tetrofosmin imaging. The difference was not statistically 
significant. Anterior wall fixed perfusion defects were identified in 16 and 19 patients 
respectively with 201x1 and 99mxc tetrofosmin imaging. Septal fixed perfusion defects 
were diagnosed in 11 and 16 patients; inferior fixed defects in 12 and 18 patients; 
lateral fixed defects in 13 and 14 patients and apical fixed defects in 13 and 15 patients 
and non- contiguous apical fixed defects in 4 and 2 patients respectively with 201xi 
and 99mxc tetrofosmin imaging (Figure 5.3.4.5.2.1). The difference in the regional 
diagnosis of fixed defects between planar 201xi and planar 99mxc tetrofosmin imaging 
were not statistically significant (p=NS) for any region.
SPECT 99mxc tetrofosmin imaging identified 41 patients as having fixed 
defects at least in one of the regions (Figure 5.3.4.5.2.2). Anterior wall fixed defects 
were noted in 13, septal defects in 14, inferior fixed defects in 20, lateral in 15 and 
apical in 17 patients. The difference between planar and SPECT 99mxc tetrofosmin 
imaging was not statistically significant.
Diagnosis of reversible ischaemia
In the identification of patients with reversible ischaemia, 201x1 imaging 
diagnosed 41 patients as having reversible ischaemia with 4 hr redistribution imaging. 
This number included patients with both completely and partially reversible ischaemia. 
99mxc tetrofosmin planar imaging, diagnosed 39 patients as having reversible 
ischaemia. The difference between 201xi and 99mxc tetrofosmin was not statistically
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significant (p=NS). In the anterior wall 201 j j  anc| 99myc tetrofosmin both identified 
13 defects each; Septal reversible defects were seen in 11 patients with 20I j]  imaging 
and 19 patients with 99m jc tetrofosmin imaging. Inferior reversible defects were 
diagnosed in 21 by both agents; lateral defects were noted in 13 each by both imaging 
agents and apical reversible defects were seen in 29 patients with 201ti imaging and 
36 patients with 99m jc imaging. Except septal defects (p<0.05), in all other regions 
the difference between the two techniques was not statistically significant (Figure
5.3.4.5.2.3). The concordance between the 2 imaging agents is dealt with in section
5.3.4.6.I.
SPECT 99m jc tetrofosmin imaging identified 44 patients as having reversible 
defects (both completely and partially reversible defects) at least in one of the regions 
(Figure 5.3.4.5.2.4). Anterior wall reversible defects were noted in 21, septal defects in 
27, inferior reversible defects in 24, lateral in 18 and apical in 35 patients. The 
difference between planar and SPECT 99mrpc tetrofosmin imaging was not statistically 
significant for any of the regions, although septal reversible defects were identified in 
more patients with SPECT than planar 99m'j,c tetrofosmin imaging.
Size of the defect at stress
A total of 1,314 segments were studied in 73 patients with each imaging 
protocol. 99mrpc tetrofosmin identified 256 abnormal segments during stress and 
201t 1 identified 250 segments as abnormal (p=NS). 201 j j  ancj 99mq^ tetrofosmin 
diagnosed respectively 45 and 50 abnormal segments in the anterior wall, 41 and 49 
segments in the septum, 64 and 57 in the inferior wall, 41 and 39 abnormal segments in 
the lateral wall and 61 and 59 segments in the apex during stress . The difference
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between the imaging agents in the identification of abnormal segments at stress was 
not significant in any of the areas.
99mTc tetrofosmin SPECT imaging identified 295 abnormal segments at stress; 
52 in the anterior wall, 50 in the septal region, 84 in the inferior wall, 47 in the lateral 
wall and 62 at the apex. Total number of abnormal segments identified by SPECT 
imaging were more and hence significantly larger defects were identified in the inferior 
wall (p<0.01) compared to planar 99m jc tetrofosmin imaging (Figure 5.3.4.5.2.5).
Ischaemic burden
Identification of amount of myocardium with reversible ischaemia (ischaemic 
burden) is an important aspect of myocardial perfiision imaging agents. Reversible 
ischaemia was identified in 106 segments with 201 imaging and 98 segments with 
99m jc tetrofosmin imaging. The difference was not statistically significant. 201x1 and 
99m jc tetrofosmin identified reversible ischaemia in 17 and 16 segments in the 
anterior wall, 23 and 22 segments in the septum, 24 and 23 in the inferior wall, 20 and 
19 in the lateral wall and 22 and 18 in the apical region respectively. The difference 
between the two imaging agents was not statistically significant in any of the areas 
(p=NS) (Figure 5.3.4.5.2.6).
Total ischaemic burden identified by SPECT 99mxc tetrofosmin imaging (123 
segments) was significantly higher than planar 99m jc tetrofosmin imaging (p<0.01). 
Twenty reversible segments were identified in the anterior wall, 26 in the septum and 
inferior wall each, 27 in the lateral wall and 24 at the apex. The size of the reversible 
defects were higher generally in all the regions with SPECT imaging compared to 
planar 99mxc tetrofosmin images, although not statistically significant. Figure
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5.3.4.5.2.7 illustrates an example of a reversible defect in the anterior wall identified 
by SPECT 99mTc tetrofosmin.
Effect of anti-anginal medication
There were 34 patients on single agent therapy and out of these, ^Oljl, planar 
and SPECT 99m jc tetrofosmin imaging identified 28 (82%), 30 (88%) and 30 (88%) 
respectively as having ischaemic heart disease (p=NS). Out of 24 patients who were on 
multiple anti-anginal medication, 201 ^  planar and SPECT 99mrpc tetrofosmin 
diagnosed 21 (88%), 21 (88%) and 22 (92%) respectively (p=NS).
Fifteen patients were on |3 adrenoceptor blocking agents and in them, 2 0 1 j i  
identified disease in 11 (73%) whereas planar and SPECT 99mrpc tetrofosmin in 13 
(87%). The difference was statistically significant (p<0.05). Forty two patients were on 
calcium antagonists and 201 j i  imaging diagnosed ischaem ic heart disease in 36 (86%); 
planar and SPECT 99m'pc tetrofosmin in 36 (86%) and 37 (88%) (p=NS).| However, 
it should be noted that all the cardioactive medication were stopped for 48 hours 
before the study day.
Diagnosis of perfusion defect in patients with and without previous myocardial ! 
infarction
There were 40 patients with documented myocardial infarction in the past, j 
Perfusion defects were identified in 33 patients by 201ti imaging (sensitivity 82.5%) 
and in 35 patients by 99mxc tetrofosmin imaging (sensitivity 87.5%) (p=NS). Out of j 
25 patients who had exertional angina without previous myocardial infarction, both 
201t 1 and 99m jc tetrofosmin imaging identified 20 patients as having a perfusion j
! '  " '  i| defect (sensitivity 80%) (p=NS). !
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(p = NS for all regions)
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Figure 53.4.5.2.1Diagnosis of fixed perfusion defects
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Figure 5.3.4.5.2.2: SPECT 99m jc tetrofosmin images showing a large defect in 
the inferior wall (arrow) with reversibility
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Figure 5.3A5.2.7: SPECT " mTc tetrofosmin images showing inferior, septal and 
apical defects with reversible ischaemia in the septum and apex 
and fixed defect in the inferior wall
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5.3.4.5.3. Sensitivity for detection of coronary artery disease
Overall diagnosis
Out of a total of 73 patients studied 65 had coronary angiography. Of these 65 
patients, 61 had evidence of documented coronary disease by coronary angiography. 
Nine patients had angiographically documented collaterals to the diseased artery.
201X1 imaging identified 50 patients as having coronary artery disease 
(sensitivity 82 %), whereas 09mte t rofosmin  planar imaging diagnosed 52 patients 
(sensitivity 85.2%) and OOm^c tetrofosmin SPECT imaging diagnosed 56 patients 
(sensitivity 91.8%). The difference between the sensitivities of the two imaging agents 
was not statistically significant (p=NS) (Figure 5.3.4.5.3.1). There was no significant 
difference in the overall sensitivity for the diagnosis of coronary artery disease between 
men and women. Out of 9 patients with collaterals, 2 were diagnosed as having normal 
perfusion scan by both 201 j j  ancj 99m j c tetrofosmin.
Identification of coronary artery disease with > 50% narrowing
Out of 61 patients who had angiographic evidence of coronary artery disease; 
19 had single vessel disease, 25 patients had two vessel disease and 17 had three vessel 
disease (42 had multi-vessel disease). 201xi and 99mxc tetrofosmin planar imaging 
identified 14 and 17 patients as having single vessel disease and 36 and 37 patients as 
having multi-vessel disease respectively. The differences between the two agents, using 
planar imaging, were not statistically significant. 99mxc tetrofosmin SPECT imaging 
identified 16 and 40 patients as having single and multi-vessel disease. The difference 
between planar and SPECT 99mjc tetrofosmin imaging for diagnosis of coronary 
artery disease with >50% narrowing was not statistically significant.
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Forty three patients had disease in the left anterior descending artery; 201ti 
and planar 99m jc tetrofosmin imaging diagnosed the lesion in 36 and 39 patients; out 
of 43 patients with diseased right coronary arteries both 201 jj  %nd 99mTc tetrofosmin 
diagnosed 37 patients each. Thirty three patients had disease in the left circumflex 
artery; 201^1 and 99m'pc tetrofosmin identified 28 and 27 patients respectively as 
having the lesion. The differences between the two agents were not statistically 
significant (Figure 5.3.4.5.3.2). 99m jc tetrofosmin SPECT imaging diagnosed 39 
patients each with left anterior descending and right coronary disease and 28 patients 
with left circumflex disease. The difference between planar and SPECT 99mrj'c 
tetrofosmin imaging was not statistically significant.
Identification of coronary artery disease with > 70% narrowing
Twenty three patients had single vessel disease and 34 patients had multi-vessel 
disease of greater than 70% luminal narrowing o f the epicardial coronary arteries. 
201t 1 and planar 99mTc tetrofosmin imaging identified 18 and 20 patients respectively 
as having single vessel disease and 32 patients each as having multi-vessel disease. The 
differences were not statistically significant. SPECT 99nrrc tetrofosmin imaging 
diagnosed single and multi-vessel disease in 22 and 33 patients respectively.
Out of 37 patients who had disease in the left anterior descending artery, 201ti 
and 99nrrc tetrofosmin planar imaging identified 33 and 36 respectively; of the 35 
patients with right coronary disease both agents diagnosed 30 patients each and of the 
27 patients with left circumflex disease 201^1 ancj 9 9 m ^  tetrofosmin identified 23 and 
22 respectively. (p=NS) (Figure 5.3.4.5.3.3). SPECT 99mTc tetrofosmin imaging 
diagnosed left anterior descending artery disease in 36, right coronary disease in 31
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and left circumflex disease in 23 patients. The diagnosis by planar imaging was not 
significantly different from SPECT 99m,pc tetrofosmin imaging.
Identification of coronary artery disease with > 90% narrowing
29 patients had single vessel disease with greater than 90% narrowing in the 
coronary arteries. 201ti and planar 99mrpc tetrofosmin imaging identified 25 and 26 of 
these patients respectively. Sixteen patients had multi-vessel disease of whom 15 each 
were identified by the two imaging agents (p=NS). 99m jc tetrofosmin SPECT 
imaging diagnosed 28 with single and 15 patients with multi-vessel disease.
Twelve patients had left anterior descending artery disease and all of them were 
correctly identified by both imaging agents. Of the 19 with right coronary disease, 
201ti identified 17 and 99m jc tetrofosmin 16. Out of the 8 left circumflex disease 
201xi and 99mxc tetrofosmin diagnosed 7 patients each (p=NS) (Figure 5.3.4.5.3.4). 
SPECT 99mxc tetrofosmin imaging identified all 12 patients with left anterior 
descending artery disease, 17 with right coronary disease and 7 with left circumflex 
disease. The diagnosis by planar imaging was not significantly different from SPECT 
99mxc tetrofosmin imaging (p=NS).
Stress induced left ventricular dilatation
Left ventricular cavity dilatation was observed in 9 patients during stress, with 
planar 99mxc tetrofosmin. The overall sensitivity for the detection of coronary artery 
disease using left ventricular dilatation alone was poor (12.3%) and for the detection of 
multi-vessel disease was 19%. Cavity dilatation was seen in 7 patients (overall 
sensitivity 9.5%) with 201xi imaging and the sensitivity for the detection of multi­
vessel disease was poor (14.3%).
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5.3.4.5.4. Specificity to detect normal coronary artery
Persons with low probability of coronary disease
In all 10 persons with low likelihood of coronary artery disease, both planar 
and SPECT 99mTc tetrofosmin imaging identified all the areas both at stress and rest 
as normal. The overall diagnosis was normal in all ten persons, and hence the normalcy 
rate using 99nr['c tetrofosmin was 100%.
Atypical chest pain with normal 2Q1T1 scan
Eight patients had atypical chest pain and a normal 201x1 scan. When coronary 
angiographic data were available, the occlusion of major vessels did not exceed 50%. 
All these 8 patients had normal planar and SPECT 99mxc tetrofosmin scans. Thus, 
in this group, the concordance between 201xi and 99mxc tetrofosmin imaging was 
100% (Figure 5.3.4.5.4.1)
Normal coronaries in patients with coronary artery disease:
Out of 61 patients with angiographic coronary artery disease, there were 76 
vessels with <50% occlusion. This included, 22 left anterior descending arteries of 
which 201xi, planar and SPECT 99mxc tetrofosmin identified 21, 20 and 20 
respectively; 22 right coronary arteries of which 20, 19 and 19 were identified as 
normal respectively and of the 32 left circumflex arteries with <50% narrowing 201x1 
identified 24 and planar 99mxc tetrofosmin identified 26 vessels and SPECT 99mxc 
tetrofosmin identified 25 vessels. The difference was not statistically significant (p=NS) 
between planar 201xi and planar 99mxc tetrofosmin and also between planar and 
SPECT 99mxc tetrofosmin imaging (Figure 5.3.4.5.4.2).
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Figure 5.3.4.5.4.1 : Planar 201T1 and 99mTc tetrofosmin images showing normal myocardial 
distribution of the tracer in a patient with normal coronary arteries.
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5.3.4.6. Analysis of concordance
5.3.4.6.1. Concordance between planar 201t 1 and planar 99mTc tetrofosmin imaging 
Overall comparison
Out of 73 patients, both 201 j j  ancj 99mTc tetrofosmin identified 14 patients as 
having normal perfusion studies and 52 patients as having abnormal perfusion scans 
concordantly (Figures 5.3.4.6.1.1 to 5.3.4.6.1.2). The overall concordance between the 
two agents for identification of normal or abnormal perfusion scans was 90% (kappa 
=0.74; 95% confidence interval 0.56 to 0.92) (Figure 5.3.4.6.1.4 a).
Type of the defect
The concordance between 201 j} ancj 99mrpc tetrofosmin for the identification 
of normal, ischaemic, infarct or mixed defect in the myocardium is shown in Figure 
5.3.4.6.1.4 b. (kappa = 0.54; 95% confidence interval 0.39 to 0.68). In 5 patients 
201t 1 identified ischaemia whereas ^^mTc tetrofosmin identified infarction. Two of 
these patients had infarction in the past and three patients had positive exercise 
electrocardiography. However, in 5 patients where 201xi diagnosed normal scans, 
99mxc tetrofosmin identified ischaemia in 2 and infarction in three. Two of these
patients had abnormal coronary angiography. The overall concordance is very high.
The kappa value shows the agreement between the different types of perfusion defects. 
Regional diagnosis
In the anterior region, 41 patients were concordantly diagnosed as having no 
defect and 29 were concordantly diagnosed as having abnormal scans. The overall 
concordance was 95% (kappa = 0.61; 95% confidence interval 0.47 to 0.73). The 
concordance to diagnose the type of the defect is shown in Figure 5.3.4.6.1.5 a. In the 
septal region, 38 patients were diagnosed as having no defects and 22 as having a
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defect; overall concordance was 82% (kappa = 0.6; 95% confidence interval 0.45 to 
0.75) (Figure 5.3.4.6.1.5 b). In the inferior wall, 34 patients were diagnosed as having 
normal region and 33 as having a defect; overall concordance between ^Ol-pj and 
99mxc tetrofosmin was 92% (kappa = 0.65; 95% confidence interval 0.51 to 0.78) 
(Figure 5.3.4.6.1.6 a). Forty four patients were identified as having a normal lateral 
wall and 24 as having a defect in that region concordantly. The overall concordance 
was 93% (kappa = 0.62; 95% confidence interval 0.48 to 0.77) (Figure 5.3.4.6.1.6 b). 
In the apical region 20 and 40 patients were concordantly diagnosed as having normal 
apex and apex with defect respectively (overall concordance was 82%; kappa = 0.46; 
95% confidence interval 0.32 to 0.61) (Figure 5.3.4.6.1.6. c).
An example of discordance between planar 201t 1 and ^^mTc tetrofosmin 
imaging is shown in Figure 5.3.4.6.1.7. Mr. RM, a 46 year old gentleman, was 
complaining of anginal chest pain. ^OIj i  stress and 4 hour redistribution imaging was 
completely normal. However at the same level of the exercise planar 99mTc 
tetrofosmin imaging showed a large reversible defect in the antero septal area. The 
patient underwent coronary angiography one week later which demonstrated a 90% 
stenosis of his proximal left anterior descending artery. Coronary angioplasty was 
performed to the diseased artery.
5.3.4.6.2. Concordance between planar and SPECT 99mjq  tetrofosmin imaging 
Overall comparison
Out of 73 patients, both planar and SPECT 9 9 m ^  tetrofosmin identified 13 
patients as having normal perfusion studies and 55 patients as having abnormal 
perfusion scans concordantly. The overall concordance between the two agents for
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identification of normal or abnormal perfusion scans was 93% (kappa =0.75; 95% 
confidence interval 0.51 to 0.93) (Figure 5.3.4.6.2.1 a).
Type of the defect
The concordance between planar and SPECT 99m jc tetrofosmin for the 
identification of normal, ischaemic, infarct or mixed defect in the myocardium is shown 
in Figure 5.3.4.6.2.1 b. (kappa = 0.58; 95% confidence interval 0.34 to 0.64). In 4 
patients planar imaging identified ischaemia whereas SPECT imaging identified as 
infarction. Two of these patients had ischaemia on 201tj scan
Regional diagnosis
In the anterior region, 37 patients were concordantly diagnosed as having no 
defect and 29 were concordantly diagnosed as having abnormal scans. The overall 
concordance was 89% (kappa = 0.65; 95% confidence interval 0.51 to 0.79). The 
concordance to diagnose the type of the defect is shown in Figure 5.3.4.6.2.2 a. In the 
septal region, 30 patients were diagnosed as having no defects and 33 as having a 
defect; overall concordance was 86% (kappa = 0.66; 95% confidence interval 0.51 to 
0.81) (Figure 5.3.4.6.2.2 b). In the inferior wall, 27 patients were diagnosed as having 
normal region and 37 as having defect; overall concordance between planar and 
SPECT 99mTc tetrofosmin was 88% (kappa = 0.69; 95% confidence interval 0.47 to 
0.82) (Figure 5.3.4.6.2.3 a). Thirty eight patients were identified as having a normal 
lateral wall and 25 as having a defect that region concordantly. The overall 
concordance was 86% (kappa = 0.61; 95% confidence interval 0.47 to 0.79) (Figure 
5.3.4.6.2.3 b). Sixteen and 46 patients were concordantly diagnosed as having a 
normal apex and apex with defect respectively (overall concordance was 85%; kappa = 
0.48; 95% confidence interval 0.34 to 0.64) (Figure 5.3.4.6.2.3. c).
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Figure 5.3.4.6.1.1 Planar images showing defect in the infero-posterior and lateral walls at 
stress (arrow). There is partial recovery in the inferior wall and complete 
recovery in the postero-lateral wall by both the tracers. N ote the 
concordance in the type as well as the region o f  the defect.
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Figure 5.3.4.6.1.2 Planar images showing large defect in the anteroseptal area during 
stress (arrow) with partial recovery by both the tracers. Note the 
concordance in the type as well as the region of the defect.
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Figure 5.3.4.6.1.6.: Concordance in regional diagnosis between Tl-201 
and Tc-99m tetrofosmin
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5.3.4.7. Relative value of Non-Invasive tests in the diagnosis of coronary artery
disease
Out of the 61 patients with documented coronary artery disease, the relative 
value of resting electrocardiography, exercise electrocardiography, planar 201xi 
imaging, planar 99mxc tetrofosmin imaging and SPECT 99mxc tetrofosmin imaging 
were compared.
Planar 99mxc tetrofosmin imaging identified 52 patients with a sensitivity of 
85.2%. 99mxc tetrofosmin SPECT imaging identified 56 patients (91.8%) as having 
ischaemic heart disease. All three imaging modalities were significantly (p<0.01) better in 
diagnosing coronary artery disease when compared to exercise electrocardiography. 
However, there was no statistically significant difference between the three imaging 
modalities (p-NS) (Figure 5.3.4.7). When exercise electrocardiography was added to 
the imaging modality, the sensitivity for diagnosis of coronary artery disease increased 
to 92% with planar 201xi and 99mxc tetrofosmin imaging and to 95% with SPECT 
99mxc tetrofosmin imaging.
5.3.4.8. Agreement between perfusion imaging and diagnosis at study entry
5.3.4.8.1. Agreement for the diagnosis of ischaemia.
Ability of the perfusion imaging agents were compared to the diagnosis that 
was made at study entry. Diagnosis at study entry included all the available information 
at the time of entry including the clinical history, resting electrocardiogram, 
investigations performed like exercise electrocardiography and coronary angiography
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when available. The agreement in the diagnosis between ^ T l  and planar 99mxc 
tetrofosmin imaging and diagnosis at study entry for the diagnosis of ischaemia was 
calculated. Ischaemia at study entry was defined as history of typical angina or 
significant ST depression on exercise electrocardiography with significant coronary 
artery disease in at least one epicardial coronary artery. Ischaemia on perfusion 
scintigraphy was considered to be present when at least two segments were found to 
have reversible perfusion defect. The results of the overall agreement between the 
planar 201ti and ^^mTc tetrofosmin imaging and the diagnosis at study entry were 
compared and are shown in Table 5.3.4.8.1. There was no significant difference 
between the imaging agents in relation to the diagnosis at study entry.
5.3.4.8.2. Agreement for the diagnosis of infarction.
201t 1 and 99m tetrofosmin planar images were compared with the diagnosis 
at study entry and the agreement between them for the diagnosis of infarction was 
evaluated. A diagnosis of myocardial infarction was made at study entry with history of 
documented infarction in the past or resting electrocardiograph showing Q-wave 
myocardial infarction or regional myocardial systolic dysfunction on the left 
ventriculogram with significant coronary artery disease. The results are shown in Table
5.3.4.8.2. The overall agreement between the planar 201 j j  %nd 99m'pc tetrofosmin 
imaging and the diagnosis at study entry were compared and there was no significant 
difference between the two imaging agents.
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5.4. STAGE III
5.4.1. Patients
Thirty patients with known or suspected ischaemic heart disease were included 
into the study. All patients satisfied the entry criteria.
5.4.2. Study design
Each patient had three study days. On the first study day, patients were 
subjected to dobutamine stress testing and 99m'pc tetrofosmin was injected at the peak 
dose of the test. SPECT imaging was performed. Within 5 days, separate day rest 
99m jc tetrofosmin imaging was performed. On a separate day, treadmill exercise 
testing was performed (Figure 5.4.2).
5.4.3. Methods
After recording the vital signs and a 12 lead electrocardiogram, dobutamine 
was given by intravenous infusion. Infusion was started at 5 pgm/kg/min dose and 
increased by 5 pgm/kg/min, every 3 minutes. Electrocardiographic monitoring was 
continued throughout the infusion and blood pressure and electrocardiogram was 
recorded every third minute. Infusion was continued until a maximum of 40 p. 
gm/kg/min was reached or when the symptoms like chest pain, dyspnoea, hypotension 
(decrease in systolic blood pressure > 3 0  mm Hg compared to previous value), ST 
depression of > 4 mm, significant hypertension (systolic > 220 mmHg or diastolic > 
120 mmHg) or significant ventricular arrhythmia developed. 99mrpc tetrofosmin was 
injected at peak dose of dobutamine infusion and the infusion was continued for a 
further period of one minute whenever possible. After stopping the infusion
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electrocardiographic monitoring was continued for 15 minutes during recovery. 
Electrocardiogram and blood pressure were recorded every 5 minutes. 99mTc 
tetrofosmin SPECT imaging was started 15 to 60 minutes post injection. Within 5 
days, on a separate day 99mTc tetrofosmin was injected at rest and the SPECT 
imaging was repeated within one hour .
Injected activity o f  99m jc tetrofosmin was 370 (30.2) and 362 (26.4)
MBq for stress and rest respectively.
5.4.3.1. SPECT imaging
A single crystal Sophy gamma camera was used for perfusion image acquisition
and analysis. The camera head contained a detector consisting of 1/2 inch thick Nal
(Tl) crystal and 37 high performance photomultiplier (PM) tubes arranged in a
hexagonal array. The camera performance and data acquisition were controlled by a
computer with advanced software. Operations and programmes were selected from a
menu list and routine acquisition procedures were programmed into function buttons
on the keyboard. The camera head was equipped with a all-purpose, parallel-hole, low
energy collimator. The system was programmed to perform self-testing once it was 
| switched on, enabling adequate sensitivity and efficiency. A new Sophy gamma camera 
I described above, was acquired before the commencement of Stage III and it was used 
| to obtain the images.
In stage III patients 296-444 MBq (8 to 12 mCi) of 99m-p^ tetrofosmin was
injected at peak infusion of dobutamine and 296-444 MBq (8 to 12 mCi) at rest.
5.4.3.2. Semi-quantitative image analysis and statistical analysis
The same methods used for analysis of the results from the patients in stage I 
group were used here as well.
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Figure 5.4.2.: Study design of patients in Stage HI
5.4.4. RESULTS
5.4.4.1. Patient demography
The study population consisted of 30 patients with suspected or known 
ischaemic heart disease and were selected randomly over a one year period. All 
patients fulfilled the entry criteria as mentioned in the section on 'Inclusion criteria'. 
There were 28 men and 2 women in the patient group. The mean (SD) age of patient 
population was 59 (9.3) years, range being 43 to 73 years. There were 19 Caucasian 
and 11 Asians in the study group.
Eleven patients had no history of cigarette smoking, 9 were ex-smokers and 10 
were smokers. Five patients had history of hypertension, 4 had diabetes mellitus and 8 
patients had hyperlipidaemia. Eight patients had a family history of ischaemic heart 
disease.
Eight patients (26.6%) had past history of documented myocardial infarction 
and also angina on exertion at the time of study entry. Six patients (20%) had history 
of documented myocardial infarction only and 16 patients (53.4%) had history of 
angina only. One patient had history of coronary artery bypass graft operation in the 
past (Figure 5.4.4.1.1)
Twenty eight patients were taking aspirin daily and 24 were on sublingual 
nitro-glycerine when required. Eighteen patients were on calcium channel blockers, 8 
on B-blockers and five patients were on diuretics. Sixteen patients were on multiple 
anti-anginal medication (Figure 5.4.4.1.2)
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The resting electrocardiogram revealed previous Q-wave myocardial infarction 
in the anterior wall in 4 patients, inferior myocardial infarction in 3 and left ventricular 
hypertrophy in 3 patients (Figure 5.4.4.1.3).
5.4.4.2. Haemodvnamic parameters during stress testing
The mean (SD) exercise time was 6.7 (2.7) minutes (range 2.2 to 10.5 
minutes). The mean duration of dobutamine infusion was 19.8 (4.1) minutes (range 12 
to 24 minutes). During treadmill testing 17 patients developed angina, 4 patients 
dyspnoea, 11 patients fatigue and two patients leg pain. The reasons for termination of 
dobutamine infusion were chest pain in 13 patients, reaching maximum dose of 
dobutamine in 6, hypotension in 3 and self terminating ventricular tachycardia in one 
patient (Figure 5.4.4.2.1). Seven patients developed intolerable symptoms of various 
types including feeling nauseous, headache, flushing etc. Horizontal or downsloping 
ST segment depression of >1 mm was seen in 21 patients during treadmill testing and 
12 patients during dobutamine stress testing. During treadmill testing the mean 
maximum heart rate achieved was 132 (22.7) beats/minute, mean maximum systolic 
blood pressure 161 (22) mmHg and mean maximum double product was 21254 
(5474.6). During dobutamine stress testing the mean maximum heart rate was 120 
(18.3) beats/minute mean maximum systolic blood pressure was 159 (26.6) mmHg and 
mean maximum double product was 19101 (4453) (Figure 5.4.4.2.2). Overall
diagnosis of fixed perfusion defect was made in 19 patients and reversible defects 
(including both completely and partially reversible) were made in 20 patients. In 
patients with fixed defects the mean duration of dobutamine infusion was 20 (3.6) 
minutes; the mean maximum heart rate achieved was 118 (16) beats/minute; mean 
maximum systolic blood pressure 161 (22.7) mmHg and mean maximum double 
product 18937 (3397). In patients with reversible defects, the mean duration of 
dobutamine infusion was 20 (3.6) minutes; mean maximum heart rate 117 (17.9)
beats/minute; mean maximum systolic blood pressure reached was 159 (24.9) mmHg 
and mean maximum double product was 18736 (4193).
There were 3 patients with single vessel disease and 25 patients with multi­
vessel disease. The mean duration of dobutamine infusion was 22 (3.5) minutes in 
patients with single vessel disease and 19.8 (3.8) minutes in those with multivessel 
disease. The reason for stopping the infusion was reaching maximum dose of 
dobutamine in all 3 patients with single vessel disease. Among those with multi-vessel 
disease, 12 developed chest pain, 2 hypotension, one developed self terminating 
ventricular tachycardia, 3 reached maximum dose and the other 7 developed intolerable 
symptoms.
5.4.4.3. Identification of coronary artery disease
The sensitivity of treadmill exercise testing for the detection of coronary artery 
disease was calculated. Out of 28 patients with documented coronary artery disease, 
21 had abnormal exercise electrocardiographic changes (horizontal or downsloping ST 
segment depression of >1 mm) (sensitivity 75%). Out of two patients with normal 
coronary arteries, treadmill exercise test was abnormal in both.
During dobutamine infusion, 12 out of 28 patients developed significant ST 
depression suggestive of a diagnosis of coronary artery disease (sensitivity 43%). In 
the two patients with normal coronary arteries there were no significant ST changes on 
the electrocardiogram during dobutamine infusion.
Angina
53.4%
MI + Angina
26.6%
MI
20.0%
MI - Myocardial Infarction
1CABG
Figure 5.4.4.1.1.: Previous cardiac history of the 
dobutamine study group (n = 30)
nu
m
be
r 
of 
pa
tie
nt
s
Figure 5.4.4.1.2.: Drug history of dobutamine study group
Anterior MI 
13.3%Normal
66.7%
Inferior MI 
10.0%
LVH
10.0%
MI - Myocardial Infarction 
LVH - Left ventricular hypertrophy
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Figure 5.4.4.2.2.: Exercise haemodynamic parameters during
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5.4.4.4. 99mTc tetrofosmin myocardial perflision imaging
5.4.4.4.1. Activity injected and quality control for labelling
The mean (SD) injected dose of ^ mTc tetrofosmin was 370 (30.2) MBq 
during stress and 362.4 (26.4) MBq during rest on a separate day.
Radiochromatographic quality control strips were assessed for detection of labelling 
efficiency. The top, middle and bottom strip percentages were 0.3 (0.2), 96.7(1.3) 
and 3 (1.1) respectively for stress injection and 0.2 (0.1), 96.8 (1.4) and 3 (1.2) for 
rest injection.
5.4.4.4.2. Quality of images
Quality of ^ mTc tetrofosmin SPECT images were assessed subjectively as 
excellent in 80% of images, 18% were assessed to be of good quality and 2% as poor 
quality. Poor quality was mainly due to interference from subdiaphragmatic activity, 
particularly at rest.
5.4.4.4.3. Time between injection and image acquisition
The mean (SD) time between stress and rest injection was 92 (15.3) hours. 
Mean time between stress injection and start of image acquisition was 35 (15) minutes 
and images were acquired after a mean of 44 (12) minutes after rest injection.
5.4.4.4.4. Diagnosis of fixed defects
Fixed perfusion defects were identified in 19 patients during ^ mTc 
tetrofosmin SPECT imaging. Fixed defects were noted in 4 patients in the anterior 
wall, in 13 in the inferior wall, 2 in the lateral wall and 4 in the apical region.
5.4.4.4.5. Diagnosis of reversible defects
99mTc tetrofosmin imaging diagnosed 20 patients as having reversible 
ischaemia. This included patients with both completely and partially reversible 
ischaemia. In the anterior wall 12 patients had reversible defects; in 8 patients septal 
reversible defects were identified; in 16 patients in the inferior wall; in 2 in the lateral 
wall and in 12 in the apical region.
5.4.4.4.6. Size of the defect at stress
A total of 540 segments were studied in 30 patients at stress. ^ mTc 
tetrofosmin identified 141 abnormal segments at stress. Of these, 24 abnormal 
segments were noted in the anterior wall, 22 in the septum, 65 in the inferior wall, 7 in 
the lateral wall and 23 at apex.
5.4.4.4.7. Ischaemic burden
Amount of myocardium with reversible ischaemia (ischaemic burden) evaluated 
by ^ mTc tetrofosmin during dobutamine stress and separate day rest injection, was 
analysed. Reversible ischaemia was identified in 102 segments in 30 patients. Number 
of segments with reversible ischaemia were 20 in the anterior wall, all the 22 segments 
in the septal region, 37 in the inferior wall, 4 in the lateral wall and 19 at the apex 
(Figure 5.4.4.4.7)
5.4.4.4.8. Effect of anti-anginal medication
In 8 patients on 6-blockers and 18 on calcium channel blockers the sensitivity 
to identify coronary artery disease was 95% and comparable to those without these 
medication (100% sensitivity).
5.4.4.4.9. Sensitivity for detection of coronary artery disease Overall diagnosis
Twenty eight patients had documented coronary artery disease. Five patients 
had angiographically documented collaterals to the diseased artery. ^ mTc 
tetrofosmin imaging diagnosed 27 patients (sensitivity 96%).
Identification of coronary artery disease with >50% narrowing
Out of 28 patients who had coronary artery disease, 3 patients had single vessel 
disease, 13 had two vessel disease and 11 had three vessel disease (25 had multi-vessel 
disease). ^ mTc tetrofosmin imaging identified 2 patients with single vessel disease 
and all the 25 with multi-vessel disease.
Twenty five patients had disease in the left anterior descending artery. ^ mTc 
tetrofosmin diagnosed the lesion in the 20 patients. Out of 20 diseased right coronary 
arteries, 18 were identified by perfusion imaging. Thirteen patients had disease in the 
left circumflex artery in the left dominant coronary system. Out of these 7 patients 
were correctly diagnosed (Figure 5.4.4.4.9.1).
Identification of coronary artery disease with >70% narrowing
Ten patients had single vessel disease and 17 had multi-vessel disease of greater 
>70% narrowing. Nine patients with single vessel disease and all 17 with multi-vessel 
disease were correctly diagnosed.
Out of 22 patients who had disease in the left anterior descending artery 18 
were identified by ^ mTc tetrofosmin; out of 15 patients with right coronary disease 
all 15 were diagnosed and of the 11 with left circumflex disease 7 were identified 
correctly (Figure 5AAA.9.2).
Identification of coronary artery disease with >90% narrowing
When greater than 90% narrowing in the coronary vessel was considered , 14 
patients were found to have single vessel disease of which 13 were identified and 10 
had multi-vessel disease of whom all were identified by ^ mTc tetrofosmin.
Sixteen patients had left anterior descending artery disease and 14 were 
correctly identified. Out of 11 with right coronary disease all were identified. There 
were no patients with greater than 90% narrowing in the left circumflex artery (Figure 
5.4A4.9.3).
Figures 5.4.4.4.9.4 and 5.4.4.4.9.5 illustrate the excellent quality of the images 
obtained during dobutamine ^rrrpc tetrofosmin study showing anterior and inferior 
reversible ischaemia respectively.
5.4.4.4.10. Specificity to detect normal coronary artery 
Patients with normal coronary arteries
There were two patients with normal coronary arteries and both were correctly 
identified as normal by ^ mTc tetrofosmin imaging (Figure 5.4.4.4.10).
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Normal coronaries in patients with coronary artery disease
Out of 28 patients with angiographic coronary artery disease, there were 20 
vessels with <50% occlusion. This included 3 left anterior descending arteries of 
which all 3 were identified as normal; 8 right coronary arteries of which ^ mTc 
tetrofosmin identified 6 and out of 9 left circumflex arteries with <50% narrowing all 9 
were correctly identified.
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Figure 5 . 4 . 4 . 4 . 9 . 4 : SPECT 99mTc tetrofosmin images obtained during dobutamine 
stress and separate day rest study showing reversible defect in 
the anterior wall.
S- stress; R- rest
4.4.4.9.5: SPECT 99mTc tetrofosmin images obtained during dobutamine
stress and separate day rest study showing a large reversible 
defect in lateral wall and partially reversible defect in the inferior 
wall
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Figure 5.4.4.4.10.: Normal SPECT 99mTc tetrofosmin images seen during 
dobutamine stress in a patient with normal coronary arteries
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DISCUSSION
Mortality from ischaemic heart disease is very high (1,026 per 100,000 in 
persons aged over 65 years; Department of Health, UK, 1993) despite some reduction 
in recent years (ISIS 3, 1993). Hence, it is an important task for a physician to identify 
patients with coronary artery disease and to identify the subset of patients at higher risk 
of subsequent events so that early intervention such as revascularization can be 
performed. Up to 12% of individuals between ages of 40 and 70 years without 
symptoms have occult coronary artery disease (Diamond et al, 1979).
Diagnosis of ischaemic heart disease is usually performed by non-invasive 
stress tests. These tests work by inducing relative ischaemia which produces an 
imbalance between myocardial oxygen demand and supply. This ischaemia is often 
manifested as angina, deviation of the ST segment on the electrocardiogram, relative 
diminution in the accumulation of perfusion tracers and regional wall motion 
abnormality etc. The principle of these non-invasive tests are more or less the same, 
however the sensitivity and specificity vary widely.
Myocardial perfusion imaging has been established as being more sensitive and 
specific than exercise electrocardiography, not only in the diagnosis of coronary artery 
disease (Okada et al 1980), but also in the risk stratification (Gibson et al 1983). 
201t 1 was developed as a myocardial perfusion agent in mid 70's and is the most 
commonly used myocardial perfusion imaging agent. Although 201j i  has good 
physiological characteristics for myocardial perfusion imaging (Berman DS, 1991) and 
detection of viability (Hendel RC, 1994) it has many physical limitations (Deutsch et al,
1979). Due to its long half life (73 hours) the amount of ^ T l  that can be injected is 
low. It has low energy and is therefore not ideal for standard gamma camera imaging. 
Thus, suboptimal image resolution is common. The absorbed| body radiation dose , is 
high. To circumvent these limitations, investigators have attempted over a decade to
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develop a myocardial perfusion agent labelled with technetium-99m, a tracer with good 
physical properties for scintillation camera imaging.
In 1977, Strauss et al suggested that a 99mTc based agent for myocardial 
perfusion imaging would increase the dose of administration by 4 fold and resolution 
by 2 fold. Although, the initial development was successful in animals, there was 
recurrent failure in man (Higley, 1994). One of the reasons could be the protein 
binding characteristics of the compounds developed (Zanelli et al, 1987). It has been 
shown now that with increased protein binding, there is decreased myocardial uptake 
with slow clearance from the background (Higley, 1994), thus rendering the 
compounds unsuitable for perfusion imaging of the heart.
Today there are two ^^mTc based compounds that are licensed for clinical use; 
99mrpc sestamibi and 99trrrc teboroxime. 99m j c teboroxime has excellent myocardial 
uptake, but also has rapid washout from the heart (Johnson et al, 1991). Due to this 
property, images have to be acquired within 5-10 minutes after injection . However, 
there is intense early hepatic activity, sometimes causing problems with separation of 
the inferior wall defects (Iskandrian et al, 1991). Taillefer et al (1992) compared 
201ti, 99nTpc sestamibi and 99nrpc teboroxime and found that 99m,pc sestamibi was 
better than the other two. 99m jc sestamibi is a cationic isonitrile compound which 
produces good quality images (Maddahi et al, 1991), but it has certain disadvantages. 
There is intense hepatic uptake initially which may persist for up to 1-2 hours after 
injection (Senior et al, 1994). There are also reports suggesting redistribution of 
99m'pc sestamibi may occur by 3 hours (Taillefer et al, 1992), thus reducing the time 
window of imaging to short interval. This question has not been resolved and it is not 
certain how much one would underestimate the defect size. Thus, many investigators 
prefer to carry out a 2 day protocol (Berman DS, 1994).
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99mxc teboroxime is far from ideal for myocardial perfusion imaging and its 
use is very marginal. H o w e v e r ,  99mrpc sestamibi, is a good agent and despite its 
shortfall it has enjoyed increasing usage.
99mYQ tetrofosmin is a newly developed myocardial perfusion agent, which 
belongs to the group of diphosphines. 99m'pc tetrofosmin is a lipophilic, cationic 
diphosphine, and was jointly developed by Amersham International pic, Amersham, 
UK (Higley et al, 1992). The pre-clinical trials showed that the agent not only worked 
in animals but also was a good myocardial perfusion agent in man. Based on these 
initial experiences, the agent was further developed in man.
Some of the experimental design may seem a little dated, this is due to the new 
restrictions imposed by regulatory bodies upon Amersham International Pic and us.
The important finding of the Phase I tetrofosmin study in normal volunteers 
was that tetrofosmin could be rapidly reconstituted from a 'kit' at room temperature, 
and excellent myocardial images could be obtained as early as 5 minutes after injection 
and up to 4 hours post injection. (Sridhara, 1993).
99mTc is readily available in most hospitals from a generator whereas 201t j  is 
not so easily available as it is cyclotron produced. Tetrofosmin used in this study was 
available as a freeze dried mixture. 99myc tetrofosmin was prepared easily at room 
temperature within 15 minutes, and this may be of considerable advantage to nuclear 
medicine laboratories and for acute studies. Furthermore, 99m'j'c tetrofosmin has a 
long shelf life of 8 hours. On the other hand, 99m'pc sestamibi requires heating and 
takes 30-45 minutes for preparation and this can cause significant delay and 
inconvenience (Gibbons, 1991). In the present study the labelling efficiency of 99m'pc
tetrofosmin (as assessed by thin layer chromatography) was over 90% in all 
preparations suggesting good labelling efficacy.
In this study, 99m jc tetrofosmin was first evaluated in 23 patients with known 
ischaemic heart disease. The labelling efficiency, safety, kinetics and imaging protocols 
were evaluated. 99m jc tetrofosmin was found to be a safe imaging agent i.e., it did 
not cause any significant changes in the clinical parameters. A small percentage (10%) 
of patients showed slight increase in the neutrophil count which returned to basal levels 
within 48 hours of injection. The exact mechanism for this is not clear, but it may be 
due to stress, diurnal variation or due to the injection of ^ mTc tetrofosmin itself. 
The safety data indicate that two injections of 99m jc tetrofosmin may be safely 
administered within four hours of one another.
Lung uptake
Increased lung uptake of Ixi has been established as an important marker of 
prognosis. Lung uptake of ^Oljl contributes to the background activity on a routine 
scan (Narahara et al, 1977). Increased lung uptake of 201xi following exercise has 
been shown to correlate with mean pulmonary capillary wedge pressure (Boucher et al, 
1980), left ventricular dysfunction (Kushner et al, 1981; Lahiri et al, 1984) and severity 
of coronary artery disease after acute myocardial infarction (Gibson et al, 1982, Wilson 
et al, 1983; Al Khawaja et al, 1988).
When 201xi is injected at peak exercise in patients with poor left ventricular 
function and severe coronary artery disease, there is high pulmonary uptake of 
radioactivity. It has been suggested that this phenomenon is caused by prolonged 
contact with the capillary bed, producing higher uptake by the pulmonary capillaries 
(Bingham et al, 1980) or transient pulmonary oedema occurring as a result of the
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raised end-diastolic pressure, the 20171 mixing with extra vascular water and being 
retained in the lung (Lahiri et al, 1984).
It has been shown from pre discharge 201xi imaging that increased lung 201xi 
uptake was an independent predictor of high risk in patients following myocardial 
infarction (Gibson et al, 1983). Furthermore, these investigators found that lung 201xi 
uptake was more sensitive than angina, ST-segment depression or coronary anatomy 
for predicting subsequent cardiac events.
In this study quantitative lung 201xi uptake, relative to myocardial uptake, was 
measured. The lung uptake of 201xi was increased after exercise. However, at the 
same level of stress, in the same group of patients, lung uptake o f  99mxc tetrofosmin 
was not increased.
The exact reason for the lack of increase in lung uptake of 99mxc tetrofosmin 
is not clear. The rapid washout and the large molecular size o f  99mxc tetrofosmin may 
account for the lack of increased uptake in the lungs. Interestingly 99mxc sestamibi 
has been shown to have increased lung uptake (Maisey et al, 1991). However, most of 
the studies with 99mxc sestamibi are performed 1-2 hours after injection and hence it 
is difficult to assess the initial post-exercise lung uptake or to evaluate its significance.
Whatever the mechanism, the lack of increased lung uptake may be a 
disadvantage with 99mxc tetrofosmin imaging. However, additional features such as 
gated imaging, which may provide both functional and perfusion information may 
compensate for the lack of lung uptake.
Right ventricular uptake
The right ventricular myocardium is not usually visualised in 201 images at 
rest because of low tracer concentration and high background activity. Using multiple 
logistic regression analysis on pre discharge 201j i  imaging, abnormal right ventricular 
201xi uptake was found to be a predictor of death by univariate analysis but did not 
provide any independent prognostic information on multivariate analysis (Nestico et al, 
1986). These authors did not include gated imaging in the multivariate analysis.
In this study, the right ventricular wall was visualised in 16% of the patients by 
201x1 and in 35% by 99mxc tetrofosmin. It was seen with similar frequency with 
anterior and inferior infarcts. Despite the slight increase in the number of patients 
having multivessel disease with 99mxc tetrofosmin right ventricular uptake, there was 
no significant correlation between right ventricular uptake and the extent of coronary 
artery disease.
Liver uptake
In this study, liver uptake of 99mxc tetrofosmin was noted in just over half of 
the patient population (56%). However, on serial imaging, there was a rapid clearance 
of the liver activity, being present in 96% of images at 5 minutes post injection and 
decreasing to 21% at 90 minutes and 4% at 2 hours. More importantly, liver uptake 
did not interfere with the overall diagnosis, even in patients with inferior wall defects. 
Even at 5 minutes post injection, the liver activity did not interfere with the diagnosis, 
allowing early imaging in acute conditions such as myocardial infarction. This would 
seem to be a significant advantage over 99mxc sestamibi.
Redistribution phenomenon
The redistribution phenomenon of 20 I j]  \s wen documented (Pohost et al, 
1977). Hence it was thought that only one injection of ^O ljl would be required for 
myocardial perfusion imaging. The process of redistribution involves disparate 
washout rates from normal and ischaemic areas (Gewirtz et al, 1978; Beller et al,
1980). However, recent studies have shown that standard 3-4 hour redistribution 
imaging, actually underestimate the amount of ischaemic myocardium and hence re­
injection of ^ O ljl has been proposed (Dilsizian, 1990; Bonow, 1991). This has lead to 
enormous controversy and highlights the disadvantage of 201xi. Thus, increased cost 
and radiation burden are the chief problems.
In this study it has been clearly shown by quantitative analysis that 99mxc 
tetrofosmin does not redistribute up to 4 hours after an injection during stress. Serial 
imaging demonstrated that even in patients who showed redistribution on 201xi 
imaging, 99mxc tetrofosmin showed no evidence of redistribution. Hence, two 
injections of 99mxc tetrofosmin were required, one at stress and another at rest. Lack 
of redistribution of 99mxc tetrofosmin has the advantage that, imaging can be 
performed up to 4 hours after an injection giving a wide window for imaging. In 
contrast to 99mxc tetrofosmin,99mxc sestamibi has been shown to redistribute partly, 
and this may be a disadvantage (Taillefer et al, 1991).
Washout and clearance of 99mxç tetrofosmin
Physiological, decay-corrected washout of 99mxc tetrofosmin was slow from 
normal and ischaemic myocardium. Planar imaging revealed washout of 4% /hour for 
first two hours after stress and much slower after an injection at rest (0.5% /hour). 
When the washout from the lung background was also taken into account, the
myocardial to background ratio was optimal for diagnostic imaging from as early as 5 
minutes after injection. Due to the slow myocardial clearance and absence of 
redistribution, 99mTc tetrofosmin allows uncoupling of the time of the injection from 
the time of imaging and thus may be clinically valuable in assessing patients undergoing 
thrombolytic therapy or other acute interventions.
Quality of images
99mTc tetrofosmin produced superior quality images. Being a 99m,j'c based 
compound with higher doses being injected and with increased number of photons, the 
resolution of ^ ^mTc tetrofosmin images were better than those of ^ OllX
Following the evaluation of safety and kinetics of 99m-pc tetrofosmin, a further 
50 patients with suspected ischaemic heart disease and 10 persons with low probability 
of coronary artery disease were studied. The sensitivity and specificity for the 
detection of coronary artery disease were evaluated using 99mrpc tetrofosmin and 
compared with those of 201xi. For these patients much lower doses of 99mxc 
tetrofosmin were injected (185-296 MBq).
Graded exercise electrocardiography
Over the past two decades exercise electrocardiography has been routinely 
used to evaluate patients with suspected coronary artery disease (Gianrossi, 1989). 
The sensitivity and specificity of exercise electrocardiography reported in literature 
vary widely. The sensitivity varies from as low as 48% (Bonoris, 1978) to as high as 
94% (Cohn, 1979). The specificity varies from as low as 17% (Senior, 1994) to as 
high as 100% (Battler, 1979). In the present study the sensitivity of exercise induced 
ST depression for the detection of coronary artery disease was 66%. The sensitivity is
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comparable to meta-analysis result published by Gianrossi et al (1989). They 
performed an overview of 147 published reports involving more than 20,000 patients. 
The mean sensitivity in the meta-analysis was 68%. This compares favourably with 
the present study, suggesting that exercise electrocardiography is suboptimal for 
detection of ischaemic heart disease.
As early as 1978, Surawicz et al suggested that 201ti imaging was useful in 
patients with non diagnostic exercise electrocardiograms. This has also been shown by 
many other authors (Berger et al, 1981; Hung et al, 1984). In the present study also 
more than 70% of patients with non diagnostic exercise electrocardiograms were 
correctly identified by planar 201j i  an(j planar 99mTc tetrofosmin imaging. The 
higher sensitivity of perfusion imaging is thought to be due to the fact that abnormal 
exercise images can frequently be seen in patients with coronary artery disease, despite 
sub maximal exercise workload or heart rates (McCarthy et al, 1979). The overall 
specificity of exercise electrocardiography in this study was only 50%. This is 
comparable with other studies (Bonoris et al, 1978).
It should be pointed out that despite the different protocols used (bicycle and 
treadmill) the overall double product was similar. The haemodynamic parameters 
achieved with stress testing during 20 ly; and 99m jc tetrofosmin stress were 
comparable. Even in subgroups with fixed or reversible defects, the haemodynamic 
parameters including maximum heart rate, systolic blood pressure and double products 
achieved were similar with 201ti and 99mj -q tetrofosmin imaging. Hence any 
difference between the two imaging agents could not be due to different levels of stress 
achieved during exercise.
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Myocardial Perfusion Imaging
Flexibility of the Imaging Protocol with 99mTc tetrofosmin
201x 1 has been used as a myocardial perfusion imaging agent of choice for 
over 15 years. The protocol for 201xi imaging is established (Pohost, 1977), although 
recent studies have shown that redistribution imaging alone will not identify all 
segments with reversible ischaemia (Tamaki, 1990). However, for the diagnosis of 
ischaemic heart disease the standard 201xi imaging protocol involves stress imaging 
soon after injection (within 15 minutes) and redistribution imaging 3-4 hours later.
The 99mxc tetrofosmin imaging protocol was established in stage I of the 
study in view of the bio-kinetics studied in that group. At stage I patients underwent 
serial imaging, and one and two day protocols were also performed involving same day 
and separate day rest injection. It was found that the time of injection could be 
uncoupled from the time of imaging. The time window for imaging was wide with 
imaging possible from 5 minutes post injection to 4 hours after injection. Early imaging 
was possible due to rapid background and liver clearance and the late imaging due to 
the absence of redistribution. Early study time is a distinct advantage of 99mxc 
tetrofosmin, as it will enable imaging in acute situations, e.g. to study the effect of 
thrombolysis and myocardial salvage in acute myocardial infarction patients. Early 
imaging is difficult with 99mxc sestamibi due to delayed clearance from the liver.
The sensitivity for the detection of reversible ischaemia was similar with one 
and day two protocols using either planar or SPECT 99mxc tetrofosmin imaging 
(Sridhara et al, 1994, a). Hence, the advantage of 99mxc tetrofosmin is that either one 
or two day imaging protocol can be used in different laboratories depending on the 
convenience of the patients and departmental practice. Based upon initial experience,
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the study stages II and III were performed using a single day protocol with stress first. 
This has the advantage that, if a stress scan is normal, then the patient need not have a 
second scan, this would save time, cost, have a low radiation burden and improve 
patient throughput.
The feasibility of a one day protocol is in contrast to 99nrrc sestamibi, for 
which a two day protocol has been found to be optimal, and from the logistic 
standpoint, this may be inconvenient in many departments (Berman DS, 1994).
Sensitivity for detection of ischaemic heart disease
The sensitivity of 201 y; imaging for the detection of coronary artery disease 
was established by the late 70's. Okada et al, (1980) summarised the reported 
sensitivity and specificity of ^Oljl imaging until 1980. The mean sensitivity of 201^1 
imaging in 817 patients studied was 82% and the mean specificity was 91%. In the 
present study, the sensitivity of 20I'll imaging for detection of coronary artery disease 
was 82%, which is similar to reported figures (Verani et al, 1978; Okada et al, 1980).
Although perfusion imaging provides a functional assessment of ischaemic 
heart disease, there is no established 'gold standard1 for evaluating these new agents. 
The best method would be the assessment of morbidity and mortality in large numbers 
of patients and was beyond the scope of my thesis.
Regulatory authorities demand that any new perfusion tracer evaluated, should 
be against ^Olxp This again is not ideal since we are not allowed to perform rest­
ing ection of 201xi due to the cumulative dose of the multiple imaging protocols. 
Furthermore, when this study began 3-4 years ago 201xi re-injection was more 
experimental and not proven, as it is today (Basu et al, 1993; Sridhara et al, 1994).
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In this study, 99mxc tetrofosmin and 201x1 imaging were compared in patients 
with angiographically proven coronary artery disease. The sensitivity for the detection 
of obstructive and significant coronary artery disease using planar 99mxc tetrofosmin 
imaging was 85% which was better than 201xi. The sensitivity of SPECT 99mxc 
tetrofosmin imaging was slightly higher (92%) than planar 99mxc tetrofosmin imaging. 
With the use of 99mxc based imaging agents, SPECT imaging is likely to become 
widely used and 99mxc tetrofosmin has high sensitivity for the detection of coronary 
artery disease.
The size and location of the defects identified were comparable for planar 
201xi and 99mxc tetrofosmin in all the regions. However, the size of the defect 
identified by SPECT 99mxc tetrofosmin imaging was significantly) larger than planar 
99mxc tetrofosmin, particularly in the inferior wall.
In addition to diagnosis of coronary artery disease, identification of patients 
with reversible ischaemia who may potentially benefit from revascularisation therapy is 
an important aspect of myocardial perfusion imaging. This is particularly true in the 
present era of interventional cardiology. The amount of myocardium in jeopardy or 
the "ischaemic burden" was comparable between planar 201xi and 99mxc tetrofosmin.
The mechanism of the reversibility of a 99mxc tetrofosmin perfusion defect is 
different from that of 201xi. Reversibility of 201xi is the result of the differential 
washout rate of 201xi from the normal and hypoperfused myocardial regions (Gewirtz 
et al, 1978). Unlike 201xi, however, 99mxc tetrofosmin does not redistribute in the 
myocardium, as shown here, thus necessitating two separate injections.
While images acquired after injection of 99mxc tetrofosmin at peak stress 
demonstrate exercise induced disparity of regional blood flow (Sinusas et al, 1994), 
images obtained after rest injection show the pattern of myocardial perfusion at rest. 
Improvement or normalisation of an exercise defect following the rest image indicates 
reversibility and implies that the tissue is viable.
The cellular mechanism of 99mxc tetrofosmin myocardial uptake is not clearly 
known. It is thought that 99m jc tetrofosmin enters mitochondria within the cell. The 
entry o f  99m jc tetrofosmin is dependant on the integrity or the 'intactness' of the cell 
membrane of the myocyte. However, the methods of development of the new 
radiopharmaceuticals have changed. The pharmaceutical industry have defined 
strategies which may not be ideal but serve their purpose. After development of the 
chemistry of the tracer and assuring safety in animals, the ligands are first tested in 
humans to identify whether the product will be effective, i.e., in the case of 99mxc 
tetrofosmin, would it detect reversible ischaemia or infarction? Only then the other 
basic studies are sponsored to determine the mechanism of entry into the cell, j These 
developmental strategies dictated the way in which 99m jc tetrofosmin was evaluated 
in the present study.
This suboptimal development strategy may not be ideal, but this has saved 
development cost and speeded up market exposure. Apparently, the regulatory bodies 
only demand that the agent is "as good" as 20171 %nd safe, and no other studies are 
required by them. There are now a few basic studies set up to define the mechanism of 
99mxc tetrofosmin uptake but the results are not yet available. However, preliminary 
studies have shown that the uptake o f  99mxc tetrofosmin parallels regional myocardial 
blood flow (Sinusas et al, 1994) and is similar in that way to 201xj %nd 99m jc 
sestamibi.
Sensitivity for detection of individual coronary lesions
While considering the severity of the coronary artery disease, some authors 
have taken >50% luminal narrowing as a significant flow limiting disease (Wackers et 
al, 1989; Kiat et al, 1989; Iskandrian et al, 1989). While others consider >70% 
narrowing in a coronary artery as significant (Taillefer et al, 1989). In the present study 
the sensitivity of 99nypc tetrofosmin was evaluated for the detection of >50%, >70% 
and >90% narrowing. Although the coronary angiograms were assessed blindly by two 
independent observers, it has been shown in previous studies that there is considerable 
interobserver variability in visually grading the degree of coronary artery stenosis (Zir 
1976; Detre 1975) particularly for less severe stenosis. Keeping in mind this fallacy it 
was felt that the sensitivities to detect various degrees of narrowing would provide a 
range of efficacy.
The ability 99m jc tetrofosmin for detection of single and multivessel disease 
was also assessed, since the identification of a patient with multivessel disease may also 
be used for risk stratification (Mock et al, 1982). In patients with multivessel disease, 
201t i  sensitivities show great variation; some studies have shown a sensitivity as low 
as 80% (Rigo et al, 1980). This may be due to various problems associated with 
prediction of individual coronary artery disease by perfusion imaging. Failure to detect 
multi-vessel disease may be due to inadequate exercise (Iskandrian et al, 1987), the 
fact that the most severely diseased vessel often limits the test due to symptoms or 
electrocardiographic changes before others show regional abnormality (Rigo et al, 
1980) and interference from extra cardiac activity (e.g. 99m jc sestamibi).
Despite these limitations it is possible to identify multivessel disease in most 
patients (Iskandrian et al, 1983). Several authors reported that 75 to 90% of diseased 
vessels can be correctly predicted (Maddahi et al, 1981; Tamaki et al, 1984), using
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20l'il  imaging. In the present study, the diagnosis of multivessel disease was high 
using planar 99m jc tetrofosmin imaging (94%, when >70% luminal narrowing was 
considered) and this was comparable to planar 201xi. The sensitivity for the detection 
of multivessel disease was slightly better with SPECT 99mxc tetrofosmin although this 
was not statistically significant.
Localisation of coronary artery disease is a distinct advantage of myocardial
perfusion scintigraphy over exercise electrocardiography. However, the sensitivity for
identification of individual coronary lesions using 201xi is not very high and varies
from 50% (Rigo et al, 1980) to 85% (Iskandrian, 1980). The use of SPECT certainly
improves localisation. It is known that the concordance between scintigraphic
segments and coronary artery disease is not absolute, due to variations in coronary
anatomy (Newman et al, 1983). This is particularly so with lesions in the right
coronary and left circumflex arteries. In addition, the significance of individual
coronary artery lesion is affected by various factors that complicate comparison with
scintigraphic data e.g. the presence of coronary collaterals may improve flow to distal
coronary beds and may lead to even a 'normal1 scintigraphic appearance (Rigo et al,
| 1980).Despite these limitations, in the present study the sensitivity for the identification
of individual coronary lesion was surprisingly high as reported by blinded observers.
Walkers et al, 1989 found that the sensitivity of planar 201xi imaging for 
detection of individual coronary disease was 69% in the 65 patients studied; Taillefer 
et al (1989) found the sensitivity of 201xi to be 74% for individual coronary lesion 
detection. In the present study sensitivity for detection of individual coronary lesions, 
using 99mxc tetrofosmin varied from 82% to 100%; being the highest for left anterior 
descending artery disease, then the right coronary lesion and lowest for left circumflex 
disease. This data is similar to previously established reports (Iskandrian, 1980), and 
may be due to the fact that the left anterior descending artery supplies a larger mass of 
myocardium and it is anteriorly located and thus readily visualised (Rigo, 1980).
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SPECT 99m jc tetrofosmin perfusion imaging in this study had higher 
sensitivity for the detection of single and multivessel disease compared to planar 
99mxc tetrofosmin imaging. Identification of individual coronary lesions was also 
better with SPECT compared to planar 99mxc tetrofosmin imaging. However, these 
differences were not statistically significant. Maublant et al (1982) showed improved 
sensitivity from 89% to 98% from planar and SPECT 201xi imaging. Tamaki et al 
(1981) showed improvement in sensitivity from 75 to 96% from planar to SPECT 
201t1 imaging. However, 201xi SPECT imaging has the disadvantage of longer 
acquisition and possible early redistribution and hence planar imaging is extensively 
used during 201xi scintigraphy.
Since the introduction of 99mxc sestamibi as a myocardial perfusion agent, 
many centres are now experienced with SPECT 99mxc sestamibi studies. Maddahi et 
al (1991) evaluated SPECT sestamibi imaging in 153 patients with coronary artery 
disease and showed that the sensitivity was 90%, compared to 89% with SPECT 
201t 1 in the same patient population.
Specificity for detection of normal coronary arteries
The normalcy rate (defined as the number of patients from the low likelihood 
group with normal scans divided by the total number of patients in the low likelihood 
group x 100) was 100% using both 201xi and 99mxc tetrofosmin (planar and SPECT) 
imaging. The normalcy rates in this study are consistent with those quoted for that of 
99mxc sestamibi (Kiat et al, 1989). The specificity for the overall identification of 
patients with all 3 normal coronary arteries was 100% for both planar 201xi and 
99mxc tetrofosmin imaging , however these values are based on only 4 patients with 
all 3 normal coronary arteries, in this study. The reported specificity of 201xi imaging
varies from 50% (Peterson et al, 1976) to 100% (Dash et al, 1979). Kiat et al (1989) 
have studied the specificity of " mTc sestamibi and found it to be 94%.
The vessel specificities derived from the normal coronary artery territories in 
coronary artery disease patients, were comparable by planar 201xi and 99mXc 
tetrofosmin (planar and SPECT imaging) (75 to 95%). Although it has been suggested 
that the catheterised population with normal coronary arteries or insignificant coronary 
artery stenoses constitute an inadequate 'gold standard' for true estimation of 
specificity (Kiat et al, 1989), in the present study, 99mxc tetrofosmin imaging has 
clearly shown a very high normalcy rate and a high specificity in patients with all three 
normal coronary arteries, suggesting the ability to identify true negatives. Since a 
negative scan is highly predictive of the absence of cardiac events (<5% in 5 years) 
(Wackers et al, 1985) the excellent normalcy rate of 99mxç tetrofosmin will improve 
patient screening for the diagnosis of coronary artery disease.
Concordance between imaging in agents
Agreement in the diagnosis between planar 201xi and planar 99mXc 
tetrofosmin imaging were analysed. Agreement was good not only for the overall, but 
also for regional diagnosis as suggested by the good concordance (82-95%) with high 
kappa value.
The agreement for the diagnosis of reversible ischaemia is of particular 
importance . There was good concordance for detection reversible defect in 7 patients 
and for mixed defects in 17 patients with an overall concordance of >90%. This 
suggests that of 99mxc tetrofosmin imaging can identify and localise a perfusion 
defect, in the manner of an established agent.
Relative value of non-invasive tests
Exercise perfusion imaging using 201ji js established as having higher 
sensitivity than exercise electrocardiography (Bailey et al, 1977; Ritchie et al, 1978). 
In this study the sensitivity for detection of coronary artery disease was 66% using 
exercise electrocardiography, 82% using planar 20I j]  imaging and 85% with planar 
99mxc tetrofosmin imaging. However, when the results of either imaging agent were 
combined with those of exercise electrocardiography the sensitivity increased to 92% 
suggesting that the exercise electrocardiographic data is complementary to the 
myocardial perfusion data.
Perfusion imaging and diagnosis at study entry
It is likely that the diagnostic capability of 99mrpc tetrofosmin is 
underestimated in this study than would be the case in routine clinical practice. The 
blinded evaluation of images, although necessary in the setting of evaluation of a new 
imaging agent, does not reflect the routine clinical situation. In the clinic, each 
physician would build experience in the use of the product and would learn to interpret 
the uptake patterns seen in different status. Knowledge of age and sex of the patient 
would also enable the physician to differentiate between normal variants and artefacts 
(such as breast attenuation) and true defects. The patient diagnosis also would not be 
made from perfusion imaging alone. Rather, the scintigraphic results would be 
considered together with patient history and the results of other diagnostic modalities 
such as exercise electrocardiography and coronary angiography before a final diagnosis 
is made. With this in mind, a comparison was made between the two perfusion agents 
and the diagnosis at study entry. There was good agreement in the identification of 
infarction and ischaemia between 201 j j  ancj 99m'pc tetrofosmin at study entry. 
Ischaemia was more readily detected by 99m jc tetrofosmin than by 201^1, in all 3
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regions except the lateral wall. However, infarction was more often identified by 
201T1 than 99mTc tetrofosmin, and this may be due to the fact that re-injection of 
201ti was not used (Basu et al, 1993).
Dobutamine stress 99nvpc tetrofosmin imaging
Gould et al (1978) have shown that scintigraphic inhomogeneity may not be 
present under conditions of resting coronary blood flow, despite the presence of 
prognostically important coronary obstructions, but will more likely be induced if 
ZOlfl is injected during hyperaemic conditions. Young et al (1987) have shown the 
importance of adequate stress during myocardial perfusion imaging using 20 I j^  They 
described that in patients with subnormal exercise during 201t i  study, the 
identification of potential myocardial ischaemia can be improved with dipyridamole 
testing. Iskandrian et al (1989) have shown that the sensitivity of SPECT 201ti 
imaging decreases when achieved peak heart rate is less than 85% of the maximum 
predicted rate.
A substantial proportion of patients (30 to 40%) with known or suspected 
coronary artery disease cannot achieve adequate levels of physical stress and hence 
cannot be adequately assessed using exercise as the hyperaemic stimulus (Iskandrian et 
al, 1981). There are now sufficient data to indicate that such patients can be better 
assessed pharmacologically, by performing perfusion imaging during pharmacological 
stress (Bateman, 1992); hence pharmacological stress imaging is being increasingly 
used.
After establishing the kinetics and sensitivity of 99mTc tetrofosmin for 
detection of ischaemic heart disease, the diagnostic capability of 99mTc tetrofosmin 
during dobutamine stress testing was assessed. Dobutamine was chosen over
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dipyridamole and adenosine as it has the advantage of increasing myocardial flow 
demand due to its chronotropic and inotropic properties thus precipitating ischaemia 
(Bateman, 1992). This is more physiological compared to dipyridamole or adenosine 
which produce greater hyperaemia and less myocardial oxygen demand and the 
disparity in perfusion to regions supplied by normal versus stenotic arteries is 
comparatively amplified without necessarily causing ischaemia (Wilson et al, 1985). In 
addition, unlike dipyridamole and adenosine, dobutamine can also be given to patients 
with obstructive airways disease. The side effects of dobutamine infusion are seen less 
often (about 50%) compared to adenosine (about 96%) and it is similar to the reported 
incidence of side effects with dipyridamole study (Bateman, 1992)
In the present study, dobutamine infusion was found to be safe, with only one 
patient developing self terminating ventricular tachycardia. There were no other 
serious side effects. Safety of dobutamine stress testing has been established also by 
several studies (Ryan et al, 1991). In a study by Senior et al (1994) dobutamine stress 
testing was found to be safe, with only 2% of patients developing significant self 
terminating ventricular arrhythmia, and none had any serious side effects.
Dobutamine stress electrocardiography
Coma-Canella et al (1990) studied 75 patients after myocardial infarction using 
dobutamine stress testing. The sensitivity of dobutamine stress electrocardiography for 
the detection of multivessel disease was 84% and the specificity was only 64%. Berthe 
et al (1986) found that the sensitivity was 80% and specificity was 62% for 
dobutamine induced ST segment depression for detection of coronary artery disease. 
In the present study, the sensitivity of exercise electrocardiography for the detection of 
coronary artery disease was 75%, but that of dobutamine-induced ST depression was
only 43%. This may be due to the fact that the maximum heart rate and double 
product achieved were less during dobutamine infusion than during exercise testing.
99m jc tetrofosmin kinetics during dobutamine stress is not clearly established, 
and therefore a two day protocol with separate day rest injection was performed in this 
study. This allowed equal activity of 99m jc t0 be injected at stress and rest. Even 
with the reduced dose of 99mq^ the SPECT images were of excellent quality.
Theoretically, dipyridamole stress testing using 201j j  could provide better 
image quality than dynamic stress 20 I j]  imaging due to significantly enhanced 
coronary flow and hence improved myocardial to background ratios (Bateman et al, 
1992). However, Leppo et al (1989) in their review of five studies with 2Olqq found 
that the sensitivity for detection of coronary artery disease was similar between 
dipyridamole and exercise imaging.
Detection of coronary artery disease
This is the first study in which 99mtet rofosmin  imaging has been used with 
dobutamine stress for the detection of coronary artery disease. In this study, the 
sensitivity for detection of coronary artery disease by dobutamine 99nvpc tetrofosmin 
imaging was excellent (96%). This is despite the fact that lower maximal heart rate 
and double products were achieved with dobutamine compared to dynamic exercise. 
Dobutamine acts as a cardiac stress agent by various mechanisms: it is an inotrope and 
increases dp/dt, stroke volume and cardiac index significantly (Meyer et al, 1976; 
Pozen et al, 1981). It increases blood flow to the normal zone and has variable effects 
on the ischaemic zone (Tuttle et al, 1977; Vatner et al, 1979; Warltier et al, 1981). 
Dobutamine also shifts blood from the endocardium to the epicardium (Carlson et al, 
1988).
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The sensitivity of dobutamine 99m j c tetrofosmin imaging shown in this study 
is similar to the sensitivity of dobutamine 2017] imaging reported by other authors. 
Mason et al (1984) studied 16 patients with coronary artery disease using dobutamine 
20171 imaging. The sensitivity was 94%. Pennell et al (1991) studied 40 patients 
using dobutamine 20171 imaging and the sensitivity for detection of coronary artery 
disease was 97%.
In only one patient out of the 30 patients in this study, was a diagnosis missed. 
This patient had single vessel disease with 70% narrowing in the mid portion of the left 
anterior descending artery. More importantly, all the patients with multi-vessel disease 
were correctly identified.
Detection of individual coronary lesions
A lesion >50% in diameter in the left anterior descending artery was detected in 
80% of the study patients and this increased to 88% when >90% narrowing was 
considered. Although the values are not exceptionally high, this discrepancy between 
an anatomical lesion and functional image is known (Pennell et al, 1991). However, 
the detection of right coronary artery disease was excellent with >90% being identified. 
It is known that the localisation of left circumflex artery lesion is difficult, even in 
SPECT imaging (Iskandrian, 1980). In the present study, the sensitivity for detection 
of a lesion in left circumflex territory was 54% when >50% narrowing was considered 
and increased to 77% when >90% narrowing was considered. Due to the overlap 
between right coronary and left circumflex territories and the dominance of the arterial 
system influencing the perfusion defect, many authors have combined the two 
territories into one, "infero-postero-lateral" area which is supplied by right coronary/ 
left circumflex artery (Pennell et al, 1991). When the two areas are combined, the 
sensitivity improves to 77% with >50% narrowing and to 100% with >90% narrowing.
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There were only two patients with all three coronary arteries normal in this 
study. Both these patients were correctly identified as normal by dobutamine 99m jc 
tetrofosmin SPECT imaging (overall specificity 100%). However, the number of 
patients is very small. Using dobutamine 20171 imaging Mason (1984) found the 
specificity of 87% and Pennell (1991) 80%. In patients with coronary artery disease, 
the specificity to identify coronary artery with <50% narrowing was very high with all 
three territories.
In a study by Senior et al (1994) dobutamine stress perfusion scintigraphy using 
99nrrc sestamibi was found to have an overall sensitivity of 95%, specificity of 71% 
and sensitivity to detect individual coronary lesions were 70%, 86% and 33% for left 
anterior descending, right coronary and left circumflex arteries. Forster et al (1993) 
found that the sensitivity of dobutamine stress 99mTc sestamibi imaging was 90% and 
the specificity was 78%.
Since 99m jc sestamibi is now widely used for dobutamine stress SPECT 
imaging, there are some anecdotal comparisons which may be relevant, since a back- 
to-back comparison was not performed between the two 99m7 c agents. The liver 
uptake o f  99m'rc sestamibi after dobutamine was very high and clearance was delayed 
to V/2 -2 hours, and sometimes longer (Senior et al, 1994). In the case o f  99mTc 
tetrofosmin during dobutamine stress there was rapid clearance of activity from the 
background and subdiaphramatic regions (within 10-15 minutes) in many patients. This 
suggests that the advantage of early imaging noted with 99m7c tetrofosmin persists 
also with dobutamine. It will be interesting to see whether the same features are seen 
with dipyridamole or adenosine. This will be a significant step in the right direction
and should be formally evaluated. However, this was beyond the scope of the present 
study.
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Summary and conclusions
This study has provided the first clinical evaluation of 99nrpc tetrofosmin. It 
has demonstrated that myocardial uptake of 99m jc tetrofosmin is similar to 
during stress and rest. The high photon flux o f  99mrpc allows better image quality than
] 201xi due to higher counts per pixel; the dose allowed is 4-5 times higher than 201xi I 
i  I
| due to less absorbed body radiation. The rapid liver clearance with 99mxc tetrofosmin
also has an advantage over 99mxc sestamibi for early imaging. 99mxc tetrofosmin has 
some important features which should be highlighted: the 'kit' formulation allows rapid, 
uncomplicated preparation at room temperature; there is a rapid clearance from liver 
and lung which produces good target to background ratios; it compares well with 
201x1 for detection of coronary artery disease; SPECT images are of excellent quality 
and good diagnostic studies are achieved and finally, pharmacological studies with 
dobutamine demonstrated excellent sensitivity for the diagnosis of coronary artery 
disease.
Future directions
The scope of this project was to establish 99mxc tetrofosmin as a clinically 
viable tracer for diagnostic studies in patients with suspected or known coronary artery 
disease. The development of quantitative SPECT, 3D image reconstruction and gated 
SPECT are likely to enhance the diagnostic role of 99mxc tetrofosmin. 99mxc 
tetrofosmin should be evaluated for the study of myocardial viability, which is one of 
the most important uses in cardiology. Other properties of 99mxc tetrofosmin may 
allow it to be used in intervention studies, such as in patients with chest pain in the 
emergency room and in the assessment of myocardial salvage following thrombolysis 
or transluminal coronary angioplasty.
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APPENDIX
Appendix I
Patient Information - Stage I
A new heart agent for diagnosis of cardiac disease fPPNIOll!:- Information for 
patients participating in clinical evaluation
You have been asked to take part in a clinical (research) trial which is being performed 
in a number of hospitals throughout Europe. This part of the project is being 
supervised by Dr A Lahiri. A total of up to 50 other patients will also be in the study.
The purpose of the study is to investigate the diagnostic value of a new radioactively 
labelled drug which may, like thallium scanning, be of use in the diagnosis and 
monitoring of heart disease. This compound has only been given to a few people (12) 
before the start of this study. No one receiving the drug thus far has suffered any 
serious ill-effects. Ultimately the advantages that this drug may produce are better 
quality pictures, which should improve diagnosis, and the possibility of a lower 
radiation dose compared to thallium scanning.
A blood sample will be collected within 14 days before the study and a physical 
examination (including ECG, pulse, blood pressure and temperature) performed. This 
is to establish that you are fit enough to take part. You have been approached to take 
part in the study because your routine clinical assessments have indicated that you have 
the type of disease which this new agent would be most probably be useful in 
diagnosing. If successful this agent might be expected to replace one or more of the 
studies that you have previously had to undergo with thallium.
You will be asked to undergo an initial thallium scan study similar to ones that you 
may have had before. You will be asked to return two days later to undergo the first 
part of the study with the new drug. This involves injecting the drug whilst you are 
resting.
Ten blood samples will be taken at various times both before and after injection of the 
drug. Samples are taken both to measure how fast the drug leaves the blood and to 
check other effects of the drug. Most of these blood samples will be taken from a 
small cannula that is placed in your arm before the drug is injected to minimise your 
discomfort.
You will have you blood pressure, pulse, temperature and ECG checked at various 
times before, during and after receiving the drug.
A number of sets of pictures (between 6 and 7 - 4  scans per set) will be taken of your 
heart using a gamma camera over the period up to about 4 hours following the 
injection of the drug. These will involve you lying still for periods of from 5 to 20 
mins and are very similar to thallium scanning.
You will have a rest between the scans performed at 2 and 4 hours after injection
during which you will be allowed to eat a light meal.
You will be asked to collect (in bottles provided) all urine passed over the 24 hour
period following each injection of the new drug. The exact procedure will be
explained to you by one of the medical staff.
A further blood sample will be taken between 24 and 48 hours following the injection 
of the drug.
Between one and three days later you will return to take part in the second part of the 
study. This will involve taking blood samples as in the previous part of the study, 
injection of the new drug whilst you are exercising (like in a thallium study) and further 
scans for a period of up to about 4 hours as in the first part of the study. Following 
this period of imaging you will be given a second dose of the drug whilst you are 
resting. The study will then continue as it did on the previous day. Once again you 
will be requested to collect all urine for a period of 24 hours from the time of the last 
injection of the drug.
You are requested to refrain from taking either alcohol or drugs (except those 
indicated by Dr Lahiri or his colleagues) for 24 hours before each study and to take 
only a light breakfast (avoiding tea, coffee or cola and other than decaffeinated) on the 
morning of each study.
As a result of participation, you will receive a radiation dose as you would from an x- 
ray. Whilst it is impossible to guarantee that any radiation dose is safe, you should 
understand that the dose itself is relatively low, and the radiation will have largely 
disappeared within 2 days of the injection.
The drug has been tested for safety and does not appear to have a significant toxic risk 
associated with it at the proposed dose. It is not anticipated that any side effects will 
be seen as a result of the injection of this compound. However, if you do suffer any 
effects you should inform Dr Lahiri or one of his colleagues as soon as possible.
Your identity in this study will be kept confidential. All information concerning your 
participation in this study will be made available to Amersham International pic (the 
manufacturer of the test drug), and to appropriate regulatory authorities. Any medical 
records related to this study may be inspected by an authorised representative of 
Amersham or an appropriate regulatory authority. The results of this study may be 
reported in publications or presentations, but your identity will not be disclosed.
If you are injured as a direct result of your participation in this study, medical 
treatment will be made available at no cost to you. Amersham agrees to abide by the 
Association of the British Pharmaceutical Industry guidelines with regard to financial 
compensation due to injury.
You will be given a medical contract card signifying that you are participating in a 
clinical trial. You should keep this with you at all times whilst you are involved in the 
trial.
If you have any questions regarding this study, you are free to contact the supervising 
doctor (Dr Lahiri) or his staff (e.g. Dr Sridhara). Participating in this study is 
voluntary, and you are free to withdraw at any time, without explanation. Any future 
medical treatment available to you will not be prejudiced if you decline to take part in 
this study.
The study has been subject to review by an independent ethics committee which has 
not objected to its taking place.
Appendix II
SAMPLES
PPN1011 HEART AGENT PHASE III STUDY 
PROTOCOL NO: P53-003
PATIENT INFORMATION/INFORMED CONSENT Stage II
You have been asked to participate in a clinical (research) trial which will 
involve up to 120 patients at a number of hospitals throughout Europe.
At .....................................  the project is under the supervision
of ....................
The purpose of the study is to investigate a new radioactive drug which may 
be of use in the diagnosis and monitoring of heart disease. This drug may 
produce better quality pictures of the heart which should improve diagnosis, 
with a lower amount of radiation compared to thallium, the currently used 
drug. If successful, this agent might replace one or more of the studies that 
you may have previously had to undergo with thallium. Prior to this study, 
the agent had been given 73 subjects. No one receiving the drug thus far has 
suffered any serious ill-effects.
YOU HAVE BEEN APPROACHED TO TAKE PART IN THIS STUDY BECAUSE YOUR ROUTINE 
CLINICAL ASSESSMENTS HAVE INDICATED THAT YOU HAVE THE TYPE OF DISEASE WHICH 
THIS AGENT MIGHT BE USEFUL IN DIAGNOSING.
Within 14 days of entry into the study a physical examination (including ECG, 
pulse and blood pressure) will be performed. This is to establish that you 
are fit enough to take part.
You will receive two injections of the new agent on the same day. The first 
whilst you are exercising (as in a thallium study) and the second, 4 hours 
later, whilst resting. Following each injection, 1 or 2 sets of pictures of 
your heart will be taken using a gamma camera. This will require you to lie
still for up to 20 minutes at a time.
You will have your blood pressure, pulse and ECG checked at various times 
before, during and after each injection. Three blood samples will be taken 
to check for other drug effects; one before each of the injections and the 
final one between 36 and 48 hours after the second injection.
You are requested to refrain from taking either alcohol or drugs (except those
indicated b y .......................  or his colleagues) before the agent is
administered and to take only a light breakfast (avoiding tea, coffee or cola 
unless decaffeinated) on the morning of the study. Before the second 
injection you will be allowed to have a light meal.
Between 1 and 14 days before or 2 and 14 days after receiving the new agent,
you will be asked to undergo a thallium study. This is so that the new agent 
can be compared to the agent which is used routinely at present.
Although it is impossible to guarantee that any radiation dose is safe, the 
dose that you will receive is relatively low, and the radiation will have 
largely disappeared within 2 days of the injection.
The drug has been tested for safety and does not appear to have a significant 
toxic risk associated with it at the proposed dose. It is not anticipated 
that any side effects will be seen as a result of the injection of this 
compound. However, if you do suffer any side effects you should inform 
........ or one of this colleagues as soon as possible.
Your identity in this study will be kept confidential. All information 
concerning your participation in this study will be made available to Amersham 
International pic (the manufacturer of the test drug), and to appropriate 
regulatory authorities. Any medical records related to this study may be 
inspected by an authorised representative of Amersham or an appropriate 
regulatory authority. The results of this study may be reported in 
publications or presentations, but your identity will not be disclosed.
If you are injured as a direct result of your participation in this study, 
medical treatment will be made available at no cost to you. Amersham agrees 
to abide by the Association of the British Pharmaceutical Industry guidelines 
with regard to compensation due to injury.
You will be given a medical contact card signifying that you are participating 
in a clinical trial. You should keep this with you at all times whilst you 
are involved in the trial.
If you have any questions regarding this study, you are free to contact the
supervising doctor (.................. ) or his staff (eg...................).
Participation in this study is voluntary, and you are free to withdraw at any 
time, without explanation. Any future medical treatment available to you 
will not be prejudiced if you decline to take part in, or withdraw, from, this 
study.
The study has been considered and approved by an independent ethical 
committee.
I ................................... . confirm that I have read the above
information and have discussed this study with.........................
I confirm that I am willing to take part in the study.
Signed: ................................................. Date:...........
I ..........................................  confirm that I have explained the
nature, purpose and possible hazards of this study to this patient.
Signed: ..................... ...........................  Date: .........
I ..................................................confirm that I have witnessed
this patient's informed consent to participate in this study.
Signed: ...............................................  Date : ...........
Appendix III
Patient information and informed consent Stage III
AN OPEN-LABEL STUDY TO EVALUATE THE USE OF A DOBUTAMINE TECHNETIUM-99m- 
TETROFOSMIN IMAGING PROTOCOL IN THE ASSESSMENT OF CORONARY ARTERY DISEASE
You have been asked to participate in a research study which will involve 
approximately 50 patients. The purpose of this study is to investigate the 
value of a new radioactive labeled medication in determining the diagnosis and 
clinical status of ischemic heart disease. This medication is similar to 
thallium, which is the agent routinely used at the present time, which allows 
pictures to be taken of the blood flow within the heart during exercise and 
at rest. You have been selected for this study because you are known to have 
or are suspected of having, coronary artery disease based on available
clinical evidence.
Procedure
Following an interview and brief physical examination by a physician or 
his/her designate, a small plastic needle will be inserted into your arm for 
the administration of the test agent. You will receive two injections of the 
new agent on two separate days. One will be administered whilst you are 
receiving dobutamine and the other will be administered whilst you are at 
rest. After each injection, pictures will be taken of your heart using 
special scanning cameras. This will require you to lie still for two periods 
of approximately 30 minutes each. Your blood pressure, pulse, and
electrocardiogram will be checked at various times, before, during and after 
injection. Your participation in this study will end upon completion of the 
second set of scans.
Discomforts and Risks
There is a small risk of a bruise or swelling from the insertion of the 
catheter in the vein. Inflammation or infection of the vein may occur, 
however, care will be taken to avoid any of these complications.
The agent has been tested for safety and does not appear to have significant
toxic risks associated with it. It is possible that a reaction that has not 
previously been documented may occur. The radiation exposure related to the 
use of this agent is within the acceptable range for many diagnostic studies. 
If you have any questions about the radiation exposure, please feel free to 
discuss this with the supervising doctor.
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You should not participate in the study if you are pregnant or think you may 
be pregnant or if you are breastfeeding.
Benefits
This research trial will help to determine potential advantages of this new 
agent. One suspected advantage is that the medication will produce pictures 
of better quality which would improve the ability to diagnose coronary artery 
disease.
Alternative Procedures
An alternative procedure to scanning with this agent is routine thallium 
imaging. An alternative to the administration of dobutamine is to exercise 
on a bicycle or treadmill. An additional alternative procedure for the 
detection of coronary artery disease is cardiac catheterization.
Confidentiality
Only your physician, his/her direct staff and authorized representatives from 
the sponsor of the study (Amersham International pic) will have access to any 
of your medical records. In all records of the study you will be identified 
by a number and your name will be known only to the researchers. Your name 
will also not be used in any scientific reports or publications of this study.
Compensation
All procedures related to study will be provided at no cost to you. All 
research-related costs will be paid by the study sponsor. If you are injured 
as a direct result of your participation in this study, medical treatment will 
be made available at no cost to you. Amersham International pic has agreed 
to abide by the ABPI guidelines with regard to financial compensation due to 
injury.
You are free to choose not to participate and if you do become a participant, 
you are free to withdraw at any time during its course. If you choose not to 
participate or if you withdraw, you will not adversely affect your 
relationship with the physicians at this hospital.
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Please feel free to ask about anything you do not understand; consider this 
information carefully - as long as you feel necessary - before agreeing to 
participate. If you have further questions regarding any aspect of your 
participation in this study please feel free to contact the supervising doctor 
(Dr A Lahiri) or his staff (e.g. Dr B Sridhara).
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CONSENT FORM
I, the undersigned voluntarily agree to take part in the open-label study to 
evaluate the use of a dobutamine technetium-99m-tetrofosmin imaging protocol 
in the assessment of coronary artery disease (Protocol No. P53-007).
I have been given a full explanation by the supervising doctor, Dr A. Lahiri 
or his appointed staff of the nature, purpose and likely duration of the study 
and what I will be expected to do and I have been advised about any discomfort 
and possible ill-effects on my health or well-being which he believes may 
result. The information document given to me is attached.
I have been given the opportunity to question Dr A. Lahiri or his appointed 
staff on all aspects of the study and have understood the advice and 
information given as a result.
I agree to Dr A. Lahiri or his appointed staff contacting my general 
practitioner to make known my participation in the study and I authorise my 
general practitioner to report details of my relevant medical or drug history, 
in confidence.
I agree to comply with any instruction given during the study and to co­
operate faithfully with Dr A. Lahiri or his appointed staff and to tell him 
immediately if I suffer any deterioration of any kind in my health or well­
being or any unexpected or unusual symptoms however they may have arisen.
I agree that I will not seek to restrict the use to which the results of the 
study may be put and, in particular, I accept that they may be disclosed to 
regulatory authorities for medicines in the UK and elsewhere.
I understand that I am free to withdraw from the study at any time without 
needing to justify my decision.
The company sponsoring the study confirms that:
(i) Subject to any overriding requirement of law necessitating the 
disclosure of documents relating to the study, the patient will not be 
referred to by name in any document concerning the study disclosed to 
any person not under the direct control of the supervising doctor.
(ii) In the event of my suffering any significant deterioration in health or 
well-being caused directly by my participation in the study, 
compensation will be paid to me by the company in accordance with 
current ABPI Guidelines with regard to financial compensation due to 
injury
(iii) The amount of such compensation shall be calculated by reference to the 
amount of damages commonly awarded for similar injuries by an English 
court if liability is admitted, provided that such compensation will be 
reduced to the extent that I, by reason of contributory fault, am 
wholly or partly responsible for the injury (or where I have received 
equivalent payment for such injury under any policy of insurance 
effected by the company, or otherwise in place, for my benefit).
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(iv) Any dispute or disagreement as to the application of clause (iii) shall 
be referred to an arbitrator to be agreed between myself and the 
company, or in the absence of agreement, to be appointed by the 
President of the Royal College of Physicians of London with power in 
the arbitrator to consult a barrister of 10 years' standing in respect 
of any issue of law including the amount of damages to be awarded as 
payment of compensation.
The agreement shall be constructed in accordance with English law and subject 
to clauses (ii), (iii), (iv) although the English courts shall have sole 
jurisdiction over any dispute which may arise out of it.
Signed by the patient ............................................... ......
Dated: ......................................................
Signed for and on behalf......................................................
of the company by
its duly authorised 
representative
Dated: ................................. ....................
I confirm that I have explained the nature, purpose and possible hazards of 
the above trial to
Signed.................... ...............................
I confirm that I have witnessed the above explanation
Signed ...............................
(witness signature)
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